

Attachment G-1

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0001	FTC-955-00005038	FTC-955-00005076	9/13/2006	Final Settlement and Release Agreement between Unimed, Besins, Par, and Paddock; Patent License Agreement between Unimed and Par	Downey-20
PTX0002	PADD018345	PADD018368	9/13/2006	Final Settlement and Release Agreement between Unimed, Besins, Par, and Paddock	
PTX0003	PADD018272	PADD018286	9/13/2006	Patent License Agreement between Unimed and Par	
PTX0004	FTC-955-00005115	FTC-955-00005140	9/13/2006	Co-Promotion Agreement between Solvay and Par; Letter from Scott Tarriff to Edward Maloney re: Designee for Backup Manufacturing and Supply Agreement	Downey-22
PTX0005	PADD018298	PADD018335	9/13/2006	Backup Manufacturing and Supply Agreement between Unimed, Besins, and Par	Kay - 17
PTX0006	PADD002209	PADD002212	9/13/2006	Letter from Scott Tarriff to Edward Maloney re: Designee for Backup Manufacturing and Supply Agreement	
PTX0007	PAR459737	PAR459747	9/13/2006	Asset Purchase Agreement between Paddock and Par	
PTX0008	SOLVAY 068788	SOLVAY 068841	8/11/1995	Document: Unimed AndroGel Agreements (Unimed-Besins 1995 License Agreement and Supply Agreement)	Bua-5
PTX0009	BESUS 000017	BESUS 000049	10/22/2001	Document: Supply Agreement between Unimed and Besins	Dale-1
PTX0010	SLV393678	SLV393679	11/7/2000	Email from Pascal Andre to Murray Kay re: FW: Latest product profitability figures w/ Attach: Product profitability 11-07 xls	
PTX0011	UPIED0189197	UPIED0189239	5/16/2001	AndroGel proposal for DSPH and Comex approval	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0012	TAP002985	TAP002996	6/7/2001	TAP Pharmaceutical Products, Inc. AndroGel History Pre-2002 File	
PTX0013	SOLVAY-ED-0043239	SOLVAY-ED-0043265	6/11/2001	Presentation: AndroGel Co-Promotion - Data Integration Summary and Coordination Reports	
PTX0014	SLV390977	SLV390978	8/31/2001	Five Year Plan - 2002-2006 (08-31)	
PTX0015	PAR00202	PAR00218	2003	Testosterone Gel Executive Summary	
PTX0016	PAD 0023632	PAD 0023633	2/11/2003	Document: Paddock Laboratories, Inc. New Product Development Status Report re: Testosterone Gel	Maloney-03
PTX0017	PAD 0000001	PAD 0000044	7/2/2003	Document: Paddock Laboratories, Inc. ANDA 76-744, Testosterone Gel, 1% File: ANDA 76-744 Submission; Letter from FDA re Receipt of ANDA Application Submission; Patent and Exclusivity Search Results; Paragraph IV Certifications	Maloney-05
PTX0018	PADD002957	PADD002959	7/2/2003	Letter from FDA to Paddock Laboratories, Inc. re: Receipt of ANDA Application Submission	
PTX0019	PADD038799	PADD038800	7/7/2003	Letter from Ron Nedich, Paddock Laboratories, Inc. to Jean-Louis Anspach, Unimed Pharmaceuticals, Inc. re: Notice of Paragraph IV Certification RE: Testosterone 1% Topical Gel	
PTX0020	W 010682	W 010722	7/7/2003	Letter from Barry White to Jean-Louis Anspach, Jay Bua, Antoine Besins re: AndroGel/Testosterone (1% testosterone gel) United States Patent No. 6,503,894 Notice of Paragraph IV Certification	Buchen-3

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0021	WTN0001567	WTN0001573	8/21/2003	Complaint, Dkt. No. 1, Unimed Pharmaceuticals, Inc. v. Watson Pharmaceuticals, Inc., 1:03-cv-2501-TWT (N.D. Ga.)	
PTX0022	PADD022577	PADD022577	10/2/2003	Email from Edward Maloney to Marcia Jendro re: FW: testim testosterone gel	
PTX0023	Buchen06	Buchen06.022	10/27/2003	Answer to First Amended Complaint and Counterclaims, Dkt. No. 8, Unimed Pharmaceuticals, Inc. and Laboratoires Besins Iscovesco v. Watson Pharmaceuticals, Inc., 1:03-cv-2501-TWT (N.D. Ga.)	
PTX0024	WTN0001757	WTN0001768	11/17/2003	Answer to Counterclaims, Dkt. No. 10, Unimed Pharmaceuticals, Inc. and Laboratoires Besins Iscovesco v. Watson Pharmaceuticals, Inc., 1:03-cv-2501-TWT (N.D. Ga.)	
PTX0025	ABBVIE-AGEL00143429	ABBVIE-AGEL00143492	3/31/2004	Promotion Agreement between Wyeth and Solvay	
PTX0026	SLV034447	SLV034447	4/15/2004	Price Increase Approval Form	
PTX0027	AGEL-MDL-008-017994	AGEL-MDL-008-018078	9/2/2004	FW: Meeting minutes, Identifying licensing opportunities in WH/MH, Amsterdam, Aug 24, 25	
PTX0028	AGELMDL012002223	AGELMDL012002247	10/22/2004	Solvay / ICOS AndroGel Co-Promotion White Paper	
PTX0029	SLV317515	SLV317515	11/5/2004	Email from Kevin Rose to James Hynd, Jean-Louis Anspach, Joe Nolan, et al. re: ICOS Co-promotion Counter Terms	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0030	FTC-ICOS00042199	FTC-ICOS00042217	11/23/2004	REICOS-SolvayTerms_SPIv1_ICOSv3_noredline.doc.rtf	
PTX0031	AGEL-MDL-022-000814	AGEL-MDL-022-000822	2/1/2005	Email from James Hynd to Harold Shlevin re: FW: ICOS, Shire w/ Attach: ICOS Summary Jan 31 05.ppt; Pentasa Jan 27 05.ppt; Summary Document for ICOS Jan 31 05 v2.doc	
PTX0032	PADD006445	PADD006445	3/1/2005	Email from Maureen Rath to Bruce Falcon, Joann Zilka, Tammy Charbonneau, et al. re: Testim Project	
PTX0033	PADD006442	PADD006442	3/3/2005	Email from Soloan Schroeder to Janine Kelley, John Fan, Bruce Falcon, et al. re: RE: Order of Testim	
PTX0034	PADD008265	PADD008266	4/5/2005	Email from William Mink to Pete Zeleny, Maureen Rath, Kelly Dodson, et al. re: RE: T-Gel Bottle Filler	
PTX0035	SLV225843_A	SLV225844_A	7/5/2005	Email from Jean-Louis Anspach to Kevin Rose, Marty Comer, Brian Mitchell, et al. re: Wesso july 18 meeting w/ Attach: BOD2004.ppt	
PTX0036	AGELMDL014000842	AGELMDL014000877	7/14/2005	Email from Brian Mitchell to Murray Kay re: RE: Agenda Time w/ Attach: McKinsey Slides.ppt	
PTX0037	AGEL-MDL-022-004370	AGEL-MDL-022-004404	7/27/2005	Email from Harold Shlevin to Oliver Engert re: FW: SARL Board Presentation_FINAL_26Jul05.ppt w/ Attach: SARL Board Presentation FINAL 26Jul05.ppt	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0038	AGELMDL008002094	AGELMDL008002099	Aug-05	Primary Care and Specialized Markets Business Unit - Monthly Business Report, August 2005	
PTX0039	AGELMDL013020020	AGELMDL013020027	8/15/2005	Email from Mark Hastings to James Hynd, Jean-Louis Anspach, Brian Mitchell, et al. re: Integrating TriCor v2.doc w/ Attach: Integrating TriCor v2.doc	
PTX0040	AGELMDL013020031	AGELMDL013020032	8/16/2005	Email from Lisa Helin to Jay Janco re: Scenario planning for Wesso meetings next week	
PTX0041	PADD019374	PADD019375	9/20/2005	Email from William Mink to Edward Maloney re: RE: t-gel equip rev2.doc w/ Attach: t-gelequip rev 3.doc	
PTX0042	AGELMDL014012630	AGELMDL014012643	Oct-05	Board of Directors Meeting October 2005	
PTX0043	AGELMDL014003530	AGELMDL014003534	10/27/2005	Email from James Hynd to Murray Kay re: FW: Status update: Abbott request of additional 300K PDEs	
PTX0044	AGELMDL008002040	AGELMDL008002049	11/11/2005	Presentation: Polaris - Accelerating Commercial Effectiveness	
PTX0045	PADD005106	PADD005109	12/13/2005	Conference call with Par	
PTX0046	SLV543228	SLV543237	12/13/2005	Email from Elaine Yang to Jean-Louis Anspach re: Tricor PDE Increase w/ Attach: 12-13-2005 increased PDE discussion v1.0.ppt; Co-promotion Increased detailing 121305-options.xls	
PTX0047	SLV455405	SLV455439	1/6/2006	Email from Brian Mitchell to James Hynd re: SARL Board Presentation w/ Attach: SARL Board PresentationFINAL-26Jul05.ppt	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0048	SLV528334	SLV528346	1/26/2006	Email from Marty Comer to Jean-Louis Anspach re: FW: Updated PBE deck and request for information w/ Attach: Solvay 1.25.06.ppt	
PTX0049	SLV551676	SLV551679	2/8/2006	Email from Jean-Louis Anspach to James Hynd, Brian Mitchell, Kevin Guthrie, et al. re: CMB - SMK January 06 report w/ Attach: Monthly Report 2006 - January.doc	
PTX0050	PAR 008495	PAR 008509	2/10/2006	Testosterone Gel 1% Executive Summary	
PTX0051	PADD021090	PADD021092	2/16/2006	Meeting invite to William Mink, Janine Kelley, John Fan, et al. re: Updated: Post-batch meeting for PE batches of T-Gel formulation 2 w/ Attach: Post-PEBatchMeeting Agenda2-15-06.doc	
PTX0052	SLV480998	SLV481000	2/21/2006	Email from Mark Hastings to Lisa Helin, Jay Janco, Juliana Hardy re: RE: Assumptions - Sales Force Study w/ Attach: 20060216 ZS Assumptions - Sales Force Study v1 1.xls	
PTX0053	PADD028529	PADD028534	2/22/2006	Email from Nandini Konar to Lisa Black re: Tgel forecast w/ Attach: winmail.dat	
PTX0054	SLV456892	SLV456914	2/27/2006	Email from Dan Frey to James Hynd, John Bienko, Kevin McCarl re: Generic contingency presentation w/ Attach: Solvay generic contingency preview v1.0.zip	
PTX0055	SLV455885	SLV455911	3/1/2006	Email from Joe Nolan to James Hynd re: Watson: Generic Strategy w/ Attach: Solvaypresentation.ppt	
PTX0056	WTN0287918	WTN0287918	Apr-06	Handwritten Notes of Edward Tykot: April 27th, 2006 Meeting	Tykot - 8

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0057	AGELMDL014020935	AGELMDL014020940	4/10/2006	Email from Elaine Yang to Murray Kay re: Tulip w/ Attach: TULIP 040806.ppt; Adrgel scenario planning 040806.xls	
PTX0058	SLV448350	SLV448408	4/13/2006	Presentation: Board of Directors Meeting and Business Review	
PTX0059	SLV577131	SLV577151	4/14/2006	Email from James Hynd to Brian Mitchell, Murray Kay re: Solvay generic transition plan summary v2 1.ppt CONFIDENTIAL w/ Attach: Solvay generic transition plan summary v2 1.ppt	
PTX0060	SLV475073	SLV475096	4/18/2006	Email from Cherry Christian to James Hynd re: FW: Tulip AndroGel Slides.ppt w/ Attach: Tulip AndroGel Slides.ppt	
PTX0061	SLV475097	SLV475116	4/19/2006	Email from Murray Kay to James Hynd re: Tulip AndroGel Slides (2).ppt w/ Attach: Tulip AndroGel Slides (2).ppt	
PTX0062	WTN0093300	WTN0093316	4/19/2006	Email from Edward Heimers to David Buchen, Edward Tykot re: Unimed Files w/ Attach: Unimed AndroGel FINAL.ppt; Unimed AndroGel LTC.ppt	
PTX0063	SLV581603	SLV581626	4/20/2006	Presentation: Tulip AndroGel Slides.ppt	
PTX0064	SLV475125	SLV475131	4/25/2006	Email from Brian Mitchell to James Hynd re: Slightly update Tulip doc w/ Attach: Tulip selling doc w charts added 042506.ppt	
PTX0065	SLV584023	SLV584024	4/26/2006	Email from Elaine Yang to James Hynd, Murray Kay re: RE: Tulip	
PTX0066	SLV587034	SLV587043	4/26/2006	Document: Urology Based Androgel Business	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0067	WTN0288577	WTN0288584	4/28/2006	Email from Edward Tykot to Edward Heimers re: Fw: Summary of Terms w/ Attach: Watson Terms.ppt	
PTX0068	SLV474741	SLV474748	4/28/2006	Email from James Hynd to Peter Edwards, Laurence Downey, Murray Kay re: Watson Terms.ppt w/ Attach: Watson Terms.ppt	
PTX0069	PAR459026	PAR459027	4/29/2006	Email from Paul Campanelli to Joseph Todisco re: Re: Solvay	
PTX0070	SLV452010	SLV452015	5/3/2006	Email from Melissa Arthur to Kate Burns, Peter Edwards re: FW: NDA w/ Attach: NonDisclosure Agreement.pdf	
PTX0071	PAR343760	PAR343761	5/3/2006	Email from Murray Kay to Paul Campanelli re: Generic Model With Three Generic Competitors xls w/ Attach: Generic Model With Three Generic Competitors xls	
PTX0072	PAR344420	PAR344420	5/8/2006	Email from Paul Campanelli to Murray Kay, Laurence Downey, Suzanne Paula re: NPV Valuation	
PTX0073	SLV510602	SLV510602	5/8/2006	Spreadsheet: Solvay Par xls	
PTX0074	SLV222074	SLV222074	5/10/2006	Presentation: AndroGel US Market 2000-2005	
PTX0075	SLV506117	SLV506120	5/18/2006	Email from Murray Kay to James Hynd re: RE: Summary of Terms	
PTX0076	SLV585024	SLV585036	5/24/2006	Email from Murray Kay to James Hynd, Brian Mitchell re: Tulip May-24 2006 (3).ppt w/ Attach: Tulip May- 24 2006 (3).ppt	
PTX0077	SLV476413	SLV476425	5/24/2006	Email from Brian Mitchell to Murray Kay, James Hynd re: Tulip May 25 Deck w/ Attach: Tulip May-24 2006.ppt	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0078	PAR344841	PAR344841	5/24/2006	Email from Paul Campanelli to Edward Maloney re: T-gel	
PTX0079	WTN0287970	WTN0287988	6/8/2006	Email from Edward Tykot to Edward Heimers, David Buchen re: Fw: Co-Promotion Agreement w/ Attach: WATSON Copromotion060806 (2).doc	Tykot - 12
PTX0080	WTN0288574	WTN0288576	6/8/2006	Email from Edward Heimers to Edward Tykot, Lynne Amato re: Re: Fw: Co-Promotion Agreement	Tykot - 11
PTX0081	SLV510899	SLV510902	6/12/2006	Email from Brian Mitchell to Paul Campanelli, James Hynd, Peter Edwards, et al. re: Par/Solvay Co-Promotion Terms w/ Attach: Par Terms_12June.ppt; Mitchell, Brian.vcf	
PTX0082	SLV409694	SLV409694	6/15/2006	Email from Jean-Louis Anspach to James Hynd, Murray Kay re: AndroGel PDEs in Urology	
PTX0083	SLV474143	SLV474153	6/28/2006	Email from Joseph Mahoney to Barry White re: AndroGel - Draft Patent License Agreement - Privileged & Confidential / Attorney Work Product w/ Attach: 13320125 1.DOC	
PTX0084	SLV186117	SLV186168	7/20/2006	Presentation: Solvay Pharmaceuticals, Inc. Business Review 2007-2011 Plan Version 1	
PTX0085	PAR463151	PAR463177	8/4/2006	Email from Murray Kay to Paul Campanelli re: FW: Par Backup Manufacturing Agreement w/ Attach: Par- Solvay Manufacturing K CLEAN 08032006.doc	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0086	SLV476694	SLV476746	8/4/2006	Email from Paul Campanelli to Murray Kay, James Hynd, Scott Tarriff, et al. re: Fw: Par/Solvay Draft Co-Promotion Agreement w/ Attach: NY-#455639-v3-Par_Solvay_Co-Promotion_Agreement.DOC; NY-#455639-vdoc-Par_Solvay_Co- Promotion Agreement.DOC	
PTX0087	SLV476772	SLV477002	8/18/2006	Email from Paul Campanelli to Murray Kay, James Hynd, Peter Edwards, et al. re: Re: Fw: Par, Unimed, Paddock, Besins Draft Settlement & Release Agreement - Privileged & Confidential/Attorney Work Product w/ Attach: Solvay.Par.Settlement Agreement.DOC; Consent Judgment.doc; Par-Solvay License.DOC	
PTX0088	SLV511179	SLV511187	8/19/2006	Email from Murray Kay to Laurence Downey, James Hynd, Peter Edwards re: Tulip August 2006.ppt w/ Attach: Tulip August 2006.ppt	
PTX0089	WTN0327082	WTN0327093	8/19/2006	Email from Fred Weihmuller to Charles Ebert, Wanda Williams, Charles McCarthy, et al. re: Weekly product Launch updates 8-18-06 w/ Attach: Weekly Prod. Launch Mtg.Min. 8-18-06.doc	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0090	SLV476968	SLV477002	8/21/2006	Email from Angus Chen to James Ferguson, Murray Kay, Peter Edwards, et al. re: Re: Fw: Par, Unimed, Paddock, Besins Draft Settlement & Release Agreement - Privileged & Confidential / Attorney Work Product w/ Attach: Solvay.Par.Settlement Agreement.DOC; Consent Judgment.doc; Par-Solvay License.DOC	
PTX0091	PAR344354	PAR344358	8/21/2006	Email from Paul Campanelli to Peter Edwards, Murray Kay re: Re: FW: Teleconference Calls with Par on Tuesday August 22, and Wednesday, August 23	
PTX0092	SLV476875	SLV476948	8/21/2006	Email from Paul Campanelli to Brian Mitchell, James Ferguson, Joseph Mahoney, et al. re: FW: Backup Manufacturing Agreement w/ Attach: NY-#457797-v5-Back-Up_Manufacturing_Agreement.DOC; NY-#457797-vdoc-Back- Up Manufacturing Agreement.DOC	
PTX0093	SLV582888	SLV582959	8/25/2006	Email from Eliot Choy to Murray Kay, Matthew Owens re: FW: Par/Solvay/Backup w/ Attach: Back- Up Manufacturing Agreement.DOC; Redline rtf	
PTX0094	SLV506508	SLV506508	8/30/2006	Email from Laurence Downey to Paul Vanderhoeven re: FW: Tulip August 2006.ppt	
PTX0095	SLV506137	SLV506140	8/30/2006	Email from Murray Kay to Matthew Owens, James Hynd re: RE: Par/Solvay	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0096	N/A	N/A	9/13/2006	Document: Final Settlement and Release Agreement, Patent License Agreement, Co-Promotion Agreement, and Stipulation of Dismissal between Unimed, Besins, and Watson	Downey 18; Buchen-25
PTX0097	WTN0286953	WTN0286969	9/13/2006	Document: Final Settlement and Release Agreement between Unimed, Besins, and Watson	Buchen - 20; GX2001-A
PTX0098	PADD018336	PADD018340	9/13/2006	Consent Judgment and Order of Permanent Injunction, Dkt. 130, Unimed Pharmaceuticals, Inc., Laboratoires Besins Iscovesco v. Paddock Laboratories, Inc., 1:03-CV-2503 (N.D. Ga.)	
PTX0099	WTN0286982	WTN0287004	9/13/2006	Document: Co-Promotion Agreement between Solvay and Watson	Buchen - 18
PTX0100	WTN0105652	WTN0105659	9/14/2006	Email from Amy Hulina to Stephen Salvucci re: Fw: AndroGel Settlement: External communications follow up	Tykot - 15
PTX0101	SLV443734	SLV443785	9/20/2006	Email from Suzanne Paula to Murray Kay re: FW: Budget Discussion w/ Attach: Business Review - 5 Year Plan Version 2 Revised_September 19 print version final.ppt	
PTX0102	SLV506194	SLV506195	9/25/2006	Email from Peter Edwards to James Hynd, Laurence Downey re: RE: FW: AndroGel Par/Paddock Tech Transfer and Backup Supply	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0103	WTN0287067	WTN0287071	9/28/2006	Email from Amy Hulina to rad@hpm.com re: Fw: ANDA 76-737, Testosterone Gel, 1% Acceptable for Filing Letter w/ Attach: 76-737 Acceptable for Filing.pdf	
PTX0104	BNS0003917	BNS0003920	9/29/2006	Document: Reciprocal Confidentiality Agreement between Besins International US, Inc. and Paddock Laboratories, Inc.	
PTX0105	PAR267496	PAR267521	10/16/2006	Email from Cecelia Heer to Mike Graves, Jackie Guerra re: BD Presentation w/ Attach: P.Campanelli_BD&L2006.ppt	
PTX0106	SLV301602	SLV301654	10/19/2006	Email from Kevin Rose to Jean-Louis Anspach, Marty Comer, Vincent Amyot, et al. re: 2007 SMK Bus. Plan Pres. To LC w/ Attach: 2007 SMK Business Plan to LC_FINAL.ppt	
PTX0107	PADD004538	PADD004539	10/30/2006	Email from Daniel DeGrande to Flo Gilson, William Mink, Charles Gancel, et al. re: RE: Paddock audit dates.	
PTX0108	BNS0004106	BNS0004109	11/7/2006	Email from Daniel DeGrande to William Mink, Charles Gancel, Jay Bua, et al. re: Preliminary technology transfer activity list w/ Attach: checklist transfer tech activities.doc	
PTX0109	SLV408357	SLV408369	11/13/2006	Email from Murray Kay to Paul Vanderhoeven, James Hynd, Laurence Downey re: Risk Analysis.xls w/ Attach: Risk Analysis.xls	
PTX0110	SLV186240	SLV186240	11/26/2006	Document: Laurence Downey: Key Accomplishments 2006	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0111	PADD004903	PADD004955	11/27/2006	Presentation: New Product Group Meeting - Program Management Monthly Project Updates	
PTX0112	PAR319478	PAR319480	12/7/2006	Email from Brian Cahill to Jerry Martino, Veronica Lubatkin, Darren Willoughby, et al. re: Accounting instructions AndroGel agreement with Solvay and Paddock w/ Attach: AndroGel agreement with Solvay and Paddock.doc	
PTX0113	SLV186279	SLV186284	12/13/2006	Document: Solvay 2007 POA, Laurence Downey: Keynote Remarks	
PTX0114	PAR-MDL-00000085	PAR-MDL-00000085	12/26/2006	Letter from Julie Szozda, Par Pharmaceutical, Inc. to Food and Drug Administration re: ANDA #76- 744, Testosterone Gel 1%, Minor Amendment - Final Approval Requested	
PTX0115	WTS 0001551	WTS 0001566	1/5/2007	Docket Report, Unimed Pharmaceuticals, Inc., et al. v. Watson Pharmaceuticals, Inc., 1:03-cv- 02501-TWT (N.D. Ga.)	
PTX0116	BNS0004397	BNS0004398	1/10/2007	Email from Jay Bua to Antoine Besins re: manufacturing	
PTX0117	SLV509645	SLV509647	1/22/2007	Email from Donald Pirkel to Dave Pederson, Lynn Dale, Patrick Kaczaral re: RE: Draft information on Paddock Lab visit	
PTX0118	SLV451381	SLV451386	2/8/2007	Email from Anabela Coutinho Fonseca to Thomas MacAllister, Jay Bua, Murray Kay, et al. re: JSC Minutes w/ Attach: Androgel Joint Steering Committee Meeting.doc	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0119	PADD022545	PADD022546	2/14/2007	Email from William Mink to Edward Maloney, Maureen Rath, Debbie Andersen, et al. re: T-gel conference call 2-14-07.doc w/ Attach: conference call 2-14-07.doc	
PTX0120	PAR344338	PAR344347	2/15/2007	Email from Lonny Wittnebel to Paul Campanelli, Edward Maloney, Lori-jean Gille, et al. re: Fw: Co- Promotion Invoice Q406	
PTX0121	PAR310456	PAR310456	2/16/2007	Email from Paul Campanelli to Stephen Montalto re: Re: 2007 Accomplishments	
PTX0122	PADD014562	PADD014563	3/26/2007	Email from Ron Nedich to Paul Stach re: FW: Testim Results	
PTX0123	SLV532538	SLV532543	3/30/2007	Email from David Jarret to Jean-Louis Anspach and Vincent Amyot re: RE: Par & Watson Payments w/ Attach: Watson Co-Promo Calculation Q4-06 xls	
PTX0124	SLV000190	SLV000239	4/5/2007	Document: AndroGel 2005 U.S. Business Plan	
PTX0125	SLV423841	SLV423842	4/9/2007	Email from Laurence Downey to Murray Kay re: RE: Comments on Audit Report	
PTX0126	PADD-MDL-00000759	PADD-MDL-00000761	5/22/2007	Email from MZrebiec@parpharm.com to William Mink, Lynn Dale, Edward Maloney, et al. re: Testosterone Gel Project: Meeting Minutes 5/21/07 9:00 am w/ Attach: Testosterone Gel Contact List Rev.xls	
PTX0127	SLV357429	SLV357430	6/11/2007	Email from Murray Kay to Laurence Downey re: FW: Besins June 2007.ppt	
PTX0128	N/A	N/A	July 2007	Document: AIPLA - Report of the Economic Survey 2007	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0129	SLV583346	SLV583360	10/3/2007	Email from Mike Dornhecker to Laurence Downey, Murray Kay re: FW: MSMT presentation 3 Oct 2007.ppt w/ Attach: MSMT presentation 3 Oct 2007.ppt	
PTX0130	PADD-MDL-00002372	PADD-MDL-00002373	11/26/2007	Email from Ken Barnes to William Mink, Matt Hommerding re: T-Gel 3 Scope w/ Attach: Back-Up Manufacturing Scope.doc	
PTX0131	PADD-MDL-00002385	PADD-MDL-00002388	11/27/2007	Email from Lincy Michael to Lynn Dale, William Mink, Benoit Laurent, et al. re: RE: List of documents needed for filing	
PTX0132	N/A	N/A	12/31/2007	Solvay Pharmaceuticals, Inc.'s CID Responses (Specifications 16, 17, 18, 19, 47, 48, 49, 50, and 52)	
PTX0133	AGEL-MDL-009-005068	AGEL-MDL-009-005069	1/7/2008	Email from Carmen Cardoso to Lynn Dale, Jmichauld@besins-international.com, Laurent.gaston@besins-international.com, et al. re: Androgel (Besins) - December 2007 w/ Attach: Androgel Besins - December 2007 xls	
PTX0134	SLV542589	SLV542604	1/17/2008	Email from Lynn Dale to James Hynd, Laurence Downey, Jean-Louis Anspach, et al. re: FW: Androgel presentation to AB w/ Attach: Androgel Manufacturing AB 20080117 - V 1.0.ppt	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0135	PADD-MDL-00003207	PADD-MDL-00003224	2/7/2008	Email from Edward Maloney to William Mink, Lonny Wittnebel, Mike Graves, et al. re: Solvay w/ Attach: Preliminary cost estimate; Solvay Capital Amortization; FW: Materials_list_for_ED.xls; BEST CASE SUMMARY.xls; WORST CASE SUMMARY.xlsx; FW: TGEL Equip Summary.xlsx	
PTX0136	WTN0287113	WTN0287116	3/19/2008	Watson Pharmaceuticals, Inc.'s CID Response (Specification 15)	Buchen - 12
PTX0137	AGEL-MDL-009-004092	AGEL-MDL-009-004093	7/7/2008	Email from Lynn Dale to Patrick Kaczaral re: FW: AndroGel Royaltys June 2008 w/ Attach: Androgel June 2008.xls	
PTX0138	AGEL-MDL-013-038841	AGEL-MDL-013-038864	8/12/2008	Email from Brian Mitchell to Jay Janco, John Rodda re: DRAFT of price increase slides w/ Attach: Brian.Mitchell@solvay.com.vcf; AndroGel Price Increase Analysis 072908.ppt	
PTX0139	FTC-955-00003326	FTC-955-00003330	10/30/2008	Spreadsheet: 08.10.30 ZS Calculations.xls	
PTX0140	PADD-MDL-00008104	PADD-MDL-00008106	1/14/2009	Email from William Mink to Edward Maloney, Jim Schwier, Gary Jossart, et al. re: Creon Back up Manufacturing Plan.docx w/ Attach: Creon Back up Manufacturing Plan.docx	
PTX0141	PADD-MDL-00008337	PADD-MDL-00008339	2/24/2009	Email from Donald Pirkl to Edward Maloney re: RE: Creon Packaging Update	
PTX0142	PADD-MDL-00008767	PADD-MDL-00008789	5/11/2009	Email from Lynn Dale to Barry Campbell, William Mink, Patrick Kaczaral, et al. re: PO and quote w/ Attach: paddock marchesini quote.pdf; marchesini po.pdf	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0143	PADD-MDL-00009045	PADD-MDL-00009046	9/18/2009	Email from Donald Pirkel to William Mink, Lynn Dale, Ken Barnes, et al. re: Stick Pack Equipment PO placed with Inever	
PTX0144	PADD-MDL-00011539	PADD-MDL-00011544	8/3/2010	Email from Patrick Kaczaral to William Mink, Lynn Dale, Ken Barnes re: FW: Inever stickpack machine w/ Attach: Impresión facturas de venta-2110.pdf	
PTX0145	ABBVIE-AGEL00269114	ABBVIE-AGEL00269114	2/8/2011	Spreadsheet: Besins 2010 xls	
PTX0146	ABBVIE-AGEL03223379	ABBVIE-AGEL03223379	3/18/2011	Spreadsheet: Detailed backup for 2484000000 UPI 8- 31-09 and 2-15-10 balances xls	
PTX0147	ABBVIE-AGEL00386066	ABBVIE-AGEL00386067	4/8/2011	Email from Randi Reff to Murray Kay re: 2011 LRP AndroGel P&L - PPD Review.xlsm w/ Attach: 2011 LRP AndroGel P&L - PPD Review.xlsm	
PTX0148	ABBVIE-AGEL03158538	ABBVIE-AGEL03158600	10/10/2011	Email from James Hynd to Jeffrey Stewart re: Acceleration Plan - Presentation & Executive Summary w/ Attach: AndroGel 1.62% Acceleration Plan Update - Executive Summary FINAL.ppt; AndroGel 1.62% Patient Transition Support FINAL_10 4 11.ppt	
PTX0149	PADD-MDL-00015363	PADD-MDL-00015363	11/17/2011	Email from Melissa Timm to William Mink, Sherry Kimball, Lisa Stokes, et al. re: RE: T-Gel sachets (PQ lots)	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0150	PADD-MDL-00015479	PADD-MDL-00015482	12/1/2011	Email from Jody Alde to William Mink, Ken Barnes, Lynn Dale, et al. re: Status Update - Qualification of Abbott equipment for AndroGel Packaging Meeting Minutes w/ Attach: 01 DEC 2011 - Abbott & Perrigo meeting Minutes.doc	
PTX0151	ABBVIE- AGEL00268948	ABBVIE- AGEL00268948	2/2/2012	Spreadsheet: Besins Royalty Calculation Dec Revised 020212.xls	
PTX0152	ABBVIE- AGEL00026559	ABBVIE- AGEL00026592	4/23/2012	Email from Meena Vairavan to James Hynd, Frank Jaeger, Michael Gautsch, et al. re: AndroGel 1.62% Patient Source of Business Monthly Update (Data thru Feb 2012) w/ Attach: TRT Mkt Patient Source of Business Update Thru Feb-12 FINAL.pptx	
PTX0153	WTN0489294	WTN0489434	1/22/2013	Email from James Williamson to Andrew Boyer re: FW: Draft Financial Reports for December w/ Attach: December Flash Package - 01-18-13.pdf; Q4 Financial Reporting Package - 01-18-13.pdf; Q4 Executive Reporting Package - 01-18-13.pdf; Q4 Global Generic Segment - 01-18-13.pdf; Q4 Global Brand Segment - 01-18-13.pdf; Q4 Global Distribution Segment - 01-18-13.pdf; Balance Sheet & Cash Flow - 01-18-13.pdf; Q4 International Results - 01-18-13.pdf; Actavis Flash Financial Reporting Package - 4Q 2012 Draft.pdf; Watson Actavis Combined Flash Package January 18 2013.pdf	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0154	ABBVIE- AGEL00231186	ABBVIE- AGEL00231187	9/13/2013	Email from Catharine Sanders to James Hynd re: FW: Low T Centers	
PTX0155	ABBVIE- AGEL00258231	ABBVIE- AGEL00258233	11/25/2013	Email from Maggie Stone to Frank Jaeger, Lisa Wortsmann re: 2014 P&L for Miami Fast Start Meeting w/ Attach: 2014 AndroGel P&L for Fast Start Miami mtg.pptx; 2014 Plan AndroGel P&L xlsx	
PTX0156	ABBVIE- AGEL00270449	ABBVIE- AGEL00270449	1/6/2014	Spreadsheet: Besins Royalty Sent 01.06.14.xlsx	
PTX0157	ABBVIE- AGEL00237139	ABBVIE- AGEL00237143	4/11/2014	Email from James Hynd to Lisa Wortsmann, Michael Gautsch re: RE: How Much of the 1.62 do we hold when 1 goes generic? percentages and absolute dollars?	
PTX0158	ABBVIE- AGEL00786689	ABBVIE- AGEL00786728	14-Jun	Presentation: TRT Market Dynamics - Metabolics MABI	
PTX0159	ABBVIE- AGEL00025744	ABBVIE- AGEL00025751	8/4/2014	Email from Virai Sarvaiya to Michael Gautsch, James Hynd, Marty Comer, et al. re: 2014 AndroGel Performance Tracking - WE 07/25/2014 (with Jun 2014 LBE) w/ Attach: 2014 AndroGel Weekly Performance Tracking_we07252014.pptx	
PTX0160	N/A	N/A	3/14/2016	Stipulation Between All Plaintiffs and Defendant Actavis, Inc., Dkt. No. 1352, In Re: Androgel Antitrust Litigation (No. II), 1:09-md-02084-TWT (N.D. Ga.)	
PTX0161	N/A	N/A	3/14/2016	Stipulation Between All Plaintiffs and Defendant Actavis, Inc. Regarding Rule 30(B)(6) Notice of Deposition, Dkt. No. 1353, In Re: Androgel Antitrust Litigation (No. II), 1:09-md-02084-TWT (N.D. Ga.)	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0162	N/A	N/A	3/14/2016	Stipulation Between All Plaintiffs and Defendant Actavis, Inc., Dkt. No. 1354, In Re: Androgel Antitrust Litigation (No. II), 1:09-md-02084-TWT (N.D. Ga.)	
PTX0163	N/A	N/A	5/16/2016	Stipulation Between Plaintiffs in the Above-Captioned Cases and Defendant Par Pharmaceutical Companies, Inc., Dkt. No. 1402, In Re: Androgel Antitrust Litigation (No. II), 1:09-md-02084-TWT (N.D. Ga.)	
PTX0164	N/A	N/A	11/28/2016	Spreadsheet: NPA CHANNEL TOTALS 2010 28NOV16.xlsx	
PTX0165	N/A	N/A	11/28/2016	Spreadsheet: NPA CHANNEL TOTALS 2014 28NOV16.xlsx	
PTX0166	N/A	N/A	1/3/2017	Spreadsheet: NPA CURRENT REPORT 03JAN17.xlsx	
PTX0167	AGEL-MDL-014-033857	AGEL-MDL-014-033857	N/A	Spreadsheet: Analysis of AndroGel Manufacturing Agreement with Par/Paddock and Summary of AndroGel Settlements with Par and Watson	
PTX0168	N/A	N/A	N/A	Spreadsheet: Perrigo Transaction Data - Androgel Gross Sales by Customer	
PTX0169	SLV000323	SLV000323	4/10/2007	Document: Solvay Pharmaceuticals, Inc. Product Profitability 2001-2009 Global Perspective	
PTX0170	TAP000003	TAP000037	4/27/2001	Presentation: Androgel Co-Promotional Opportunity	
PTX0171	WTN0287911	WTN0287917	N/A	Presentation: Solvay/Watson Co-Promotion of AndroGel to Urologists: Proposed Preliminary Terms with handwritten notes	Tykot - 10

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0172	AGEL-MDL-014-034470	AGEL-MDL-014-034565	N/A	Presentation: Business Review 2006-2010 Plan Version 3	
PTX0173	PAR-MDL-00218628	PAR-MDL-00218628	N/A	Spreadsheet: Testosterone Gel Direct Sales from 9/1/15-12/31/15	
PTX0174	N/A	N/A	N/A	Spreadsheet: IMS Data 1999-2008 NPA.xlsx	
PTX0175	SLV455227	SLV455232	N/A	Document: Solvay Pharmaceuticals, Inc. AndroGel Sales Spreadsheets 2000-2007	
PTX0176	N/A	N/A	N/A	Spreadsheet: abbvie_rebates_all_ndc.xlsx	
PTX0177	PADD020873	PADD020873	4/18/2006	Email from Edward Maloney to Lonny Wittnebel re: RE: T-gel	
PTX0178	ABBVIE-AGEL00283813	ABBVIE-AGEL00283824	8/6/2014	Email from Richard Yang to Michael Gautsch, Pablo Hernandez, Marty Comer, et al. re: Testim AG writers first look w/ Attach: Testim AG Writers First Look.pptx	
PTX0179	WTN0287037	WTN0287063	5/6/2003	Email re Generic Strategy and Encl Watson Presentation to Solvay	Buchen - 5
PTX0180	AGEL MDL 004-002742	AGEL MDL 004-002857	4/29/2008	4/29/2008 Downey IH Transcript	
PTX0181	SLV506122	SLV506122	6/21/2006	Email re Jay Bua Discussion	
PTX0182	SLV585460	SLV585462	9/15/2006	FW: Androgel Generic Settlement Focuses on Co-Promotion Deals	
PTX0183	BESINS-FTC-SUB2015-0000007	BESINS-FTC-SUB2015-0000008	11/13/2012	Email from C. Gancel to O. Raux with attachment	Besins - 5
PTX0184	BNS0004083	BNS0004089	6/30/2004	Email from C. Remant to H. Shlevin w/attachment	Besins - 12
PTX0185	PADD023873	PADD023880	2/21/2007	Solvay Supplier Audit Report	Dale - 07
PTX0186	AGEL-MDL-009-00394	AGEL-MDL-009-00395	12/19/2007	Email from L. Dale to P. Kaczaral, M. Donald, L. Michael, and D. Pederson, :re FW: T-Gel 3 Scope.doc" with attached T-Gel 3 Scope.doc	Dale - 13

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0187	AGEL-MDL009000930	AGEL-MDL-009000932	3/4/2004	Email chain from T. Elder to L. Dale, "Fw: Action items from Feb 26th meeting"	Dale - 14
PTX0188	SLV507774	SLV507779	6/8/2007	Email chain from J. Anspach to M. Kay, J. Hynd, and L. Dale, "Re: Besins June 2007.ppt" with attached Besins manufacturing status 5 june 2007.ppt	Dale - 20
PTX0189	SLV357453	SLV357453	8/21/2007	Email from Patrick Kaczaral to Lynn Dale, Laurence Downey, Jay Bua, et al. re: Agenda for AndroGel discussion	Dale - 21
PTX0190	SLV542589	SLV542604	1/17/2008	Email chain from L. Dale to J. Hynd, L Downey, J. Anspach, et al., "Fw: Androgel presentation to AB" with attached Androgel Manufacturing AB 20080117 - v 1.0.ppt	Dale - 22
PTX0191	N/A	N/A	10/9/2015	30(b)(6) Notice of Deposition to Defendant Actavis, Inc.	Clark - 01
PTX0192	WTN0571625	WTN0571625	3/16/2011	Forecast model for generic Androgel 1%	Clark - 06
PTX0193	WTN0557492	WTN0557493	12/11/2014	Email from C. Miller to N. Clark, "re: FM-Testosterone (Androgel).xlsx" with attached FM-Testosterone (Androgel).xlsx (forecast model for generic AndroGel 1%)	Clark - 07
PTX0194	WPI-000027	WPI-000027	9/15/2005	Forecast model	Clark - 11
PTX0195	AGEL-MDL-006-0003534	AGEL-MDL-006-0003535	2/27/2006	Email from L. Downey to J. Wessolowski, "FW: Watson"	Downey - 03
PTX0196	SLV511170	SLV511170	4/6/2006	Email from L. Downey to M. Kay, et al., "Re: Tulip"	Downey - 05
PTX0197	SLV579462	SLV579466	4/10/2006	Email from E. Yang to B. Mitchell, "re: Tulip" with attached TULIP 040806.ppt	Downey - 06
PTX0198	SLV421979	SLV421981	4/24/2006	Email chain from L. Downey to J. Bua, "re: April 20th, 2006"	Downey - 07

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0199	SLV475060	SLV475072	4/24/2006	Email from J. Hynd to L. Downey, "re: Tulip-WATSON 042406-v1.ppt" with attached Tulip-WATSON 042406-v1.ppt	Downey - 08
PTX0200	SLV584025	SLV584037	4/26/2006	Email from E. Yang to J. Hynd, M. Kay, B. Mitchell, and J. Janco, "re: Tulip with Murray's inputs" with attached Tulip-042606-v2.ppt	Downey - 09
PTX0201	SLV586999	SLV587011	4/26/2006	Email from E. Yang to M. Kay, J. Hynd, B. Mitchell and J. Janco, "re: Tulip updates" with attached Tulip-042606-v3.ppt	Downey - 10
PTX0202	SLV506470	SLV506471	5/11/2006	Email chain from M. Kay to L. Downey, J. Hynd, and P. Edwards, "Re: NPV Valuation"	Downey - 13
PTX0203	SLV586333	SLV586334	5/12/2006	Solvay Pharmaceuticals Marketing & Licensing Agenda	Downey - 14
PTX0204	WPI-E-0900021	WPI-E-0900044	9/13/2006	Co-Promotion Agreement between Solvay on behalf of Unimed and Solvay	Downey - 19; Buchen - 26
PTX0205	FTC-955-00005077	FTC-955-00005114	9/13/2006	Backup Manufacturing and Supply Agreement between Unimed, Besins, and Par	Downey - 21
PTX0206	N/A	N/A	1/23/2008	Watson Pharmaceuticals and Unimed Pharmaceuticals Investigational Hearing Transcript of Laurence J. Downey, M.D.	Downey - 23
PTX0207	SLV452143	SLV452144	9/8/2006	Email chain from L. Downey to P. Campanelli, "re: Press Release/Bear Stearns Conference"	Downey - 24
PTX0208	SLV341038	SLV341038	10/29/2004	My thoughts on Androgel Co-promotion	Yang - 1
PTX0209	SLV189091	SLV189091	11/28/2001	TGEL Sales Graph	Yang - 2
PTX0210	AGELMDL014003739	AGELMDL014003739	2/24/2004	Lasalle and Besins US valuation	Yang - 4

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0211	SOLVAY ED 0080817	SOLVAY ED 0080817	2/3/2003	v06_FSD T-Gel_Order of Entry Scenarios. Xls	Yang - 5
PTX0212	SOLVAY ED 0138178	SOLVAY ED 0138178	7/30/2001	Marcochem's proposal on Androgel Forte	Yang - 6
PTX0213	AGELMDL013004652	AGELMDL013004654	4/1/2004	AndroGel, the Fourth Go Around ... For internal discussion purpose only	Yang - 7
PTX0214	AGEL-MDL-008-017647	AGEL-MDL-008-017678	10/22/2003	AndroGel LCM and ANDROGEL Life-cycle Strategy v10-17-03.ppt	Yang - 8
PTX0215	SLV385456	SLV385456	2/27/2006	DCF's	Yang - 12
PTX0216	AGELMDL014021564	AGELMDL014021565	3/2/2006	FW: and ADRGEL Scenario planning 022406.xls	Yang - 13
PTX0217	AGELMDL014000027	AGELMDL014000028	3/6/2006	Updated version on Androgel options; Androgel 030606.ppt; Adrgel Scenario planning 022406.xls	Yang - 14
PTX0218	SLV510551	SLV510552	3/24/2006	RE: Patent litigation update-client-attorney privilege	Yang - 15
PTX0219	SLV583394	SLV583395	3/31/2006	Re: Tulip	Yang - 16
PTX0220	SLV477709	SLV477712	4/8/2006	Project TULIP	Yang - 18
PTX0221	AGELMDL014020906	AGELMDL014020910	4/9/2006	Email re: For discussion w/ Attach: TULIP 040806.ppt; Adrgel scenario planning 040806 xls	Yang - 19
PTX0222	SLV583983	SLV583994	4/23/2006	Project Tulip update	Yang - 21
PTX0223	SLV583995	SLV583995	4/24/2006	Re: Project Tulip Update	Yang - 22
PTX0224	SLV510888	SLV510889	4/25/2006	Generic Drug Payoff Draws Gov't Interest	Yang - 23
PTX0225	SLV585072	SLV585085	4/26/2006	Tulip updates and Tulip-042606-v3.ppt	Yang - 25
PTX0226	AGELMDL 006-0009651	AGELMDL 006-0009652	4/26/2006	RE: counter offer ideas	Yang - 26
PTX0227	SLV577202	SLV577208	5/2/2006	Generic Model.xls	Yang - 27
PTX0228	AGELMDL014021775	AGELMDL014021776	5/15/2006	RE: Watson Settlement and Adrgel scenario planning 051506-PAR&Watson. Xls	Yang - 28

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0229	SLV582878	SLV582883	5/19/2006	Fw: Androgel COGs and Mfg Besins.xls	Yang - 29
PTX0230	SLV585102	SLV585104	5/24/2006	Tulip-Marino Co-promotion and Tulip May-24-2006.ppt	Yang - 31
PTX0231	AGEL MDL 004-003300	AGEL MDL 004-003478	5/16/2008	Yang Investigational Hearing transcript	Yang - 32
PTX0232	AGELMDL-004-000253	AGELMDL-004-000478	1/18/2008	FTC Deposition Transcript of Lynne M. Amato	Amato - 01
PTX0233	WTN0005585	WTN0005635	10/12/2006	Solvay/Watson Co-promote Discussion	Amato - 04
PTX0234	WTN0004832	WTN0004841	11/16/2006	Subsequent Question and Answer related to your 2007 Oxytrol Business plan data request	Amato - 05
PTX0235	WTN0070623	WTN0070627	11/17/2006	Subsequent Question and Answer related to your 2007 Oxytrol Business plan data request	Amato - 06
PTX0236	WTN0017284	WTN0017328	N/A	Lynne Amato Vice President Brand Sales and Marketing	Amato - 08
PTX0237	ICOS0000001	ICOS0000020	1/28/2005	CO-PROMOTION AGREEMENT	Blum - 03
PTX0238	FTC-ICOS00257419	FTC-ICOS00257433	10/12/2005	ICOS 2nd Detail Update.ppt	Blum - 10
PTX0239	WTN0287064	WTN0287066	1/27/2006	Letter from FDA to Watson	Buchen - 11
PTX0240	WPI-E-1000014	WPI-E-1000019	1/7/2006	Email from David Buchen to Barry White	Buchen - 23
PTX0241	SLV474709	SLV474713	4/13/2006	Email from David Buchen to Peter Edwards	Buchen - 24
PTX0242	WPI-E-1000738	WPI-E-1000744	9/14/2006	Email from Ed Heiners to Patty Eisenhaur	Buchen - 27
PTX0243	WPI-E-1000768	WPI-E-1000779	7/5/2006	Email from Amy Hulina to David Buchen and Stephen Salvucci and attachment	Buchen - 28
PTX0244	SLV474156	SLV474184	7/31/2006	Email from Barry White to James Ferguson and Joseph Mahoney and attachment	Buchen - 29
PTX0245	WPI-E-1400210	WPI-E-1400211	7/18/2006	Email string between Joseph Mahoney, Steven Sunshine, and James Ferguson	Buchen - 30
PTX0246	WPI-E-1000044	WPI-E-1000062	6/21/2006	Email from Barry White to Amy Hulina and David Buchen and attachment	Buchen - 31

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0247	SLV474224	SLV474256	8/27/2006	Email from Joseph Mahoney to Barry White and Steven Sunshine and attachment	Buchen - 33
PTX0248	WPI-E-1401059	WPI-E-1401088	8/11/2006	Email from Barry White to Amy Hulina and David Buchen and attachment	Buchen - 34
PTX0249	WTN0301810	WTN0301815	11/9/2003	Fax from Wanda Williams to Watson Pharma R&D Team	Buchen - 36
PTX0250	WTN0311777	WTN0311784	11/10/2005	Fax to Watson Pharma R&D Team	Buchen - 37
PTX0251	N/A	N/A	1/12/2005	Perrigo Press Release	Buchen - 38
PTX0252	PAR-MDL-00214349	PAR-MDL-00214353	5/2/2006	Email from Kate Burns to Peter Edwards with attachment	Campanelli - 3
PTX0253	PAR-MDL-00214379	PAR-MDL-00214383	6/12/2006	Email string between Brian Mitchell, Paul Campanelli, Jim Hynd, Peter Edwards, John MacPhee with attachment	Campanelli - 4
PTX0254	PAR-MDL-00215978	PAR-MDL-00216012	8/21/2006	Email from Angus Chen to James Ferguson, Murray Kay, Peter Edwards, Vera Nackovic, Matthew Owens, Vicid Harrison with attachment	Campanelli - 5
PTX0255	PAR462681	PAR462752	4/24/2006	Email from Paul Campanelli to Scott Tarriff, Jerry Martino, Thomas Haughey, et al. re: Fw: Solvay Model w/ Attach: Androgel 4.20.06 xls	Campanelli - 6
PTX0256	REMOVED AS DUPLICATE				
PTX0257	PAR344612	PAR344614	5/10/2006	Email from Ed Maloney to Paul Campanelli re: Deal	Campanelli - 9
PTX0258	McKinsey-000327	McKinsey-000328	8/24/2005	Memo Confirming McKinsey's Arrangements re Supporting Solvay's Project Inspire - Enhancing U.S. Performance and Building a Bridge to the Bx Launch	Engert - 2

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0259	AGEL-MDL-016-003373	AGEL-MDL-016-003404	11/17/2005	Solvay Presentation: "Update of US Go-To-Market" Team Discussion	Engert - 4
PTX0260	AGEL-MDL-015-005690	AGEL-MDL-015-005772	12/1/2005	Solvay Presentation: "US Go-To-Market Appendix" Team Discussion	Engert - 5
PTX0261	SLV421973	SLV421978	1/31/2006	Email re FDA Approves Watson's Generic AndroGel ANDA	Cautreels - 5
PTX0262	SLV186377	SLV186435	4/0/2006	Solvay Board of Directors Meeting and Business Review	Cautreels - 7
PTX0263	SLV584091	SLV584091	4/27/2006	Email re Androgel Update	Cautreels - 9
PTX0264	SLV511205	SLV511212	5/12/2006	Email re and Encl Presentation: Project Tulip	Cautreels - 10
PTX0265	AGEL-MDL-009-004008	AGEL-MDL-009-004017	N/A	Presentation: Besins MSMT Meeting Ixelles January, 31st Ph Castellino/Dale	Cautreels - 19
PTX0266	WPI-E-0900902	WPI-E-0900903	9/25/2006	Re: Solvay and Androgel Terms 9.25.06.xls	Yeomans - 6
PTX0267	WTN0358030	WTN0358032-019	7/18/2011	FW: Global Brand Annual Forecast and 2011 Full Year Forecast v2.xls	Yeomans - 8
PTX0268	WTN0318844	WTN0318845-003	6/20/2008	Re: 2008-2010 PM and 2008-2010 Planning Model.xls	Yeomans - 9
PTX0269	WTN0567844-001	WTN0567844-002	N/A	Watson Pharmaceuticals, Inc. Brand Division 2013-2014 Other Revenue	Yeomans - 13
PTX0270	PAR458951	PAR458952	4/24/2006	Email re Solvay Model and Encl Rough Androgel Settlement Model	Tarriff - 7
PTX0271	PAR344694	PAR344694	5/13/2006	Email re Par Agreement	Tarriff - 8
PTX0272	AGEL-MDL-006-0003474	AGEL-MDL-006-0003498	6/1/2001	Co-Promotion Agreement Between Unimed Pharmaceuticals, Inc. and Tap Pharmaceutical Products Inc.	Shlevin - 4
PTX0273	AGEL-MDL-016-000410	AGEL-MDL-016-000426	5/9/2001	Memo re Androgel Co-Promotion Agreement	Shlevin - 5

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0274	AGEL-MDL-016-000129	AGEL-MDL-016-000131	9/4/2002	Letter Confirming Conversation re Reasoning Behind Tap Pharmaceutical's Imminent Termination of the Co-Promotion Agreement	Shlevin - 7
PTX0275	SLV004630	SLV004648	1/28/2005	Co-Promotion Agreement Between Solvay Pharmaceuticals, Inc and ICOS Technology Services, LLC	Shlevin - 8
PTX0276	AGEL-MDL-022-000510	AGEL-MDL-022-000515	12/20/2004	Email re and Encl ICOS Briefing Document re Promotion of Androgel	Shlevin - 9
PTX0277	AGEL-MDL-010-001530	AGEL-MDL-010-001531	12/7/2005	Cover Email to Resend Presentation for Today's Solvay Call (no attachment)	Shlevin - 14
PTX0278	UPIED0124125	UPIED0124128	2/26/2001	RE: Androgel Proposal Outline	Nolan - 5
PTX0279	Solvay ED 0001585	Solvay ED 0001587	11/19/2002	FW: TAP/Solvay - Androgel	Nolan - 9
PTX0280	TAP002547	TAP002549	12/6/2002	TAP/Androgel	Nolan - 10
PTX0281	AGEL-MDL-019-011376	AGEL-MDL-019-011421-002	10/8/2007	NBD Options Mar 06.ppt	Nolan - 13
PTX0282	SLV528749	SLV528750	3/1/2006	FW: Androgel: Generic Strategy	Nolan - 16
PTX0283	TAP001138	TAP001140	12/15/2000	Letter from N. Manusos to R. Dudley re: meeting and TAPs interest in Androgel	Manusos - 04
PTX0284	TAP000939	TAP000962	4/3/2001	Email chain from K. Robertson to J. Weinstein	Manusos - 08
PTX0285	UPIED0216524	UPIED0216525	4/9/2001	Email chain from J. Anspach to J. Feldhouse, J. Weet, et al., "re: FW: Androgel - Due Diligence"	Manusos - 09
PTX0286	TAP002474	TAP002489	5/2/2001	AndroGel Sales Forecast 2001 - 2003	Manusos - 12
PTX0287	TAP000747	TAP000773	6/1/2001	Co-Promotion Agreement between Unimed Pharmaceuticals, Inc. and TAP Pharmaceutical Products Inc.	Manusos - 14
PTX0288	TAP000460	TAP000462	9/4/2002	Letter from R. Masterson to J. Hynd re: TAP Co-promotion	Manusos - 17

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0289	TAP002547	TAP002549	12/6/2002	Email chain from N. Manusos to J. Young, C. Carter, R. Masterson, D. Cole, K. Dolan, "re: TAP/AndroGel"	Manusos - 19
PTX0290	TAP002534	TAP002540	12/9/2002	TAP Pharmaceutical Products Inc. 2003 AndroGel Forecast Proposal Summary	Manusos - 20
PTX0291	TAP000978	TAP000983	1/6/2003	Letter from H. T. Watkins to H. Shlevin, "re: Termination Notice"	Manusos - 21
PTX0292	PAR345227	PAR345229	2/24/2006	Email chain from J. MacPhee to P. Campanelli, "Re: Solvay"	MacPhee - 02
PTX0293	PAR343751	PAR343753	4/28/2006	Email chain from J. MacPhee to P. Campanelli, N. Greene, and S. Tarriff, "Re: Meeting"	MacPhee - 03
PTX0294	PAR455870	PAR455892	5/23/2006	Solvay Pharmaceuticals, Inc. and Par Pharmaceutical	MacPhee - 05
PTX0295	PAR267749	PAR267751	9/24/2006	Email chain from J. MacPhee to S. Tarriff, P. Campanelli, S. Tarriff, "Re: Megace ES: Incremental Net Sales from Targeting Top 4 Quintiles with 100% Response"	MacPhee - 09
PTX0296	PAR319376	PAR319378	1/18/2007	Email chain from J. MacPhee to N. Greene, "re: Fw: Summary of AndroGel Call Panel: Updated Version 11/16/07"	MacPhee - 10
PTX0297	PAR-MDL-00001139	PAR-MDL-00001141	3/19/2007	Email chain from N. Green to J. MacPhee, T. Fogarty, P. Eldridge, "Fw: Report to the Board for February" with attached Marketing 2-07.doc; Marketing 2-07NG Comm.doc	MacPhee - 11
PTX0298	N/A	N/A	8/24/2015	Par Pharmaceutical Companies, Inc.'s Responses to Plaintiff Federal Trade Commission's Third Set of Interrogatories	MacPhee - 12

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0299	PAR070240	PAR070241.xls	10/24/2006	Email from E. Capra to J. MacPhee, "re: Updated Plan Schedules" with attached 2007 Plan Presentation.xls	MacPhee - 13
PTX0300	PAR085730	PAR085731.xls	11/27/2006	Email from E. Capra to J. MacPhee, "re: Updated 2007 Expense Analysis" with attached 2007 Plan Presentation.xls	MacPhee - 14
PTX0301	PAR085695	PAR085696.xls	11/27/2006	Email chain from R. Angulo to N. Green, J. MacPhee, E. Capra, and M. del Pilar Villegas, "re: Brand P&L 112106.xls" with attached Brand P&L 112106.xls	MacPhee - 15
PTX0302	PAR-MDL-00184213	PAR-MDL-00184214	12/2/2008	Email from E. Capra to J. MacPhee and C. Moretto, "re: Strativa P&L by Product.xls	MacPhee - 16
PTX0303	PAR-MDL-00185626	PAR-MDL-00185627	4/20/2009	Email from E. Capra to N. Green with attached 2009 Strativa P&L by Product.xls	MacPhee - 17
PTX0304	PAR-MDL-00187463	PAR-MDL-00187464	9/29/2009	Email chain from K. Kucinski to J. MacPhee, "re: Updated Divisional and Product P&L's" with attached 2010 Operating Plan - P&L by Product.xls	MacPhee - 18
PTX0305	PAR-MDL-00187841	PAR-MDL-00187843	10/20/2009	Email chain from C. Moretto to J. MacPhee, N. Greene, K. Kucinski, "re: 2010 Operating Plan" with attached 2010 Operating Plan-P&L by Product.xls	MacPhee - 19
PTX0306	PAR-MDL-00189271	PAR-MDL-00189272	6/22/2010	Email from C. Moretto to J. MacPhee and K. Kucinski, "re: 2010-2013 P&Ls - Updated" with attached 2010 June LE - Product P&Ls.xls	MacPhee - 20
PTX0307	PAR-MDL-00213277	PAR-MDL-00213279	6/29/2010	Email chain from P. Campanelli to M. Wilson, C. Cruz, J. MacPhee, K. Kucinski, C. Moretto, and D. Elvin, "re: AndroGel Co-Promote & Amendment"	MacPhee - 21

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0308	PAR-MDL-00189725	PAR-MDL-00189727.xls	10/13/2010	Email chain from J. MacPhee to J. Ameres, "Fw: Sales Forecasts - 2011 Operating Plan" with attached 2011 Operating Plan P&L's.xls; 2011 Operating Plan vs. Board Meeting.xls; Nascobal TRX Graph.xls	MacPhee - 22
PTX0309	PAR-MDL-00083127	PAR-MDL-00083130	11/13/2009	Email from J. MacPhee to K. burns, M. Martin, "re: Self-appraisal" with attached SelfAppraisal 2009.doc	MacPhee - 23
PTX0310	PAR-MDL-00188485	PAR-MDL-00188486	3/3/2010	Email chain from P. LePore to J. MacPhee and T. Haughey, "Re: AndroGel Co-promotion agreement"	MacPhee - 24
PTX0311	PAR343589	PAR343591	2/25/2006	Email chain from P. Campanelli to J. MacPhee, "Re: Solvay"	MacPhee - 25
PTX0312	PAR-MDL-00056907	PAR-MDL-00056907	5/4/2009	Email chain from J. Ameres to J. MacPhee, "Re: Striant"	MacPhee - 26
PTX0313	PAR-MDL000031355	PAR-MDL-00031357	9/13/2006	Unanimous Written Consent of Par-Solvay AndroGel Joint Commercial Committee ("JCC") dated as of December __, 2007	MacPhee - 27
PTX0314	PAR-MDL-00000635	PAR-MDL000000636	3/1/2007	Email chain from N. Green to L. Maloney, "Fw: Electronic Version of 2007 Plan" with attached 2007 FINAL Plan to Marketing Team.xls	MacPhee - 29
PTX0315	PAR00184213	PAR00184214.xls	12/2/2008	Email from E. Capra to J. MacPhee and C. Moretto, "re: Strativa P&L" with attached 2009 Strativa P&L by Product.xls	MacPhee - 30

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0316	PAR-MDL-00189776	PAR-MDL-00189781	11/18/2010	Email chain from M. Gustafson to E. Zaccaro, S. Carey, R. Minogue, et al., "Re: Contract Circulation: Abbott Laboratories (Solvay) Androgel CoPromote Amendment" with attached Abbott - 1st Amd to CoPromote w Solvay of 9-12-06 eff 11-10-2010.pdf	MacPhee - 32
PTX0317	PAR-MDL-00189782	PAR-MDL-00189783	11/19/2010	Email from M. Gustafson to E. Zaccaro, S. Carey, R. Minogue, B. Cahill, C. Cruz, et al., "Re: Contract Circulation: Various Agreements" with attached Abbott - termination of Solvay co-promote as of 1-1-2011.pdf; AstraZeneca Distribution Agreement Nov 19 2010 Zafirlukast.pdf	MacPhee - 33
PTX0318	PAR458757	PAR458773	10/26/2005	Agreement between Par Pharmaceutical and Valeant Pharmaceuticals North America	MacPhee - 34
PTX0319	PAR063219; PAR334639	PAR334694	9/13/2006	Email from J. MacPhee to N. Greene, T. Fogarty, L. Kramer, S. Engel, and G. Cahill, "re: Presentation" with attached Board of Directors91906.ppt	MacPhee - 35
PTX0320	PAR-MDL-00008643	PAR-MDL-00008645	6/20/2007	Email from L. Koby to N. Greene, "re: Follow up minutes" with attached Post JCC Call Summary.doc; ATTRUKPX	MacPhee - 36
PTX0321	PAR-MDL-00057103	PAR-MDL-00057106	4/20/2009	Strativa and Solvay JCC Meeting Minutes April 20, 2009	MacPhee - 37
PTX0322	WPI-E-1512249	WPI-E-1512265	4/19/2006	Email re Unimed Files with attached Unimed Presentation	Heimers - 2
PTX0323	WTN0287117	WTN0287142	9/11/2006	Email Fw: Solvay/Watson co-promotion agreement 06/08/06 with attached agreement	Heimers - 9
PTX0324	WTN0106588	WTN0106589	8/25/2006	Email Re: Co-Promotion/ patent settlement	Heimers - 11

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0325	WTN0570872-001	WTN0570872-008	2/19/2016	Spreadsheet re Calculation of Co-Promotion Fees	Heimers - 17
PTX0326	WTN00291970	WTN00291976	1/27/2006	FDA approval Letter for Testosterone gel 1% to Watson	Gwinn - 3
PTX0327	N/A	N/A	9/13/2006	Final Settlement Agreement and Patent License Agreement	Gwinn - 4
PTX0328	WTN0594293	WTN0594293	N/A	Spreadsheet with testosterone information on it	Gwinn - 9
PTX0329	N/A	N/A	2/12/2016	Plaintiffs' 30(b)(6) Notice of Deposition to Defendant Abbvie Products LLC	Hynd - 1
PTX0330	SLV513449	SLV513457	2/24/2006	Handwritten Notes	Hynd - 4
PTX0331	SLV474986	SLV474987	5/11/2006	Email Chain re NPV Valuation	Hynd - 5
PTX0332	SLV510887	SLV510887	6/9/2006	Email Chain FW: Tulip---PAR Update	Hynd - 6
PTX0333	SLV510554	SLV510555	9/5/2006	Email Chain RE: Settlement Agreement	Hynd - 7
PTX0334	TAP000469	TAP000469	1/6/2003	Letter re Termination Notice	Hynd - 10
PTX0335	SLV313387	SLV313407	10/20/2004	ICOS Incremental Value Assessment Presentation	Hynd - 12
PTX0336	ICOS0000021	ICOS0000021	10/24/2005	Correspondence re Co-Promotion Agreement with Solvay Pharmaceuticals dated January 28, 2005	Hynd - 13
PTX0337	ABBVIE-AGEL00237138	ABBVIE-AGEL00237138	4/12/2014	Email re quick question	Hynd - 14
PTX0338	N/A	N/A	1/00/2006	Solvay Pharmaceuticals Contingency Plan	Hynd - 15
PTX0339	ABBVIE-AGEL00693327	ABBVIE-AGEL00693332	5/23/2010	Email re 2008-2013 CREON and AndroGel brand reviews	Hynd - 17
PTX0340	ABBVIE-AGEL02074348	ABBVIE-AGEL02074351	4/11/2014	Email re AndroGel	Hynd - 20
PTX0341	AGEL-MDL-014-026038	AGEL-MDL-014-026039	7/17/2007	Email Fw: Androgel Transfer - July 12, 2007	Hynd - 23
PTX0342	SLV333530	SLV333566	7/11/2007	2007 BF2 2008-2012 Version 1 Presentation	Hynd - 34

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0343	WPI-000032	WPI-000032	2/15/2006	Androgel Generic Forecast	Tykot - 23
PTX0344	WPI-000035	WPI-000035	8/15/2006	Androgel Generic Forecast	Tykot - 24
PTX0345	WPI-E-0900904	WPI-E-0900904	9/25/2006	Email re Solvay and Requesting Financial Projections for Androgel	Tykot - 27
PTX0346	WTN0524877	WTN0524877	N/A	Androgel Calculation of Co-Promotion Fees 2006-2010	Tykot - 29
PTX0347	WTN050872-001	WTN050872-008	N/A	Androgel Calculation of Co-Promotion Fees Q4 2006- Q4 2014	Tykot - 30
PTX0348	WTN0524541	WTN0524547	9/7/2011	Email re Urology and Encl Abbott Presentation: Androgel 1.62% Performance Among Urologists	Tykot - 31
PTX0349	WTN0348521	WTN0348521	7/17/2012	Email re Feedback as to Possible Watson Desire to Explore Early End to the Androgel Co-Promotion Agreement	Tykot - 32
PTX0350	WTN0348531	WTN0348531	8/1/2012	Email re Feedback -Watson Does Not Have Interest in Early Termination of the Androgel Co-Promote	Tykot - 33
PTX0351	WTN0592356	WTN0592373	6/8/2006	Draft Co-Promotion Agreement Between Solvay and Watson	Tykot - 34
PTX0352	WTN0096751	WTN0096758	9/14/2006	Email re Androgel Settlement - External Communications Follow-Up	Tykot - 37
PTX0353	WTN0357137	WTN0357139	1/17/2012	Global Brands Non GAAP Trended Contribution Statement 2012 Budget vs 2011 Actual and Year Over Year Comparison 2011-2012	Tykot - 38
PTX0354	WTN0358295	WTN0358295	N/A	Global Brands Non GAAP Trended Contribution Statement Actual 2010-Q3 2011 and Q4 2011-2014 Forecasted	Tykot - 39

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0355	WTN00291347	WTN00291373	8/24/2007	Service Agreement Between Galderman Laboratories and Watson Pharma, Inc. re Tri-Luma	Tykot - 40
PTX0356	WTN0334837	WTN0334880	9/21/2007	Amended and Restated Promotion Agreement between Depomed, Inc. and Watson Pharma re ProQuin XR	Tykot - 41
PTX0357	WTN0334881	WTN0334912	1/9/2009	Co-Promotion Agreement between Watson Pharma, Inc. and Galen (Chemicals) Limited re Femring	Tykot - 42
PTX0358	WTN0334768	WTN0334793	8/1/2005	Co-Promotion Agreement between Watson Pharmaceuticals, Inc. and Aqua Pharmaceuticals, LLC re Cordran	Tykot - 43
PTX0359	WTN0334993	WTN0335017	2/24/2006	Co-Promotion Agreement between Watson Pharmaceuticals, Inc. and Ferndale Laboratories, Inc. re Condyllox	Tykot - 44
PTX0360	PAR266277	PAR266281	2/27/2004	Par Pharmaceutical, Inc. Business Development NPP Meeting Minutes	Todisco - 1
PTX0361	PAR463086	PAR463090	9/15/2005	Action Items from 9/15/2005 NPL Meeting	Todisco - 3
PTX0362	PAR267497	PAR267521	2006	Presentation: Par Business Development & Licensing Division Overview 2006	Todisco - 4
PTX0363	PAR318648	PAR318650	2/24/2006	Email re Solvay - Upcoming Preliminary Meeting re AndroGel	Todisco - 6
PTX0364	PAR343710	PAR343710	4/5/2006	Email re Solvay Promotion	Todisco - 8
PTX0365	AGEL MDL 004-002148	AGEL MDL 004-002190	3/13/2006	FTC Deposition Transcript of Joseph Todisco	Todisco - 9
PTX0366	PAR343638	PAR343639	4/20/2006	Email re: Solvay Model w/ Attach: AndroGel 4.20.06.xls	Todisco - 10
PTX0367	PAR343757	PAR343758	4/29/2006	Email re Solvay	Todisco - 11
PTX0368	PAR147432	PAR147433	5/1/2006	Email re and Encl AndroGel Forecast	Todisco - 12
PTX0369	PAR459029	PAR459030	5/1/2006	Email re and Encl AndroGel Model	Todisco - 13

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0370	PAR343770	PAR343772	5/3/2006	Email re and Encl Model - Impact of Generic Competition in 2007 with Three Generic Competitors	Todisco - 14
PTX0371	PAR344373	PAR344374	5/3/2006	Email Re and Encl Revised Solvay Model	Todisco - 16
PTX0372	PAR344397	PAR344398	5/5/2006	Email Re and Encl Spreadsheet re Solvay-Par Estimating a NPV Based on Solvay's Thought Process	Todisco - 17
PTX0373	AGEL-MDL-013-057625	AGEL-MDL-013-057716	00/00/2006	Solvay Pharmaceuticals: Forecasting Process Goals, Issues, & Best Practices 2006	Janco - 15
PTX0374	ABBVIE-AGEL00692673	ABBVIE-AGEL00692673	7/13/2009	Email from J. Janco to J. Hardy, "re: Stuff"	Janco - 24
PTX0375	SLV479180	SLV479183	1/30/2006	Email chain from E. Yang to J. Janco, "FW: Watson Pharmaceuticals Receives FDA Approval for Testosterone Gel Product" with attached ANDROGEL0130.doc	Janco - 26
PTX0376	SLV477708	SLV477708	3/21/2006	Email chain from E. Yang to J. Janco and B. Mitchell, "FW: Attorney-Client privileged; Vital signs of WATSON and PAR"	Janco - 27
PTX0377	N/A	N/A	10/23/2015	30(b)(6) Notice of Deposition for Janis Picurro	Picurro - 1
PTX0378	PAR-MDL-00214342	PAR-MDL-00214343	11/10/2015	Par Product FDA Correspondence Log	Picurro - 2
PTX0379	PAR343732	PAR343733	11/1/2004	Email exchange between Michelle Bonomi, Wendy Saunders, Janis Picurro, Robert Campanelli, Paul Campanelli, Tina DeAngelo, Mike Graves	Picurro - 3
PTX0380	PAR-MDL-00000015	PAR-MDL-00000018	10/27/2004	FDA Letter to Todd Delehant at Paddock Labs	Picurro - 4
PTX0381	PAR461807	PAR461821	9/13/2006	Patent License Agreement	Picurro - 5

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0382	PAR-MDL-00000204	PAR-MDL-00000208	10/21/2003	Letter from Food and Drug Administration to Julie Szozda, Par re: ANDA Approval	Picurro - 6
PTX0383	PAR463031	PAR463036	12/29/2005	New Product Launch Meeting Action Items	Picurro - 7
PTX0384	PAR343962	PAR343966	10/5/2006	New Product Launch Meeting Action Items	Picurro - 8
PTX0385	PAR259404	PAR259405	9/24/2003	Email To Executive Group, Michelle Bonomi-Huvala and Wendy Saunders, Dan Rockcliffe, David Rosenberg	Picurro - 9
PTX0386	PAR266154	PAR266155	9/24/2003	Email exchange between Michelle Bonomi, Paul Campanelli, Mike Graves, Scott Tarriff	Picurro - 10
PTX0387	PAR463302	PAR463305	6/16/2006	Email and Paddock/Par Biweekly Meeting Summary Report	Picurro - 11
PTX0388	PAR344801	PAR344804	9/8/2006	Email from Tatiana Forman to Lisa Black, Angus Chen, Bill Giglio, Francine Rubin, Julie Szozda, Rebecca Taylor, Thomas Vogel, Farhan Aslam, Nicole Pace, Paul Campanelli, Robert Campanelli with attachment	Picurro - 12
PTX0389	PAR463341	PAR463344	10/3/2006	Email from Tatiana Forman to Lisa Black, Angus Chen, Bill Giglio, Francine Rubin, Julie Szozda, Rebecca Taylor, Thomas Vogel, Farhan Aslam, Nicole Pace, Paul Campanelli, Robert Campanelli with attachment	Picurro - 13
PTX0390	PAR343988	PAR343992	10/19/2006	Email exchange between Suzanne Messier, Nicole Pace, Paul Campanelli, Lonny Whitehead	Picurro - 14
PTX0391	PFE00598	PFE00599	9/4/2008	Letter from Mary Todas at Pfizer to Jennifer Simons at Paddock	Picurro - 15
PTX0392	PAR-MDL-00000596	PAR-MDL-00000598	6/7/2011	Letter from Vilayat Sayeed to Julie Szozda	Picurro - 18
PTX0393	PAR-MDL-00214122	PAR-MDL-00214123	4/13/2015	Letter from FDA to Zuriash Berhe at Par	Picurro - 19

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0394	PAR-MDL-00160616	PAR-MDL-00160617	9/15/2009	Email from Karen Rocco to Michelle Bonomi, Matthew Zrebiec, Julie Szozda, Donna Carluccio	Picurro - 20
PTX0395	PAR-MDL-00000032	PAR-MDL-00000052	12/13/2006	Letter from Julie Szozda from Par to Martin Shimer FDA	Picurro - 21
PTX0396	N/A	N/A	4/16/2008	William Mink FTC Investigational Hearing testimony	Mink - 01
PTX0397	PADD014645	PADD014682	9/13/2006	Backup Manufacturing and Supply Agreement between Unimed, Besins & Par	Mink - 02
PTX0398	PADD020855	PADD020855	9/5/2006	Re: T-gel	Mink - 03
PTX0399	PADD002070	PADD002071	10/27/2006	RE: T-gel tech transfer	Mink - 04
PTX0400	PADD037506	PADD037506	8/30/2006	Fw: Par/Solvay/Backup Manufacturing and Supply Agreement	Mink - 06
PTX0401	PADD-MDL-00001651	PADD-MDL-00001653	10/4/2007	RE: protocol of analytical transfer of control methods of Androgel	Mink - 07
PTX0402	PADD019849	PADD019851	4/11/2007	RE: analytical transfer	Mink - 08
PTX0403	PADD-MDL-00016895	PADD-MDL-00016897	7/9/2007	RE: AGel presentations	Mink - 09
PTX0404	PADD-MDL-00018276	PADD-MDL-00018277	2/3/2009	RE: Filing acknowledgement letter for Androgel alternate manufacturing site - Paddock laboratories	Mink - 10
PTX0405	PADD-MDL-00008621	PADD-MDL-00008622	4/15/2009	Email re: Paddock Approval	Mink - 11
PTX0406	PADD-MDL-00008693	PADD-MDL-00008694	4/21/2009	Capital equipment requirements for Paddocks.xls	Mink - 12
PTX0407	PADD-MDL-00006382	PADD-MDL-00006382	6/13/2008	Email and Capital equipment requirements for Paddock.xls	Mink - 13
PTX0408	PADD-MDL-00008767	PADD-MDL-00008789	5/11/2009	PO and quote	Mink - 14

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0409	PADD-MDL-00009045	PADD-MDL-00009046	9/18/2009	Stick Pack Equipment PO placed with Inever	Mink - 15
PTX0410	PADD-MDL-00009169	PADD-MDL-00009173	10/1/2009	RE: Holding tanks quote	Mink - 16
PTX0411	PADD-MDL-00011539	PADD-MDL-00011544	8/3/2010	FW: Inever stickpack machine	Mink - 17
PTX0412	PADD-MDL-00013174	PADD-MDL-00013174	8/4/2011	Telecon	Mink - 18
PTX0413	PADD-MDL-00015479	PADD-MDL-00015482	12/1/2011	Status Update - Qualification of Abbott equipment for AndroGel Packaging Meeting Minutes	Mink - 19
PTX0414	PADD-MDL-00015613	PADD-MDL-00015613	1/27/2012	RE: Testosterone Gel	Mink - 20
PTX0415	PADD00016480	PADD00016481	5/17/2012	RE: AndroGel	Mink - 21
PTX0416	PADD-MDL-00016537	PADD-MDL-00016539	7/11/2012	RE: T-Gel Data - Please discontinue the stability study	Mink - 22
PTX0417	PADD-MDL-00015924	PADD-MDL-00015924	4/11/2012	Email re Abbott T-Gel project	Mink - 23
PTX0418	PADD-MDL-00013261	PADD-MDL-00013261	8/17/2011	FW: Abbott T-Gel Batches	Mink - 24
PTX0419	PADD018244	PADD018244	8/2/2005	Testosterone Gel Team Meeting	Mink - 25
PTX0420	PADD029406	PADD029409	3/31/2005	Testosterone Gel 1%	Mink - 26
PTX0421	PADD-MDL-00008265	PADD-MDL-00008266	4/5/2005	RE: T-Gel Bottle Filler	Mink - 27
PTX0422	PADDMDL002118	PADDMDL002119	9/30/2005	Testosterone Gel	Mink - 28
PTX0423	ABBVIE- AGEL0809669	ABBVIE- AGEL0809674	6/9/2011	Email from Sales Communications to M. Kay, "Metabolics and GI Care A-LIST for Managers: 06.09.11	Jaeger - 13
PTX0424	ABBVIE- AGEL03267224	ABBVIE- AGEL03267224	00/00/0000	AndroGel Historical Information 2004-2015	Lipinski - 2

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0425	ABBVIE- AGEL03147984	ABBVIE- AGEL03147985	5/28/2015	FYI, attaching AndroGel Historical Information	Lipinski - 3
PTX0426	ABBVIE- AGEL00269527	ABBVIE- AGEL00269527	00/00/0000	Solvay Pharmaceuticals - Androgel Sales Report for the Watson Co-Promotion Agreement FY 2010	Lipinski - 7
PTX0427	Petrie01-031616	Petrie01-031616	3/14/2016	Stipulation between all Plaintiffs and Defendant, Actavis, Inc., regarding Rule 30(b)(6) notice of deposition	Petrie - 1
PTX0428	Petrie02-031616	Petrie02-031616	11/1/1995	Manual of Policies and Procedures Center for Drug Evaluation and Research	Petrie - 2
PTX0429	WTN00291967	WTN00291969	10/31/2006	Documentation of Litigation/Settlement Outcome for ANDA No. 76-737 1% Testosterone Gel	Petrie - 4
PTX0430	WTN0423327	WTN0423329	5/12/2014	FW: Androgel & Testim Update (ABBV, AUXL): FDA May Assign Therapeutic Equivalence Codes To 1% Testosterone Gels During Last Week of July 2014	Petrie - 5
PTX0431	WTN0315151	WTN0315165	5/25/2006	Proprietary R&D Meeting Minutes May 25, 2006	Petrie - 6
PTX0432	WTN0093989	WTN0094007	10/19/2006	Proprietary R&D Meeting Minutes - Draft	Petrie - 7
PTX0433	WTN0332444	WTN0332449	1/31/2011	Re: Testosterone Gel 1% ANDA. #076737	Petrie - 8
PTX0434	WTN0367686	WTN0367688	8/7/2014	Approval of sANDA	Petrie - 9
PTX0435	WTN0594217	WTN0594229	5/28/2008	Testosterone Gel 1% (Project #1529) Cross Functional Pre-Submission Team Meeting Minutes 5-28-08	Petrie - 10
PTX0436	WTN0532483	WTN0532483	September- 2004	Salt Lake City Supply Consensus September 2014	Petrie - 11

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0437	WTN0522878	WTN0522878	1/6/2012	RE: Androgel - can you have Janie start pushing FDA to approve the alternate API for Androgel - we might need to b ready sooner than later.	Petrie - 12
PTX0438	WTN0334538	WTN0334545	9/20/2013	Re: ANDA. 076737	Petrie - 13
PTX0439	WTN0404230	WTN0404236	2/13/2015	Re: ANDA. 076737/S-005 Testosterone Gel, 1% Sequence 0033	Petrie - 14
PTX0440	WTN0408989	WTN0408990	3/17/2015	Approval letter regarding sANDA	Petrie - 15
PTX0441	Petrie16-031616	Petrie16-031616	N/A	Actavis, Inc. - AndroGel Post-Approval Regulatory Chronology	Petrie - 16
PTX0442	WTN0093257	WTN0093260	3/23/2006	Email and Proprietary R&D Meeting Minutes March 23, 2006	Petrie - 17
PTX0443	WTN0323386	WTN0323469	3/23/2006	SLC Monthly Proprietary R&D Meeting	Petrie - 18
PTX0444	WTN0301512	WTN0301518	4/20/2006	Proprietary R&D Meeting Minutes	Petrie - 19
PTX0445	WTN0324864	WTN0324865	4/27/2006	Testosterone Gel Pump - Androgel Project Cross-Functional Team Meeting - 4/27/2006	Petrie - 20
PTX0446	WTN0324084	WTN0324129	N/A	Project Update dated July 20, 2006	Petrie - 21
PTX0447	WTN0315447	WTN0315449	8/18/2006	Re: Fw: t-gel pump activities D14EA5059E96994DF872571CD0078EB63	Petrie - 22
PTX0448	WTN0591651	WTN0591659	5/22/2015	Re: Testosterone Gel 1% ANDA. #076737, Sequence 0038 Proposed REMS with Medication Guide and REMS Supporting Document	Petrie - 23
PTX0449	WTN0593206	WTN0593208	8/19/2015	Re: Testosterone Gel 1% ANDA. #076737, Sequence 0041 Amendment to Proposed REMS with Medication Guide and REMS Supporting Document	Petrie - 24
PTX0450	WTN0594278	WTN0594289	11/5/2015	Supplement Approval	Petrie - 25

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0451	WTN0591677	WTN0591679	5/27/2015	Re: Testosterone Gel 1% ANDA. #076737, Sequence 0039 Labeling Supplement - Class Safety Labeling Update to Match RLD Approved Labeling	Petrie - 26
PTX0452	WTN0594290	WTN0594292	11/5/2015	Changes Being Effected Supplement Approval	Petrie - 27
PTX0453	N/A	N/A	4/1/2004	Guidance for Industry Changes to an Approved NDA or ANDA	Petrie - 28
PTX0454	WTN0313126	WTN0313162	3/24/2006	March 23 Proprietary R&D meeting draft minutes	Petrie - 29
PTX0455	WTN0313832	WTN0313928	4/21/2006	April 20 R&D meeting draft minutes	Petrie - 30
PTX0456	WTN0328635	WTN0328647	9/2/2006	Weekly Product Launch Updates 9-01-06	Petrie - 31
PTX0457	WTN0521977	WTN0521983	7/9/2010	Generic Operations Meeting Minutes	Petrie - 34
PTX0458	N/A	N/A	9/16/2016	HEB Purchase Data 1/1/2006-9/16/2010	
PTX0459	N/A	N/A	12/13/2010	Amerisource Bergen Invoice/Credits Data for Three Walgreen Chains 1/1/2004-12/13/2010	
PTX0460	N/A	N/A	9/23/2010	Ahold Purchase Data 1/3/2006-9/23/2010	
PTX0461	N/A	N/A	9/23/2010	Ahold Purchase Data 2/2/2006-9/23/2010	
PTX0462	N/A	N/A	3/31/2011	Safeway Purchase Data 1/1/2011-3/31/2011	
PTX0463	N/A	N/A	3/31/2012	Safeway Purchase Data 1/1/2012-3/31/2012	
PTX0464	N/A	N/A	6/31/2012	Safeway Purchase Data 4/1/2011-6/31/2011	
PTX0465	N/A	N/A	9/30/2011	Safeway Purchase Data 7/1/2011-9/30/2011	
PTX0466	N/A	N/A	12/31/2011	Safeway Purchase Data 10/1/2011-12/31/2011	
PTX0467	N/A	N/A	12/31/2010	Safeway Purchase Data 10/2/2010-12/31/2010	
PTX0468	ASCARXTD000000001	ASCARXTD000000001	2/2/2015	American Sales Company Purchase Data 9/24/2010-2/2/2015	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0469	ASCARXTD000000002	ASCARXTD000000002	1/29/2015	American Sales Company Purchase Data 5/8/2012-1/29/2015	
PTX0470	ASCARXTD000000003	ASCARXTD000000003	2/29/2016	American Sales Company Purchase Data 1/29/2015-2/29/2016	
PTX0471	ASCARXTD000000004	ASCARXTD000000004	2/4/2016	American Sales Company Purchase Data 1/29/2015-2/4/2016	
PTX0472	N/A	N/A	11/29/2010	Cardinal Health, Inc. Sales to Walgreens 1/2/2008-11/29/2010	
PTX0473	N/A	N/A	9/9/2010	Cardinal Health, Inc. Sales Data 1/4/2004-9/9/2010	
PTX0474	N/A	N/A	9/16/2010	HEB Purchase Data from 1/1/2006-9/16/2010	
PTX0475	HEBARXED000000001	HEBARXED000000001	1/15/2015	HEB DSD and Whse Purchases by Vial 9/10/2010-1/16/2015	
PTX0476	HEBARXTD000000002	HEBARXTD000000002	1/30/2016	HEB Purchase Data 1/2/2015-1/30/2016	
PTX0477	N/A	N/A	2/8/2016	Cardinal Health, Inc. Sales to Safeway 1/17/2015-2/8/2016	
PTX0478	N/A	N/A	9/30/2010	Walgreens Mail Service Purchases 1/1/2006-9/30/2010	
PTX0479	N/A	N/A	9/30/2010	Walgreens DSD and DC Purchases 1/1/2006-9/30/2010	
PTX0480	N/A	N/A	2006	Androgel 2006 Sales History - Safeway	
PTX0481	N/A	N/A	2007	Androgel 2007 Sales History - Safeway	
PTX0482	N/A	N/A	2008	Androgel 2008 Sales History - Safeway	
PTX0483	N/A	N/A	2009	Androgel 2009 Sales History - Safeway	
PTX0484	N/A	N/A	2010	Androgel 2010 Sales History - Safeway	
PTX0485	SFWARXED00005436	SFWARXED00005436	1/17/2015	Safeway Purchase Data 4/2/2012-1/17/2015	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0486	SFWARXED00005437	SFWARXED00005437	1/17/2015	Safeway Purchase Data 4/2/2012-1/17/2015	
PTX0487	SFWARXED00005438	SFWARXED00005438	1/17/2015	Safeway Purchase Data 4/2/2012-1/17/2015	
PTX0488	N/A	N/A	9/30/2010	SuperValu Androgel Sales History 1/1/2006-9/30/2010	
PTX0489	WLGARXTD00000001	WLGARXTD00000001	1/13/2015	Walgreens Purchase Data 1/1/2010-1/13/2015	
PTX0490	WLGARXTD00000002	WLGARXTD00000002	2015	Walgreens Purchase Data 2010-2015	
PTX0491	WLGARXTD00000003	WLGARXTD00000003	11/26/2013	Walgreens Purchase Data 9/23/2008-11/26/2013	
PTX0492	WLGARXTD00000004	WLGARXTD00000004	1/26/2015	Amerisource Bergen Invoice/Credits Data for Walgreen Accounts 12/13/2010-1/26/2015	
PTX0493	WLGARXTD00000005	WLGARXTD00000005	1/26/2015	Amerisource Bergen Invoice/Credits Data for Walgreen Accounts 12/13/2010-1/26/2015	
PTX0494	WLGARXTD00000006	WLGARXTD00000006	1/26/2015	Amerisource Bergen Invoice/Credits Data for Walgreen Accounts 12/13/2010-1/26/2015	
PTX0495	WLGARXTD00000007	WLGARXTD00000007	1/26/2015	Amerisource Bergen Summary Reports of Androgel for Walgreen Accounts 12/13/2010-1/26/2015	
PTX0496	WLGARXTD00000008	WLGARXTD00000008	1/26/2015	Amerisource Bergen Invoice/Credits Data for Walgreen Accounts 12/13/2010-1/26/2015	
PTX0497	WLGARXTD00000009	WLGARXTD00000009	Jan. 2016	Walgreen Purchase Data 1/2015-1/2016	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0498	WLGARXTD00000010	WLGARXTD00000010	1/29/2016	Walgreen Purchase Data 1/2/2015-1/29/2016	
PTX0499	WLGARXTD00000011	WLGARXTD00000011	1/30/2016	Walgreen Material Usage Report 1/2/2015-1/30/2016	
PTX0500	WLGARXTD00000012	WLGARXTD00000012	1/22/2015	Walgreen Purchase Data 9/3/2013-1/22/2015	
PTX0501	WTN0286660.14	WTN0286660.14	5/8/2005	WTN0286660.14 - WPI-000014 - FM4-4-Testosterone Gel v2.xls	
PTX0502	AGELMDL014-021565	AGELMDL014-021565	3/2/2006	Spreadsheet Tabs "Patent Upholds" and "Patent Invalid" showing that NPV would be nearly \$1.4 billion without generic entry but only \$200 million if generics entered	
PTX0503	AGEL MDL 014-021614	AGEL MDL 014-021614	3/22/2006	Spreadsheet tabs "Options", "Patent Upholds -5% growth", "Patent Upholds-flat sales"	
PTX0504	AGELMDL014000002	AGELMDL014000002	3/22/2006	AndroGel NPV (2006-2020, Five year plan sales) - docs discuss what-ifs re: winning or losing patent litigation	
PTX0505	AGEL MDL 014-021745	AGEL MDL 014-021745	5/1/2006	Spreadsheet tabs "Sheet1" Assume 3-player generic market - Watson and Par; "Options" AndroGel NPV (2006-2020, 3% increased sales line); "Settlement Income"; "Par Income"	
PTX0506	PAR 462827	PAR 462827	5/1/2006	Spreadsheet tabs "Par Generic Forecast - 1"; "Par Generic Forecast -2"; "Par Generic Forecast -3"; "Authorized Generic"	
PTX0507	AGEL-MDL-008-006635	AGEL-MDL-008-006635	N/A	Tab "AndroGel (Testim Patent)	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0508	AGELMDL014021579	AGELMDL014021579	3/6/2006	Sheet 1 - Androgel NVP (2006-2020) ~ Summary Solvay Option 1 ~ Patent Upholds ~ Patent Invalid ~ Solvay Authorized Generic ~ Watson #1- AG~Par #2-AG~Mrinol~Prometrium~Androgel Settlement~Watson-No AG~Par A....	
PTX0509	PAR-MDL-00172996	PAR-MDL-00172996	5/3/2010	Testosterone Gel Pk Forecast Apr 2010.xls	
PTX0510	PAR-MDL-00218635	PAR-MDL-00218635	N/A	Testosterone Gel Pk (Androgel) Forecast Jan 2015.xlsx	
PTX0511	PAR-MDL-00218636	PAR-MDL-00218636	N/A	Testosterone Gel Pk (Androgel) Forecast July 2015 - new cogs.xlsx	
PTX0512	PAR-MDL-00218637	PAR-MDL-00218637	N/A	Testosterone Gel Pk (Androgel) Forecast June 2015 NPF.xlsx	
PTX0513	PAR-MDL-00218638	PAR-MDL-00218638	N/A	Testosterone Gel Pk (Androgel) Forecast Sep 2014.xlsx	
PTX0514	PAR-MDL-00218639	PAR-MDL-00218639	N/A	Testosterone Gel Pk (Androgel) forecast Sept 2015 launch fcst.xlsx	
PTX0515	PAR-MDL-00218640	PAR-MDL-00218640	N/A	Testosterone Pump Forecast Feb 2014.xlsx	
PTX0516	PER-00000004	PER-00000004	7/26/2013	Androgel 1% Model - 7-24-13 (BD).xlsx	
PTX0517	PER-00000945	PER-00000945	1/27/2015	Book1.xlsx	
PTX0518	PER-00000946	PER-00000946	12/13/2011	Androgel Model Comparison - 11-9-11 (1).xlsx	
PTX0519	PER-00000947	PER-00000947	5/15/2012	Androgel 1%.xlsx	
PTX0520	PER-00000948	PER-00000948	6/6/2012	Androgel 3 scenarios.xlsx	
PTX0521	PER-00000950	PER-00000950	7/19/2012	Androgel Model - 8-7-2008.xlsx	
PTX0522	WTN0286660.06	WTN0286660.06	1/1/2006	WTN0286660.06 - WPI-000006 - FM4-2- Testosterone Gel v1.xls	
PTX0523	WTN0286660.07	WTN0286660.07	1/1/2006	WTN0286660.07 - WPI-000007 - FM4-2- Testosterone Gel v2.xls	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0524	WTN0286660.10	WTN0286660.10	1/1/2006	WTN0286660.10 - WPI000010 - FM4-3-Testosterone Gel v1.xls	
PTX0525	WTN0286660.11	WTN0286660.11	1/1/2006	WTN0286660.11 - WPI000011 - FM4-3-Testosterone Gel v2.xls	
PTX0526	WTN0286660.12	WTN0286660.12	9/28/2004	WTN0286660.12 - WPI-000012 - FM4-4-Testosterone Gel TEST.xls	
PTX0527	WTN0286660.13	WTN0286660.13	10/11/2014	WTN0286660.13 - WPI-000013 - FM4-4-Testosterone Gel v1.xls	
PTX0528	WTN0286660.19	WTN0286660.19	1/5/2004	WTN0286660.19 - WPI-000019 - FM4.1-Testosterone v1-R.xls	
PTX0529	WTN0286660.21	WTN0286660.21	1/5/2004	WTN0286660.21 - WPI-000021 - FM4.1-Testosterone v2-R.xls	
PTX0530	WTN0286660.24	WTN0286660.24	5/18/2005	WTN0286660.24 - WPI-000024 - FM5-1-Testosterone Gel v1.xls	
PTX0531	WTN0476839	WTN0476839	11/18/2011	Brand Name Androgel Brand Dollars FY (IMS data) (000,000s) 1057 Generic Name Testosterone Gel	
PTX0532	WTN0526606	WTN0526606	6/1/2011	Brand Name Androgel Brand Dollars FY (IMS data) (000,000s) 993 Generic Name Testosterone Gel	
PTX0533	WTN0550824	WTN0550824	9/28/2010	Brand Name Androgel Brand Dollars FY (IMS data) (000,000s) 811 Generic Name Testosterone Gel	
PTX0534	WTN0550825	WTN0550825	1/25/2011	Brand Name Androgel Brand Dollars FY (IMS data) (000,000s) 863 Generic Name Testosterone Gel	
PTX0535	WTN0550826	WTN0550826	7/7/2010	Brand Name Androgel Brand Dollars FY (IMS data) (000,000s) 760 Generic Name Testosterone Gel	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0536	WTN0550827	WTN0550827	11/4/2011	Brand Name Androgel Brand Dollars FY (IMS data) (000,000s) 1058 Generic Name Testosterone Gel	
PTX0537	WTN0571867	WTN0571867	9/6/2011	Brand Name Androgel Brand Dollars FY (IMS data) (000,000s) 1058 Generic Name Testosterone Gel	
PTX0538	WTN0571988	WTN0571988	11/18/2011	Brand Name Androgel Brand Dollars FY (IMS data) (000,000s) 1057 Generic Name Testosterone Gel	
PTX0539	WTN0572110	WTN0572110	2/23/2012	Brand Name Androgel Brand Dollars FY (IMS data) (000,000s) 1128 Generic Name Testosterone Gel	
PTX0540	WTN0572362	WTN0572362	8/15/2012	Brand Name Androgel Brand Dollars FY (IMS data) (000,000s) 1226 Generic Name Testosterone Gel	
PTX0541	WTN0572488	WTN0572488	12/6/2012	Brand Name Androgel Brand Dollars FY (IMS data) (000,000s) 1348 Generic Name Testosterone Gel	
PTX0542	WTN0572613	WTN0572613	3/5/2013	Brand Name Androgel Brand Dollars FY (IMS data) (000,000s) 1408 Generic Name Testosterone Gel	
PTX0543	WTN0572739	WTN0572739	5/24/2013	Brand Name Androgel Brand Dollars FY (IMS data) (000,000s) 1432 Generic Name Testosterone Gel	
PTX0544	WTN0572865	WTN0572865	8/23/2013	Brand Name Androgel Brand Dollars FY (IMS data) (000,000s) 1438 Generic Name Testosterone Gel	
PTX0545	WTN0572991	WTN0572991	1/2/2014	Brand Name Androgel Brand Dollars FY (IMS data) (000,000s) 1422 Generic Name Testosterone Gel	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0546	WTN0573117	WTN0573117	2/28/2014	Brand Name Androgel Brand Dollars FY (IMS data) (000,000s) 1413 Generic Name Testosterone Gel	
PTX0547	WTN0573368	WTN0573368	7/10/2014	Brand Name Androgel Brand Dollars FY (IMS data) (000,000s) 1413 Generic Name Testosterone Gel	
PTX0548	WTN0574192	WTN0574192	11/18/2011	Brand Name Androgel Brand Dollars FY (IMS data) (000,000s) 1057 Generic Name Testosterone Gel	
PTX0549	WTN0594329	WTN0594329	N/A	Spreadsheet	
PTX0550	WTN0594331	WTN0594331	N/A	N/A	
PTX0551	N/A	N/A	N/A	Watson Forecast (45b49877-1241-41e0-9462-0e73a3d2e509.xlsx)	
PTX0552	AGEL-MDL-BUR-000007	AGEL-MDL-BUR-000007	N/A	N/A	
PTX0553	AGEL-MDL-020-000007	AGEL-MDL-020-000007	N/A	N/A	
PTX0554	AGEL-MDL-020-000008	AGEL-MDL-020-000008	N/A	N/A	
PTX0555	AGEL-MDL-020-000009	AGEL-MDL-020-000009	N/A	N/A	
PTX0556	AGEL-MDL-020-000010	AGEL-MDL-020-000010	N/A	N/A	
PTX0557	AGEL-MDL-020-000011	AGEL-MDL-020-000011	N/A	N/A	
PTX0558	AGEL-MDL-020-000012	AGEL-MDL-020-000012	N/A	N/A	
PTX0559	AGEL-MDL-020-000015	AGEL-MDL-020-000015	N/A	N/A	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0560	AGEL-MDL-020-000016	AGEL-MDL-020-000016	N/A	N/A	
PTX0561	AGEL-MDL-020-000017	AGEL-MDL-020-000017	N/A	N/A	
PTX0562	AGEL-MDL-020-000018	AGEL-MDL-020-000018	N/A	N/A	
PTX0563	AGEL-MDL-020-000019	AGEL-MDL-020-000019	N/A	N/A	
PTX0564	AGEL-MDL-020-000020	AGEL-MDL-020-000020	N/A	N/A	
PTX0565	AGEL-MDL-020-000936	AGEL-MDL-020-000936	N/A	N/A	
PTX0566	AGEL-MDL-020-003832	AGEL-MDL-020-003832	N/A	N/A	
PTX0567	AGEL-MDL-020-000001_2003	AGEL-MDL-020-000001_2003	N/A	Production Replacement File for AGEL-MDL-020-000001_2003	
PTX0568	AGEL-MDL-020-000001_2004	AGEL-MDL-020-000001_2004	N/A	Production Replacement File for AGEL-MDL-020-000001_2004	
PTX0569	AGEL-MDL-020-000001_2005	AGEL-MDL-020-000001_2005	N/A	Production Replacement File for AGEL-MDL-020-000001_2005	
PTX0570	AGEL-MDL-020-000001_2006	AGEL-MDL-020-000001_2006	N/A	Production Replacement File for AGEL-MDL-020-000001_2006	
PTX0571	AGEL-MDL-020-000001_2007	AGEL-MDL-020-000001_2007	N/A	Production Replacement File for AGEL-MDL-020-000001_2007	
PTX0572	AGEL-MDL-020-000001_2008	AGEL-MDL-020-000001_2008	N/A	Production Replacement File for AGEL-MDL-020-000001_2008	
PTX0573	AGEL-MDL-020-000001_2009	AGEL-MDL-020-000001_2009	N/A	Production Replacement File for AGEL-MDL-020-000001_2009	
PTX0574	AGEL-MDL-020-000001_2010_Q1Q3	AGEL-MDL-020-000001_2010_Q1Q3	N/A	Production Replacement File for AGEL-MDL-020-000001_2010_Q1Q3	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0575	AGEL-MDL-020-000001_2010_Q4	AGEL-MDL-020-000001_2010_Q4	N/A	Production Replacement File for AGEL-MDL-020-000001_2010_Q4	
PTX0576	PRGO-00000332	PRGO-00000332	N/A	N/A	
PTX0577	ABC00000091	ABC00000091	N/A	N/A	
PTX0578	N/A	N/A	N/A	USC 52153_2011 to Apr 2013.xlsx	
PTX0579	N/A	N/A	N/A	Berger and Montague NSP.xlsx	
PTX0580	N/A	N/A	N/A	NSP_USC 52153_2007-2010_2007.xls	
PTX0581	N/A	N/A	N/A	NSP_USC 52153_2007-2010_2008.xls	
PTX0582	N/A	N/A	N/A	NSP_USC 52153_2007-2010_2009.xls	
PTX0583	N/A	N/A	N/A	NSP_USC 52153_2007-2010_2010.xls	
PTX0584	N/A	N/A	N/A	Berger and Mont 52153 NSP_0616.xlsx	
PTX0585	N/A	N/A	N/A	52150.xls	
PTX0586	N/A	N/A	N/A	Androgel Medi-Span PriceRX WAC Data.xlsx	
PTX0587	N/A	N/A	N/A	Androgens PriceRX WACs.xlsx	
PTX0588	N/A	N/A	N/A	Androgel & Generics PriceRx Price History.xls	
PTX0589	N/A	N/A	N/A	T5AB volumes.xlsx	
PTX0590	MEI_ANDRO 00032300B	MEI_ANDRO 00032300B	N/A	N/A	
PTX0591	ABBVIE- AGEL00519014	ABBVIE- AGEL00519014	12/31/2013	Androgel Historical Information 2004-2013_V8.xlsx	
PTX0592	ABBVIE- AGEL00913051	ABBVIE- AGEL00913051	N/A	Spreadsheet: Androgel Indirect Sales from 01-Apr-2011 to 10-Mar-2015v2.CSV	
PTX0593	PRGO-00000331	PRGO-00000331	N/A	Spreadsheet: Perrigo Transaction Data	
PTX0594	ABBVIE- AGEL03268523	ABBVIE- AGEL03268523	1/12/2016	Spreadsheet: Androgel Direct Sales from 01-Apr-2011 to 12-Jan-2016.xlsx	
PTX0595	PAR-MDL-00218627	PAR-MDL-00218627	N/A	Spreadsheet: Testosterone Gel 2015 Rebates Data	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0596	ABBVIE- AGEL03267050	ABBVIE- AGEL03267050	N/A	Spreadsheet: Androgel Indirect Sales from 11-Mar-2015 to 31-Dec-2015.xlsx	
PTX0597	AGELMDL014019987	AGELMDL014019987	5/1/2006	Sheet 1 - Assume 3 player generic market ~ Options - Androgel NVP (2006-2020, 3% increased sales line) ~ Settlement Income ~ Par Income ~ Patent Upholds-3%....	
PTX0598	PAR463037	PAR463037	3/26/2007	Target Launch	
PTX0599	LWD00001	LWD00001	N/A	Androgel Purchases from October 2004-2005	
PTX0600	LWD00002	LWD00002	N/A	Androgel Purchases from 2006-2010	
PTX0601	LWD00202	LWD00202	N/A	Androgel Purchases from 10/1/2010-6/12/2015	
PTX0602	LWD00203	LWD00203	N/A	Androgel Purchases from 6/12/2015-1/31/2016	
PTX0603	LWD00204	LWD00204	N/A	Generic Androgel Purchases from 1/01/2015-2/02/2016	Gielen - 5
PTX0604	LWD00205	LWD00205	N/A	Chargebacks re Generic Androgel from 1/01/2015-2/02/2016	
PTX0605	MEI_ANDRO 0000001	MEI_ANDRO 0000001	N/A	Meijer Androgel Purchase Data from Oct. 2004 to December 2005	
PTX0606	MEI_ANDRO 000000002	MEI_ANDRO 000000002	N/A	Meijer Androgel Purchase Data from December 2005 to August 2010	
PTX0607	MEI_ANDRO 00000004	MEI_ANDRO 00000004	N/A	Kerr Androgel Purchase Data and Kerr Androgel Sales to Meijer from Jan. 2006 to September 2010	
PTX0608	MEI_ANDRO_0003230 0B	MEI_ANDRO_0003230 0B	N/A	Replacement File for both MEI_ANDRO 00032300 and MEI_ANDRO 00032300A	
PTX0609	MEI_ANDRO_0003230 1	MEI_ANDRO_0003230 1	N/A	Data 2015.0228 to 2016.0131 (2.25.16)(FINAL)	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0610	RDC00003	RDC00003	N/A	Rochester Drug Cooperative, Inc. Monopril HCT Purchases from 10/01/2004 through 6/27/2011	
PTX0611	RDC00004	RDC00004	N/A	Rochester Drug Cooperative, Inc. Monopril HCT Product Chargebacks from 10/01/2004 through 6/27/2011	
PTX0612	RDC00005	RDC00005	N/A	Rochester Drug Cooperative, Inc. AndroGel Product Sales from 10/01/2004 through 06/27/2011	
PTX0613	RDC00006	RDC00006	N/A	Rochester Drug Cooperative, Inc. Monopril HCT Product Sales from 10/01/2004 through 6/27/2011	
PTX0614	RDC00007	RDC00007	N/A	Rochester Drug Cooperative, Inc. Wellbutrin XL Product Sales from 10/01/2004 through 6/27/2011	
PTX0615	RDC00033	RDC00033	N/A	Rochester Drug Cooperative, Inc. Monopril HCT Purchases from 1/1/2002 through 9/30/2004	
PTX0616	RDC00034	RDC00034	N/A	Rochester Drug Cooperative, Inc. Monopril Product Sales from 1/1/2002 through 9/30/2004	
PTX0617	RDC000250	RDC000250	N/A	Rochester Drug Cooperative, Inc. Item Purchases from 1/1/2015 through 2/15/2016	
PTX0618	RDC000251	RDC000251	N/A	Rochester Drug Cooperative, Inc. Selected Product Chargebacks from 1/1/2015 through 2/15/2016	
PTX0619	RDC000252	RDC000252	N/A	Rochester Drug Cooperative, Inc. AndroGel Product Sales from 6/28/2011 through 2/15/2016	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0620	RDC000248	RDC000248	N/A	Rochester Drug Cooperative, Inc. Item Purchases from 10/29/2010 through 6/30/2015	
PTX0621	RDC000249	RDC000249	N/A	Rochester Drug Cooperative, Inc. Selected Product Chargebacks from 10/29/2010 through 6/30/2015	
PTX0622	N/A	N/A	N/A	Kerr Androgel Sales and Purchases 2004-2011	
PTX0623	AGEL_MDL_004-001501	AGEL_MDL_004-001792	3/5/2008	FTC Transcript of James B. Hynd	
PTX0624	SLV474982	SLV474982	8/15/2006	Emails re: Project Tulip	
PTX0625	WTN0039287	WTN0039293	9/14/2006	Email re: AndroGel Settlement: External communications follow up	
PTX0626	WTN0106958	WTN0106959	9/25/2006	Email re: Solvay (with attached forecast)	
PTX0627	AGEL-MDL-014-034235	AGEL-MDL-014-034236	3/13/2006	Email re: Confidential- Client attorney privileged: Androgel settlement scenarios (with attached scenario planning)	
PTX0628	AGEL-MDL-014-034236	AGEL-MDL-014-034252	3/13/2006	Spreadsheet: Adrgel scenario planning 031306.xls	
PTX0629	PAR343761	PAR343761	00/00/2019	Impact of Generic Competition in 2007 with Three Generic Competitors	
PTX0630	AGEL-MDL-012-005928	AGEL-MDL-012-005929	2/1/2007	Email re: Risk Analysis (with attached Analysis)	
PTX0631	SLV448079	SLV448079	00/00/2010	Spreadsheets showing impact of different factors	
PTX0632	WTN0286660.25	WTN0286660.25	5/18/2005	Spreadsheet	
PTX0633	WTN0286660.27	WTN0286660.27	9/12/2005	Spreadsheet	
PTX0634	WTN0286660.35	WTN0286660.35	6/15/2006	Spreadsheet	
PTX0635	AGEL-MDL-019-002994	AGEL-MDL-019-003108	00/00/0000	Power Point Presentation: Forecasting Essentials	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0636	AGEL MDL 001-014921	AGEL MDL 001-014947	5/19/2003	Email re: Definitive Agreement	
PTX0637	PAR147488	PAR147488	00/00/2007	Impact of Generic Competition in 2007 with Three Generic Competitors	
PTX0638	PAR345028	PAR345028	00/00/2006	Androgel IMS	
PTX0639	SLV587000	slv587012	00/00/0000	Power Point Presentation: Business Outlook without Settlement	
PTX0640	AGELMDL008002633	AGELMDL008002645	00/00/0000	Power Point Presentation: Life Cycle Management Plan Low Volume Gel Update	
PTX0641	WTN0320633	WTN0320634	5/13/2004	Agenda- Monthly Proprietary R&D Meeting	
PTX0642	WTN0312650	WTN0312651	6/16/2005	Agenda- Monthly Proprietary R&D Meeting	
PTX0643	WTN0313265	WTN0313271	4/13/2006	Watson Pharmaceuticals, Inc. R & D Monthly Update Meeting	
PTX0644	WTN0300495	WTN0300521	7/19/2005	Watson Laboratories- Inc. Installation and Operational Qualification Protocol: 575 Compressed Air System T-Gel Renovation Final Report	
PTX0645	WTN0323227	WTN0323229	1/28/2006	Email re: T-Gel (ANDA #76-737) Approved 27 Jan 2006	
PTX0646	BNS0004158	BNS0004158	7/28/2006	Email re: Androgel-litigation update- Confidential	
PTX0647	PAR343586	PAR343588	2/24/2006	Email re: Solvay	
PTX0648	WTN00289626	WTN00289722	11/3/2008	Letter with attached Memo in support of the Androgel Agreements	
PTX0649	AGEL-MDL-014-029990	AGEL-MDL-014-030039	9/19/2006	Solvay Pharmaceuticals, Inc. Business Review 2007-2011 Plan Version 2	
PTX0650	N/A	N/A	7/1/2011	Paul Campanelli IH Transcript	
PTX0651	N/A	N/A	7/10/2008	Scott Tarriff FTC IH Transcript	
PTX0652	N/A	N/A	2/6/2008	John MacPhee FTC IH Transcript	
PTX0653	N/A	N/A	6/10/2015	Difei Yang IH Transcript	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0654	N/A	N/A	8/14/2013	Par Pharmaceuticals Companies, Form S-4 Registration Statement	
PTX0655	N/A	N/A	2/14/2012	Watson Subsidiaries of the Company	
PTX0656	N/A	N/A	12/31/2005	Solvay 2005 Annual Report	
PTX0657	N/A	N/A	12/31/2006	Solvay 2006 Annual Report	
PTX0658	N/A	N/A	12/31/2005	Watson 2005 Annual Report	
PTX0659	N/A	N/A	12/31/2006	Watson 2006 Annual Report	
PTX0660	N/A	N/A	12/31/2005	Par 2005 Annual Report	
PTX0661	N/A	N/A	12/31/2006	Par 2006 Annual Report - 10-K	
PTX0662	N/A	N/A	2/26/2015	Solvay 2014 Results Presentation	
PTX0663	N/A	N/A	00/00/0000	Model v11 no AG	
PTX0664	N/A	N/A	00/00/0000	Model v11	
PTX0665	N/A	N/A	00/00/0000	ParPaddock Consolidated Projection	
PTX0666	N/A	N/A	00/00/0000	Solvay Consolidated Projection	
PTX0667	N/A	N/A	00/00/0000	Watson Consolidated Projection	
PTX0668	N/A	N/A	00/00/0000	Reverse Payment Calculation	
PTX0669	N/A	N/A	00/00/0000	Weighted average cost	
PTX0670	N/A	N/A	00/00/0000	Diversification	
PTX0671	N/A	N/A	00/00/0000	Elasticity Analysis	
PTX0672	N/A	N/A	00/00/0000	Introduction to Finance- Excerpt	
PTX0673	N/A	N/A	00/00/0000	Model v11 figure 17a	
PTX0674	N/A	N/A	00/00/0000	Model v11 Par payoffs	
PTX0675	N/A	N/A	00/00/0000	Model v11 Par withdraw from Lit	
PTX0676	N/A	N/A	00/00/0000	Model v11 risk aversion	
PTX0677	N/A	N/A	00/00/0000	Modification A of Cremieux Exhibit 12	
PTX0678	N/A	N/A	00/00/0000	Modification B of Cremieux Exhibit 12	
PTX0679	N/A	N/A	00/00/0000	Par Ownership v2	
PTX0680	N/A	N/A	00/00/0000	Watson Ownership v2	
PTX0681	N/A	N/A	00/00/0000	Model v11 Excl Backup Mfgr	
PTX0682	PAR462899	PAR462899	00/00/0000	Forecast	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0683	PAR458952	PAR458952	00/00/0000	Forecast	Campanelli 6
PTX0684	AGEL-MDL-014-021840	AGEL-MDL-014-021840	N/A	Forecast	
PTX0685	AGEL-MDL-014-021596	AGEL-MDL-014-021596	N/A	Forecast	
PTX0686	AGEL-MDL-014-020062	AGEL-MDL-014-020062	N/A	Forecast	
PTX0687	AGEL-MDL-014-019956	AGEL-MDL-014-019956	N/A	Forecast	
PTX0688	N/A	N/A	N/A	COMPOSITE: Back-up Materials to Keith Leffler's Reply Report Date 05/19/2017	
PTX0689	N/A	N/A	N/A	COMPOSITE: Back-Up Materials to Keith Leffler's Expert Report Date 08/19/2016	
PTX0690	CVSMKS-ANDRO-000001	CVSMKS-ANDRO-000001		McKesson subpoenaed data	Griffin - 04 03/16/2016
PTX0691	CVS-ANDRO-0078407	CVS-ANDRO-0078407	10/31/2012	CVS DC Purchase Data 2011 - 2012	Griffin - 13 03/16/2016
PTX0692	CVS-ANDRO-0078406	CVS-ANDRO-0078406	12/23/2015	Attorney Client Work Document, Mail Direct Generic purchases for Perrigo Testosterone NDC 45802-0116-65 March-December 2015	Griffin - 11 03/16/2016
PTX0693	CVS-ANDRO-0078405	CVS-ANDRO-0078405	12/31/2015	McKesson AndroGel Brand and Generic	Griffin - 07 03/16/2016
PTX0694	CVS-ANDRO-0078404	CVS-ANDRO-0078404	12/31/2015	PR Brand AndroGel Sales March 2015 - December 2015	Griffin - 06 03/16/2016
PTX0695	CVS-ANDRO-0078403	CVS-ANDRO-0078403	12/31/2015	Cardinal AndroGel Brand and Generic	Griffin - 05 03/16/2016
PTX0696	CVS-ANDRO-0076402	CVS-ANDRO-0076402	12/31/2015	DC Receipts for Testosterone Items 135377 and 135378	Griffin - 12 03/16/2016
PTX0697	CVS-ANDRO-0061321	CVS-ANDRO-0061321	3/31/2003	McKesson Corp. Generic Delay Androgel CVS Sales 12/1/2012 - 3/31/2013	Griffin - 03

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0698	CVS-ANDRO-0061320	CVS-ANDRO-0061320	11/30/2012	McKesson Corp. Generic Delay Androgel CVS Sales 9/1/2012 - 11/30/2012	Griffin - 03
PTX0699	CVS-ANDRO-0061319	CVS-ANDRO-0061319	09/31/2012	McKesson Corp. Generic Delay Androgel CVS Sales 9/1/2011 - 8/31/2012	Griffin - 03
PTX0700	CVS-ANDRO-0061318	CVS-ANDRO-0061318	11/30/2013	McKesson Corp. Generic Delay Androgel CVS Sales 8/1/2013 - 11/30/2013	Griffin - 03
PTX0701	CVS-ANDRO-0061317	CVS-ANDRO-0061317	7/31/2013	McKesson Corp. Generic Delay Androgel CVS Sales 4/1/2013 - 7/31/2013	Griffin - 03
PTX0702	CVS-ANDRO-0061316	CVS-ANDRO-0061316	8/31/2011	AndroGel Stat File Detail, McKesson Corp. Generic Delay AndroGel CVS Sales 1/1/2011 - 8/31/2011	Griffin - 03 03/16/2016
PTX0703	CVS-ANDRO-0061315	CVS-ANDRO-0061315	3/31/2015	CVSHealth, Cardinal-23141, January 2011 - March 2015	Griffin - 10 03/16/2016
PTX0704	CVS-ANDRO-0061314	CVS-ANDRO-0061314	3/12/2015	CVSHealth - Retail 12/01/13 - 3/12/15	Griffin - 09 03/16/2016
PTX0705	CVS-ANDRO-0061313	CVS-ANDRO-0061313	3/12/2015	CVSHealth - Mail 12/1/13 - 3/12/15	Griffin - 08 03/16/2016
PTX0706	CVS-ANDRO-0000007	CVS-ANDRO-0000007	1/31/2011	Data	Griffin - 18 (05/24/2012)
PTX0707	CVS-ANDRO-0000006	CVS-ANDRO-0000006	01/31/2011 & 08/19/2016	Data	Griffin - 11 (05/24/2012)
PTX0708	RA-ANDRO-0034574	RA-ANDRO-0034574	3/31/2015	Rite Aid Indirect Purchases 4/1/2015-13/31/15	McMahon - 05 (03/30/2016)
PTX0709	RA-ANDRO-0034573	RA-ANDRO-0034573	3/31/2015	Rite Aid Indirect Purchases 12/1/10 - 3/31/15	McMahon - 04 (03/30/2016)
PTX0710	RA-ANDRO-0034572	RA-ANDRO-0034572	3/31/2015	Rite Aid Androgel Direct Purchases 12/01/10 - 03/31/15	McMahon - 02 (03/30/2016)
PTX0711	RA-ANDRO-0034576	RA-ANDRO-0034576	5/16/2016	Rite Aid DSD Purchases 12/1/10 - 5/16/16	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0712	RA-ANDRO-0034575	RA-ANDRO-0034575	7/31/2007	Brooks/Eckerd Direct Purchases January 2006 - November 2006, January 2007 - July 2007	
PTX0713	RA-ANDRO-0000010	RA-ANDRO-0000010	12/20/2010	Rite Aid DC purchases	McMahon - 06 (02/24/2012)
PTX0714	RA-ANDRO-0000009	RA-ANDRO-0000009	11/30/2010	Rite Aid DSD purchases	McMahon - 05 (02/24/2012)
PTX0715	ABBVIE- AGEL01560132	ABBVIE- AGEL01560135	N/A	AndroGel_Revised 1% Discontinuation HCP Emails_2.19.14.pdf	
PTX0716	ABBVIE- AGEL03147973	ABBVIE- AGEL03147975	4/1/2015	First Amendment to Co-Promotion Agreement between AbbVie Products LLC and Actavis Pharma	
PTX0717	ABC00000071	ABC00000078	4/2/2012	Brand to Generic Impact FY 13-15-V7.xlsx	
PTX0718	AGEL MDL 001- 000902	AGEL MDL 001- 000925	N/A	ANDRODERM	Armstrong - 2
PTX0719	AGEL MDL 001- 001003	AGEL MDL 001- 001056	N/A	Testosterone Deficiency in Men: Causes, Diagnosis, and Treatment Options With information on Androderm CIII Testosterone Transdermal System	Armstrong - 8
PTX0720	AGEL MDL 001- 001080	AGEL MDL 001- 001086	3/28/2002	Watson Laboratories - Utah Generic Testosterone Topical Gel (Project 8703) Joint Corona/SLC Team Meeting March 28, 2002 in Utah Minutes	Armstrong - 13
PTX0721	AGEL MDL 001- 001087	AGEL MDL 001- 001093	N/A	Androgel Sales forecast	Armstrong - 14
PTX0722	AGEL MDL 001- 004301	AGEL MDL 001- 004375	12/1/2002	AndroGel 2003 Business Plan AndroGel (testosterone gel) 1% CIII	Casbon - 2
PTX0723	AGEL MDL 001- 004395	AGEL MDL 001- 004413	Jun-00	AndroGel Unimed Pharmaceuticals, Inc. June, 2000	Casbon - 5

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0724	AGEL MDL 002-011853	AGEL MDL 002-011877	10/31/2002	Letter from Department of Health & Human Services to Diane Myers (Auxilium Pharmaceuticals, Inc.) re NDA dated December 31, 2001 for Testim 1%, 50 mg, 100 mg	
PTX0725	AGEL-MDL-001-014873	AGEL-MDL-001-014879	5/2/2003	Fax re: Binding Term Sheet w/ Attach signed Binding Term Sheet between Par Pharmaceutical and Paddock Labs	
PTX0726	AGEL-MDL-006-0003787	AGEL-MDL-006-0003807	2/28/2006	Solvay Pharmaceuticals, Inc. Strategic Response to Generic Competition Preview of Preliminary Findings	
PTX0727	AGEL-MDL-008-007567	AGEL-MDL-008-007569	6/13/2008	Email from Brian Mitchell to Jean-Louis Anspach re AndroGel Pricing Strategy	
PTX0728	AGEL-MDL-008-009603	AGEL-MDL-008-009615	Apr-07	New Business Development Steering Committee	
PTX0729	AGEL-MDL-008-012844	AGEL-MDL-008-012858	8/12/2008	Solvay AndroGel Price Increase Recommendation	
PTX0730	AGEL-MDL-013-034583	AGEL-MDL-013-034663	4/21/2008	Solvay Pharmaceuticals, Inc. AndroGel Marketing Strategy	
PTX0731	AGEL-MDL-013-042143	AGEL-MDL-013-042143	3/15/2007	Email from Frederick Waithe to Brian Hare, Juliana Hardy, Jay Janco re Testim Generic Assumption in 5YP	
PTX0732	AGEL-MDL-015-005627	AGEL-MDL-015-005675	N/A	AndroGel 2009 Business Plan Submitted by Brian Mitchell, John Rodda, Derek Rieder, Sara Lehr September 2008	
PTX0733	McK00280	McK00286	6/7/2007	McKesson Intra Company Correspondence from Anthony Dolan to Jack Fragle re Albertsons/SuperValu - Fourth Amendment to Supply Agreement	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0734	PADD015598	PADD015612	9/13/2006	Par/Paddock- Solvay Patent License Agreement dated September 13, 2006	Kay - 14
PTX0735	PADD016201	PADD016230	10/8/2003	Par Pharmaceutical Product Development, Manufacturing and Supply Agreement by and between Paddock Laboratories, Inc., and Par Pharmaceutical, Inc. Dated as of October 8, 2003	
PTX0736	PAR 00137	PAR 00145	8/21/2003	Email from Joseph Todisco to Mary Beth Rehberger re Par Strategic Plan 8.21.2003	Campanelli
PTX0737	PAR 455754	PAR 455770	6/10/2005	Testosterone Gel 1% Executive Summary	
PTX0738	PAR381907	PAR381927	9/13/2006	Co-Promotion Agreement between Solvay Pharmaceuticals, Inc., Unimed Pharmaceuticals, Inc., and Par Pharmaceutical Companies	Kay - 16
PTX0739	PAR455999	PAR456016	5/11/2006	IMS Update 1Q06 Testosterone Gel 1% Executive Summary	
PTX0740	SLV305423	SLV305438	N/A	AndroGel Financial Planning Assumptions (Testim Generic -15%)	
PTX0741	SLV506500	SLV506507	8/21/2006	Project Tulip 21 August 2006	
PTX0742	SLV526640	SLV526645	N/A	Draft AndroGel 2007 Executive Summary	
PTX0743	SOLVAY 016745	SOLVAY 016774	7/18/2003	Draft AndroGel 1% (testosterone gel) CIII Internal Q&A	
PTX0744	SOLVAY 033648	SOLVAY 033909	6/25/2003	AndroGel Pricing Research Introduction of AndroGel Pump and New Competitive Entries Final Report - Consumers	
PTX0745	SOLVAY 040776	SOLVAY 040797	6/30/2002	2003 AndroGel Business Planning Meeting Androgen Market Trends & Projections	
PTX0746	SOLVAY 104970	SOLVAY 104980	12/6/2001	AndroGel Life-Cycle Proposal: Generic Opportunities	Kay - 23; Janco - 3
PTX0747	SOLVAY 108895	SOLVAY 108925	8/28/2001	AndroGel 2002 Business Plan	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0748	Solvay ED 0082431	Solvay ED 0082434	6/18/2002	AndroGel Generic Proposal. Sub-headings: Product Situation, Market Potential, Historic Innovator Approaches, Recommendations and Rationale	Kay - 24; Janco - 4
PTX0749	SOLVAY034604	SOLVAY034605	4/6/2000	From Pascal Andre to Bob Dudley and Bob Solheim Ref UNIMED - OUTLOOK 2000	
PTX0750	UPIED0109688	UPIED0109806	6/18/1999	Email from David Knocke to Michele Alm, et al. re FW: ppt slides W/ Attach: ADNROGEL 6-17-99.ppt, Timeline.xls	
PTX0751	UPIED0109976	UPIED0109979	3/1/2000	AndroGel Pricing March 1, 2000	
PTX0752	UPIED0127894	UPIED0128011	12/14/2004	AndroGel (testosterone gel) CIII Product Plan	
PTX0753	WTN0040163	WTN0040331	1/5/2004	Androgel Information	Ebert 10;
PTX0754	WTN0047400	WTN0047587	N/A	Androgel Information	Ebert - 11;
PTX0755	WTN0047749	WTN0047918	9/12/2005	Androgel Information	Ebert - 12;
PTX0756	WTN0066156	WTN0066167	9/13/2006	Patent License Agreement between Unimed and Watson	Kay - 16A
PTX0757	WTN0164155	WTN0164161	5/31/1999	Clinical Review: Current Status of Testosterone Replacement Therapy in Men by Stephen J. Winters, MD	
PTX0758	N/A	N/A	8/19/2010	U.S. Department of Justice (DOJ) and Federal Trade Commission (FTC), Horizontal Merger Guidelines, (2010) - available at https://www.ftc.gov/sites/default/files/attachments/merger-review/100819hmg.pdf	
PTX0759	N/A	N/A	June 2009	Federal Trade Commission, "Authorized Generics: An Interim Report," June 2009 ("2009 FTC Study")	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0760	N/A	N/A	July 2002	Federal Trade Commission, "Generic Drug Entry Prior to Patent Expiration," July 2002	
PTX0761	N/A	N/A	August 2011	Federal Trade Commission, "Authorized Generic Drugs: Short-Term Effects and Long-Term Impact," August 2011	
PTX0762	N/A	N/A	November 2008	https://www.jpmorgan.com/treasury/demo/orderto pay/Unleashing_New_Working_Capital_Potential .pdf	
PTX0763	N/A	N/A	6/18/2014	Federal Trade Commission, "Generic Pharmaceuticals--Note by the United States," prepared for the 121st meeting of the OECD Competition Committee, June 18-19, 2014, (available at http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DAF/COMP/WD(2014)51 &docLanguage=En)	
PTX0764	N/A	N/A	6/11/2014	"Auxilium Pharmaceuticals, Inc. Announces Launch of Authorized Generic Version of Testim (Testosterone Gel)," June 11, 2014. Available at http://www.sec.gov/Archives/edgar/data/1182129/000110465914045215/a14-15198_1ex99d1.htm .	
PTX0765	N/A	N/A	7/2/2014	"Upsher-Smith Announces Launch of the First and Only Generic Transdermal Testosterone Gel Available in Three Convenient Configurations," available at http://www.upsher-smith.com/wpcontent/uploads/109429-01-VGX-MNR-Press-Release-FINAL.pdf .	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0766	N/A	N/A	9/8/2014	Endo Launches Generic Fortesta Gel - (http://www.empr.com/generics-news/endo-launches-generic-fortesta-gel/article/370184/ .)	
PTX0767	N/A	N/A	12/00/2001	Guidance for Industry - Major, Minor and Telephone Amendments to Abbreviated New Drug Applications	
PTX0768	WTN0193617	WTN0193619	1/7/2003	Testosterone Gel (8703) Team Meeting Minutes	Choy - 3
PTX0769	WTN0258625	WTN0258628	7/7/2003	Letter from Gregory Davis for Wm Peter Rickman to Watson Labs re ANDA	Choy - 11
PTX0770	PAD 0062342	PAD 0062345	10/27/2004	Letter from Gary Buehler to Todd Delehant re tentative approval of ANDA	
PTX0771	WTN0329660	WTN0329661	3/18/2005	Email re T Gel Cross Functional Team Members	Williams - 4
PTX0772	ParPaddIH00746	ParPaddIH00810	6/19/2008	FTC Transcript of Edward Maloney	
PTX0773	WTN0324545	WTN0324546	3/25/2005	Project Cross-Functional Team Meeting	Williams - 6
PTX0774	WTN321093	WTN321093	4/27/2005	Project Cross-Functional Team Meeting	Williams - 7
PTX0775	WTN0321116	WTN0321119	5/12/2005	Project Cross-Functional Team Meeting	Williams - 8
PTX0776	WTN0314263	WTN0314270	9/8/2005	R&D Monthly Update Meeting	Williams - 9
PTX0777	WTN0312517	WTN0312524	10/13/2005	R&D Monthly Update Meeting	Williams - 10
PTX0778	WTN0329655	WTN0329657	3/21/2005	Email FW T-Gel Facility & Equipment Subteam Meeting Minutes 3/17/2005	Williams - 5
PTX0779	N/A	N/A	3/25/2011	30(b)(6) Notice of Deposition to Defendant Watson Pharmaceuticals Inc.	Ebert - 2
PTX0780	WTN0334758	WTN0334761	9/9/2013	Contact Report and letter from Andre Raw to Janie Gwinn	
PTX0781	WTN0334558	WTN0334560	9/25/2013	Letter from Janie Gwinn to Kathleen Uhl - Gratuitous Amendment	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0782	WTN0334591	WTN0334596	4/4/2014	Letter from Janie Gwinn to Kathleen Uhl - Minor Complete Response Amendment	
PTX0783	WTN0403284	WTN0403286	7/31/2014	Letter from Janie Gwinn to Kathleen Uhl - Amendment to PAS	
PTX0784	WTN0366978	WTN0366981	9/24/2014	Letter from Paul Schwartz to Janie Gwinn - Complete Response	
PTX0785	PADD002106	PADD002107	1/30/2006	Email Chain re T-Gel	
PTX0786	PADD020876	PADD020876	2/1/2006	Email Chain re T-Gel	
PTX0787	PADD015671	PADD015694	9/13/2006	Final Settlement and Release Agreement between Unimed, Besins, Par and Paddock - Execution Copy	Maloney - 7
PTX0788	PAR-MDL-00000324	PAR-MDL-00000325	1/5/2010	Prior Approval Supplement	
PTX0789	PAR-MDL-00000523	PAR-MDL-00000526	6/11/2010	Amendment to PAS	
PTX0790	PAR-MDL-00192630	PAR-MDL-00192632	9/18/2014	Minor Amendment	
PTX0791	PAR-MDL-00214099	PAR-MDL-00214100	4/2/2015	Amendment to a Prior Approval Supplement	
PTX0792	WTN0594332	WTN0594358	2/12/2010	Prior Approval Supplement	
PTX0793	WTN0594855	WTN0594856	6/10/2010	Approval Letter	
PTX0794	WTN0311794	WTN0311796	5/25/2005	Project Cross-Functional Team Meeting	
PTX0795	PAR-MDL-00195907	PAR-MDL-00195908	6/5/2012	Email fw Testosterone Meetings	
PTX0796	PADD001037	PADD001040	9/9/2004	Executive Staff Meeting	
PTX0797	PAR141654	PAR141655	9/28/2004	Email Chain re Androgel - New Package	
PTX0798	PADD009441	PADD009446	11/3/2004	Email Chain re Our Meeting Last Thursday	
PTX0799	PADD028967	PADD028968	11/5/2004	Email Chain FW Project	
PTX0800	PADD022327	PADD022330	4/13/2005	Project Scope Change	
PTX0801	PADD 028749	PADD 028751	4/14/2005	Executive Staff Meeting	
PTX0802	PADD 029029	PADD 029030	1/9/2006	Email FW Bottle/pouch assembly (w/o adapter resin)	
PTX0803	PADD-MDL-00015577	PADD-MDL-00015578	1/18/2012	Email Chain re Testosterone Monthly Call	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0804	N/A	N/A	5/29/2012	Center for Drug Evaluation and Research Approval Package for ANDA 077575	
PTX0805	SLV475257	SLV475258	3/29/2007	Email from Jean-Louis Anspach to James Hynd re: RE: Besins	
PTX0806	SLV585172	SLV585174	6/30/2004	Alternative Manufacturing Site - AndroGel Memorandum from BESINS	
PTX0807	SLV585025	SLV585036	5/25/2006	Discussion Document Par/Solvay Meeting May 25, 2006	
PTX0808	PADD001998	PADD001999	10/24/2006	Email from Ed Maloney to Thomas MacAllister, Mary Beth Erstad, Bill Mink, et al re Rescheduled: Tech Transfer Kick-Off Meeting: Testosterone Gel (Oct 26 09:00AM EDT in Dial In)	
PTX0809	SLV508633	SLV508636	6/28/2007	Email from Lynn Dale to Bill Mink re Paddock visit	
PTX0810	SLV585243	SLV585244	6/13/2007	Draft Minutes of the Besins-Solvay Alliance Meeting	
PTX0811	PADD000695	PADD000695	8/25/2006	Email from Lonny Wittnebel to Ed Maloney re Par / Paddock NPV	
PTX0812	SLV451382	SLV451386	2/8/2007	Draft Minutes of the Androgel Second Global Joint Steering Committee Meeting	
PTX0813	SLV542455	SLV542456	3/30/2007	Email from Lynn Dale to Jean-Louis Anspach, Dave Pederson re Besins w/ Attach: Meeting_report_March_20.doc	
PTX0814	SLV357458	SLV357462	9/6/2007	Email from Jay Bua to Laurie Downey re follow- up of JSC meeting	
PTX0815	AGEL-MDL-006- 0003499	AGEL-MDL-006- 0003522	8/11/1995	License Agreement between Unimed and Besins	
PTX0816	AGEL MDL 001- 001098	AGEL MDL 001- 001106	10/22/2002	Forecasting Worksheet Template	Ebert - 6

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0817	AGEL MDL 001-001107	AGEL MDL 001-001112	10/22/2002	Forecasting Worksheet Template	Ebert - 7
PTX0818	AGEL MDL 001-001113	AGEL MDL 001-001118	10/22/2002	Forecasting Worksheet Template	Ebert - 8
PTX0819	AGEL MDL 001-001119	AGEL MDL 001-001124	10/22/2002	Forecasting Worksheet Template	Ebert - 9
PTX0820	WTN0040622	WTN0040660	N/A	Watson Pharmaceuticals Generic Pipeline Valuation	Ebert - 14
PTX0821	WTN0321093	WTN0321099	4/27/2005	Testosterone Gel - AndroGel Project Cross-Functional Team Meeting - 4/27/05	Ebert - 15
PTX0822	WTN0320557	WTN0320563	3/11/2004	Watson Pharmaceuticals, Inc., R&D Monthly Update Meeting dated March 11, 2004	Ebert - 16
PTX0823	WTN0038392	WTN0038412	8/12/2003	Watson Pharmaceuticals, Inc., R&D Department Meeting dated August 12, 2003	Ebert - 19
PTX0824	WTN0287901	WTN028902	00/00/0000	Handwritten Notes	Tykot - 6
PTX0825	WTN0287919	WTN0287919	2/27/2006	Handwritten Notes	Tykot - 7
PTX0826	WTN0288341; WTN0096054	WTN0096060	4/28/2006	Email from E. Tykot to E. Heimers, "FW: Summary of Terms"	Tykot - 9
PTX0827	SLV474901	SLV474925	6/27/2006	Co-Promotion Agreement between Solvay Pharmaceuticals, Inc. and Unimed Pharmaceuticals, Inc.	Tykot - 13
PTX0828	WTN0093300; WTN0287885	WTN0287900	4/19/2006	Email from E. Heimers to D. Buchen, "re: Unimed Files"	Tykot - 5
PTX0829	AGEL MDL 002-007324	AGEL MDL 002-007382	12/1/1999	Androgel Launch Plan - Executive Summary	Hynd 2011 - 04
PTX0830	AGEL MDL 002-011409	AGEL MDL 002-011421	5/4/2001	Memo re Androgel Co-Promotion Agreement	
PTX0831	AGEL-MDL-006-0000025	AGEL-MDL-006-0000219	3/26/2007	Solvay Responses to CID, Nos. 10 and 11	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0832	AGEL-MDL-006-0009820	AGEL-MDL-006-0009821	9/19/2006	Email re Negotiated settlement summary with attached presentation	Kay - 13
PTX0833	AGELMDL012002224	AGELMDL012002247	10/22/2004	Proposal for Solvay/ICOS Co-Promotion of AndroGel	
PTX0834	AGELMDL012002509	AGELMDL012002514	1/31/2005	Summary Document - Solvay/ICOS Co-Promotion of AndroGel	
PTX0835	AGELMDL012002544	AGELMDL012002550	3/17/2005	Active Business Development Projects - US	
PTX0836	AGELMDL014034402	AGELMDL014034409	8/21/2006	Presentation re Project Tulip	Kay - 12
PTX0837	AGEL-MDL-022-000505	AGEL-MDL-022-000509	12/15/2004	Briefing Document for Solvay/ICOS Co-Promotion of AndroGel	
PTX0838	AGEL-MDL-022-001511	AGEL-MDL-022-001568	2/21/2005	Presentation: "Project Impact"	
PTX0839	AGEL-MDL-023-005173	AGEL-MDL-023-005174	11/29/2005	Solvay Cost Team Update - Team Discussion 11/29/2005	
PTX0840	AHDARXHC00000001	AHDARXHC00000002	5/29/2014	Agreement for Assignment of Claims Between McKesson Corporation and Ahold USA, Inc.	James - 19
PTX0841	ANDROASC00018	ANDROASC00019	5/18/2009	Agreement for Assignment of Claims Between American Sales Company, Inc. and Cardinal Health, Inc.	
PTX0842	ANDROASC00020	ANDROASC00021	7/27/2012	Agreement for Assignment of Claims Between American Sales Company, Inc. and Cardinal Health, Inc.	James - 18
PTX0843	ANDROHEB00001	ANDROHEB00002	5/18/2009	Agreement for Assignment of Claims Between HEB Grocery Company, LP and Cardinal Health, Inc.	Nevers - 05

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0844	ANDROHEB00003	ANDROHEB00004	7/27/2018	Agreement for Assignment of Claims Between HEB Grocery Company, LP and Cardinal Health, Inc.	Nevers - 06
PTX0845	ANDROHEB00005	ANDROHEB00006	2/9/2016	Agreement for Assignment of Claims Between HEB Grocery Company, LP and McKesson Corporation	Nevers - 07
PTX0846	ANDROSFY00001	ANDROSFY00002	4/8/2009	Agreement for Assignment of Claims Between Safeway, Inc. and McKesson Corporation	Johnson - 16
PTX0847	ANDROSFY00021	ANDROSFY00022	9/21/2012	Agreement for Assignment of Claims Between Safeway, Inc. and McKesson Corporation	Johnson - 17
PTX0848	ANDROSFY00023	ANDROSFY00024	2/3/2015	Agreement for Assignment of Claims Between Safeway, Inc. and Cardinal Health, Inc.	Johnson - 18
PTX0849	ANDROSVU00001	ANDROSVU00002	3/15/2010	Agreement for Assignment of Claims Between Supervalu Inc. and McKesson Corporation	
PTX0850	ANDROSVU00008	ANDROSVU00009	10/14/2009	Agreement for Assignment of Claims Between Supervalu Inc. and McKesson Corporation	
PTX0851	ANDROSVU00035	ANDROSVU00036	7/24/2012	Agreement for Assignment of Claims Between Supervalu Inc. and McKesson Corporation	Johnson - 04
PTX0852	ANDROSVU00037	ANDROSVU00038	2/9/2016	Agreement for Assignment of Claims Between Supervalu Inc. and McKesson Corporation	Johnson - 05
PTX0853	FTC-ICOS00001472	FTC-ICOS00001474	10/24/2005	Solvay's Notification Letter Notification Terminating the 1/28/2005 Co-Promotion Agreement with ICOS	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0854	FTC-ICOS00035259	FTC-ICOS00035263	4/1/2005	ICOS/Solvay Commercial Committee Meeting Minutes	
PTX0855	iVH 00452	iVH 00487	2/14/2002	Service Agreement Between Ventiv Health U.S. Sales LLC and Allergan Sales, Inc.	
PTX0856	iVH 02551	iVH 02633	10/1/2010	Sales and Promotional Services Agreement Between Centiv Commercial Services, LLC and Endo Pharmaceuticals Inc.	
PTX0857	PAD 0000007	PAD0000196	5/21/2003	Paddock Letter Re and Encl ANDA 76-744 Volume 1	
PTX0858	PADD037949	PADD037959	9/13/2006	Asset Purchase Agreement Between Paddock Laboratories, Inc. and Par Pharmaceutical, Inc.	
PTX0859	PDI0358	PDI0452	7/27/2011	Contract Sales and Services Agreement Between Fidia Pharma USA Inc., Interpace BioPharma, LLC, Fidia farmaceutici S.p.A. and PDI, Inc.	
PTX0860	PDI0749	PDI0797	7/3/2012	Established Relationship Team Agreement Between Novartis Pharmaceuticals Corporation and PDI, Inc.	
PTX0861	PDI0980	PDI1036	1/1/2012	Task Order No. 7 Between Pfizer Inc. and PDI, Inc.	
PTX0862	PFE 00001	PFE 00042	4/28/2000	Letter Re and Enclosing Annual Update to Drug Master File #3190 Testosterone USP	
PTX0863	PFE 00043	PFE 00097	6/25/2001	Letter Re and Enclosing Annual Update to Drug Master File #3190 Testosterone USP	
PTX0864	PFE 00098	PFE 00129	8/15/2002	Letter Re and Enclosing Annual Update to Drug Master File #3190 Testosterone USP	
PTX0865	PHCG00000713	PHGC00000748	6/1/2013	Project Agreement Between Astrazeneca Pharmaceuticals LP and Publicis Touchpoint Solutions, Inc.	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0866	PHCG00001092	PHCG00001126	1/23/2012	Project Agreement Between Astrazeneca LP and Publicis Touchpoint Solutions, Inc.	
PTX0867	PHCG00001127	PHCG00001157	12/1/2014	Project Agreement Between Astrazeneca Pharmaceuticals LP and Publicis Touchpoint Solutions, Inc.	
PTX0868	PHCG00001285	PHCG00001311	11/19/2013	Project Agreement CSO Summit Program Between Astrazeneca Pharmaceuticals LP and Publicis Touchpoint Solutions, Inc.	
PTX0869	Quintiles_FTC_Barr-0001	Quintiles_FTC_Barr-0051	5/21/2004	Third Amendment And Extension to Trexall Sales Force Services Agreement Between Barr Laboratories, Inc. and Innovex Inc.	
PTX0870	Quintiles_FTC_GSK-00001	Quintiles_FTC_GSK-00027	5/26/2005	Sales Services for Lotronex Agreement Between SmithKline Beechman Corporation and Innovec, Inc.	
PTX0871	Quintiles_FTC_Novo Nordisk-0001	Quintiles_FTC_Novo Nordisk-0032	6/25/2004	Sales Force Services Agreement Between Novo Nordisk Pharmaceuticals Inc. and Innovex Inc.	
PTX0872	SLV033541	SLV033544	09/00/2003	Androgel with September 2003 Generic Competition Priced Equal to Androgel	Kay -27
PTX0873	SLV456272	SLV456291	3/24/2006	Solvay Pharmaceuticals, Inc. Strategiv Response to Generic Competition Transition Planning	
PTX0874	SLV466869	SLV466870	5/12/2006	Email chain re Par Agreement	Kay - 08
PTX0875	SLV474980	SLV474981	4/26/2006	Email Chain re Counter offer ideas	Kay - 11
PTX0876	SLV474988	SLV474988	8/10/2006	Email chain fw: Meeting for Monday	Kay - 10
PTX0877	SLV519055	SLV519055	2007	2007 Par Call Performance Report	
PTX0878	SLV586987	SLV586998	00/00/0000	Presentation re Business Outlook without Settlement	Kay - 03
PTX0879	SLV587026	SLV587033	N/A	AndroGel Assumptions Model re Solvay, Watsona and Par	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0880	SOLVAY068788	SOLVAY068841	N/A	Composite of Unimed Androgel Agreements:	Dudley - 08
PTX0881	TAP000746	TAP000803	6/1/2001	Co-Promotion Agreement Between Unimed Pharmaceuticals, Inc. and Tap Pharmaceutical Products Inc.	
PTX0882	WALG00072	WALG00073	6/29/2009	Agreement for Assignment of Claims Between Walgreen Co. and Cardinal Health, Inc.	Pike - 14
PTX0883	WALG00074	WALG00075	11/6/2009	Agreement for Assignment of Claims Between Walgreen Co. and AmerisourceBergen Drug Corporation	Pike - 16
PTX0884	WALG00076	WALG00077	7/27/2012	Agreement for Assignment of Claims Between Walgreen Co. and Cardinal Health, Inc.	Pike - 15
PTX0885	WALG00078	WALG00079	2/26/2016	Agreement for Assignment of Claims Between Walgreen Co. and AmerisourceBergen Drug Corporation	Pike - 17
PTX0886	WTN0288585	WTN0288588	12/31/2007	Watson Pharmaceuticals, Inc. Response to Specification 15	
PTX0887	WTN0334794	WTN0334836	7/18/2007	Promotion Agreement Between Depomed, Inc. and Watson Pharma, Inc.	
PTX0888	WTN0287578	WTN0287582	2006	2006 Urology P&L	
PTX0889	AGEL-MDL-013-060490	AGEL-MDL-013-060490	N/A	Product Assumptions - 2006 BF2 and 2007-2011 Plan for Gastroenterology, Womens Health, Specialized Markets, Cardiovascular and Neuroscience	
PTX0890	N/A	N/A	9/9/2005	Watson's Memorandum of Law in Support of Its Motion for Partial Summary Judgment	Buchen - 7

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0891	N/A	N/A	1/19/2005	Watson's Reply Memorandum of Law in Support of its Motion for Partial Summary Judgment of Invalidity of Claims 1-30 for Failure to Comply With The Written-Description Requirement	Buchen - 10
PTX0892	WTN0288356	WTN0288373	4/19/2006	Re: Unimed Files	Buchen - 14
PTX0893	WTN0286970	WTN0286981	9/13/2006	Watson Execution Copy agreement with Unimed	Buchen - 21
PTX0894	WTN0287005	WTN0287023	6/21/2006	AndroGel Draft Settlement & Release Agreement	Buchen - 22
PTX0895	WTN0287024	WTN0287028	4/13/2006	Contract Information	GX2076
PTX0896	WTN0287175	WTN0287210	5/8/2005	Watson Sales Forecast	GX2104
PTX0897	AGEL_MDL_003-001407	AGEL_MDL_003-001411	5/17/2006	Transcript of Telephone Conference Proceedings Before The Hon. Thomas W. Thrash, Jr.	
PTX0898	N/A	N/A	2/10/2012	Docket Sheet, Unimed v. Paddock, 1:03-cv-2503-TWT (N.D. Ga.)	
PTX0899	N/A	N/A	4/21/2011	30(b)(6) Notice of Deposition to Defendant Paddock Laboratories, Inc.	Maloney - 1
PTX0900	PADD 026923	PADD 026926	12/13/2000	Testosterone Gel Status Report	Maloney - 2
PTX0901	PAD-ER 0349	PAD-ER 0352	3/3/2003	Email chain FW Notes from 2/5/03 Conference call	Maloney - 4
PTX0902	PADD018901	PADD018902	9/14/2006	Email re Testosterone Gel	Maloney - 9
PTX0903	N/A	N/A	00/00/0000	AndroGel Marketing Material	Maloney - 10
PTX0904	PADD014645	PADD014682	9/13/2006	Backup Manufacturing and Supply Agreement - Execution Copy	Maloney - 12
PTX0905	PADD 026627	PADD 026630	9/13/2006	Letter from Scott Tarriff to Ed Maloney	Maloney - 13
PTX0906	PADD016165	PADD016165	9/15/2006	Email Chain re T-gel change control	Maloney - 15
PTX0907	PADD023873	PADD023880	2/21/2007	Supplier Audit Report	Maloney - 17

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0908	N/A	N/A	9/15/2006	Consent Judgment and Order of Permanent Injunction	Maloney - 18
PTX0909	ABBVIE-AGEL03267225	ABBVIE-AGEL03267261	10/28/2010	Metabolic Business Review Meeting AndroGel Presentation	
PTX0910	AGEL-MDL-002-007324	AGEL-MDL-002-007382	12/00/1999	AndroGel Launch Plan Executive Summary Buffalo Grove, IL	
PTX0911	AGEL-MDL-006-0004921	AGEL-MDL-006-0004943	4/20/2006	AndroGel (testosterone gel) 1% CIII Overview	
PTX0912	AGEL-MDL-013-046721	AGEL-MDL-013-046721	1/25/2007	Email from F. Waithe to B. Mitchell and M. Comer, "re: Androgel TRx History (w requested Chart changes) with attached Androgel TRx History 012407.xls	Janco - 13
PTX0913	CVS-ANDRO-0000001	CVS-ANDRO-0000002	5/19/2009	Agreement for Assignment of Claims between CVS and Cardinal Health	Griffin - 03
PTX0914	CVS-ANDRO-0000003	CVS-ANDRO-0000004	3/10/2009	Agreement for Assignment of Claims between CVS and McKesson	Griffin - 04
PTX0915	CVS-ANDRO-0059485	CVS-ANDRO-0059485	00/00/2010	Market Share: Testosterone Transdermal and Buccal	
PTX0916	CVS-ANDRO-0078408	CVS-ANDRO-0078409	5/25/2016	Agreement for Assignment of Claims between CVS and Cardinal Health	
PTX0917	CVS-ANDRO-0078410	CVS-ANDRO-0078411	7/11/2016	Agreement for Assignment of Claims between CVS and McKesson	
PTX0918	N/A	N/A	9/25/2006	Letter from B. Albert to FTC Premerger Notification Office re: Prescription Drug, Improvement, and Modernization Act of 2003	Edwards - 5
PTX0919	N/A	N/A	8/19/2016	Table 1 - Expert Report of Keith Leffler	
PTX0920	PAR 00201	PAR 00218	N/A	S&U of 4 Qtrs with PPG	Campanelli - 21

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0921	RA-ANDRO-0000001	RA-ANDRO-0000002	3/10/2009	Agreement for Assignment of Claims between Rite Aid, Brooks/Eckerd and McKesson Corporation	McMahon - 27
PTX0922	RA-ANDRO-0025342	RA-ANDRO-0025342	12/19/2014	Email from M. Barton to O. McMahon, M. Gogets, M. de la Hoz, et al., "re: Surprise Launch - December 26th"	
PTX0923	RA-ANDRO-0034577	RA-ANDRO-0034578	7/8/2016	Agreement for Assignment of Claims between Rite Aid, Brooks/Eckerd and McKesson Corporation	
PTX0924	SLV421989	SLV421989	8/14/2006	Email from L. Downey to R. Bickerstaffe and N. Hirsch, "re: Project Tulip"	
PTX0925	SOLVAY 103763	SOLVAY 103796	8/12/2001	AndroGel 2002 Business Plan	
PTX0926	SOLVAY 104973	SOLVAY 104973	12/6/2001	AndroGel Life-Cycle Background and Proposal	
PTX0927	SOLVAY ED 0137191	SOLVAY ED 0137313	00/00/2003	AndroGel 2003 Business Plan	
PTX0928	WTN0044143	WTN0044393	00/00/0000	Forecast	
PTX0929	WTN0245792	WTN0245818	5/6/2003	Email from E. Tykot to J. Nolan, "re: Generic Strategy"	Tykot 1
PTX0930	CVS-ANDRO-0000005	CVS-ANDRO-0000005	1/31/2011	Data	Griffin - 12; Griffin - 13; Griffin - 14; Griffin - 15; Griffin - 16; Griffin - 17
PTX0931	N/A	N/A		Excerpt from McKesson subpoenaed CVS data 10/1/2004-12/31/2004	Griffin - 19

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0932	PAR379184	PAR379185	9/13/2006	Press Release - PAR PHARMACEUTICAL ANNOUNCES AGREEMENT WITH UNIMED Doctitle Re: Fw: Press Release - PAR PHARMACEUTICAL ANNOUNCES AGREEMENT WITH UNIMED	
PTX0933	PAR319071	PAR319072	1/17/2007	Re: Fw: Summary of Androgel Call Panel: Updated Version 11/16/17	
PTX0934	PAR317830	PAR317830	5/31/2006	CD	
PTX0935	PAR103566	PAR103566	12/15/2006	Androgel targets	
PTX0936	PAR079514	PAR079535	11/20/2006	Fw: Solvay Contract	
PTX0937	PAR366118	PAR366153	12/27/2006	2007 business plans	
PTX0938	PAR318665	PAR318666	9/7/2006	RE: 2007 Plan- Androgel Assumptions	
PTX0939	N/A	N/A	N/A	Econ One 6.22.2012 - Exhibit 3 Annual AndroGel Class Sales Volumes and Prices 2004-2010	
PTX0940	N/A	N/A	N/A	Econ One 8.3.2012 - Exhibit 3 Annual AndroGel Class Sales Volumes and Prices 2004-2010	
PTX0941	N/A	N/A	N/A	Econ One 8.3.2012 - Exhibit 4 Generic Penetration Rates Used in Overcharge Calculations	
PTX0942	N/A	N/A	N/A	Econ One 8.3.2012 - Exhibit 5a Implied Generic Price Projections - Par	
PTX0943	N/A	N/A	N/A	Econ One 8.3.2012 - Exhibit 5b Implied Generic Price Projections - Solvay	
PTX0944	N/A	N/A	N/A	Econ One 8.3.2012 - Exhibit 5c Implied Generic Price Projections - Watson	
PTX0945	N/A	N/A	N/A	Econ One 8.3.2012 - Exhibit 5d Average But-For Generic Price	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0946	N/A	N/A	N/A	Econ One 8.19.2016 - Exhibit F Prices Relative to Brand WAC	
PTX0947	N/A	N/A	N/A	Exhibit 2 Plaintiff Purchase Volume	
PTX0948	N/A	N/A	N/A	Exhibit 3A Plaintiff Overcharges	
PTX0949	N/A	N/A	N/A	Exhibit 3B Plaintiff Overcharges	
PTX0950	N/A	N/A	N/A	Excerpt from Safeway Androgel Purchases from McKesson 1/1/2006-12/31/2006	Alcaine - 05
PTX0951	N/A	N/A	N/A	Excerpt of Safeway Androgel Purchases from McKesson 1/1/2007-12/31/2007	Alcaine - 06
PTX0952	N/A	N/A	N/A	Excerpt of Safeway Androgel Purchases from McKesson 1/1/2008-12/31/2008	Alcaine - 07
PTX0953	N/A	N/A	N/A	Excerpt of Safeway Androgel Purchases from McKesson 1/1/2009-12/31/2009	Alcaine - 08
PTX0954	N/A	N/A	N/A	Excerpt of Safeway Androgel Purchases from McKesson 1/1/2010-9/30/2010	Alcaine - 09
PTX0955	N/A	N/A	9/30/2010	Summary of Walgreen Androgel Purchases Through Its Mail Service Facilities 1/1/2006-9/30/2010	Allen - 03
PTX0956	N/A	N/A	9/30/2010	Cardinal Health Purchases of Androgel and Walgreen Distribution Center Purchases of Androgel form 1/1/2006-9/30/2010	Allen - 04
PTX0957	N/A	N/A	N/A	Excerpt from Amerisource Bergen Purchases of Androgel Into Walgreens Facilities	Allen - 05
PTX0958	N/A	N/A	N/A	Excerpt from ASC Purchase Data	James - 11
PTX0959	N/A	N/A	N/A	Excerpt from ASC Purchase Data	James - 12
PTX0960	N/A	N/A	N/A	Excerpt from McKesson Sales to ASC Warehouses and DSD to Ahold Pharmacies	James - 13

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0961	N/A	N/A	N/A	Excerpt from McKesson Sales to ASC Warehouses and DSD to Ahold's Pharmacies	James - 14
PTX0962	N/A	N/A	N/A	Excerpt of SuperValu Purchases from McKesson	Johnson - 05
PTX0963	ANDROSVU00003	ANDROSVU00017	10/13/2009	Email Re and Encl 10/14/2009 Agreement for Assignment of Claims between Supervalu and McKesson	Johnson - 07
PTX0964	N/A	N/A	N/A	Excerpt from SuperValu DSD and DC Purchases of AndroGel from McKesson	Johnson - 02
PTX0965	N/A	N/A	N/A	Excerpt from Safeway Purchase Data 1/1/2010-12/31/2010	Johnson - 03
PTX0966	N/A	N/A	N/A	Excerpt from Safeway Purchase Data 4/1/2011-6/31/2011	Johnson - 04
PTX0967	N/A	N/A	N/A	Excerpt from Safeway Purchase Data 7/1/2011-9/31/2011	Johnson - 05
PTX0968	N/A	N/A	N/A	Excerpt from Safeway Purchase Data 10/1/2011-12/31/2011	Johnson - 06
PTX0969	N/A	N/A	N/A	Excerpt from Safeway Purchase Data 1/1/2011-3/31/2011	Johnson - 07
PTX0970	N/A	N/A	N/A	Excerpt from Safeway Purchase Data 1/1/2012-3/31/2012	Johnson - 08
PTX0971	N/A	N/A	N/A	Excerpt from Safeway Purchase Data 4/2/2015-1/17/2015	Johnson - 09
PTX0972	N/A	N/A	N/A	Excerpt from Safeway Purchase Data 4/2/2015-1/17/2015	Johnson - 10
PTX0973	N/A	N/A	N/A	Excerpt from Safeway Purchase Data 4/2/2015-1/17/2015	Johnson - 11
PTX0974	N/A	N/A	N/A	Excerpt from Cardinal Health Androgel Sales to Safeway 1/17/2015-2/8/2016	Johnson - 12

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0975	N/A	N/A	N/A	Excerpt from HEB Purchase Data	Nevers - 02
PTX0976	N/A	N/A	N/A	Excerpt from HEB Purchase Data	Nevers - 03
PTX0977	N/A	N/A	N/A	Excerpt from Walgreen Purchase Data From 11/2010-1/2015	Pike - 04
PTX0978	N/A	N/A	N/A	Excerpt from Walgreen DSD Purchases from Cardinal 1/2004-11/2010	Pike - 05
PTX0979	N/A	N/A	N/A	Excerpt from Walgreen DC Purchases from Cardinal 3/2006-1/2012	Pike - 06
PTX0980	N/A	N/A	N/A	Excerpt from Walgreen DSD, DC and Mail Purchases from Cardinal 11/2010-11/2015	Pike - 07
PTX0981	N/A	N/A	N/A	Excerpt From Walgreen Warehouse Purchase Data 9/2008-11/2013	Pike - 08
PTX0982	N/A	N/A	N/A	Excerpt from Walgreen DSD and Mail Purchases From ABDC 7/2014-2/6/2015	Pike - 09
PTX0983	N/A	N/A	N/A	Excerpt from Walgreen DSD and Mail Purchases From ABDC 12/2010-6/2014	Pike - 10
PTX0984	N/A	N/A	N/A	Excerpt from ASC Androgel Purchases from Cardinal	Schneider - 08
PTX0985	N/A	N/A	N/A	Excerpt From ASC Androgel Purchase History	Schneider - 09
PTX0986	N/A	N/A	Sep-10	Summary of HEB Purchases From Cardinal 1/2006-9/2010	Stripling - 06
PTX0987	N/A	N/A	9/17/2010	HEB Daily Purchase Summary of Androgel 1/1/2006-9/17/2010	Stripling - 07
PTX0988	BESFR006287	BESFR006288	3/22/1999	Re: T-Gel NDA, CMC Issues, Renewed Time-Line, Production Plans	Bua - 7
PTX0989	BESFR006237	BESFR006241	10/8/1999	Five-Year Strategic Business Plan for Androgel	Bua - 10

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX0990	FTC-955-00002068	FTC-955-00002126	9/25/2006	Re: Filing Pursuant to Section 1112(a) of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003	
PTX0991	BNS00004399	BNS00004403	10/31/2006	FW: Paddock audit dates. Fyi	
PTX0992	AGEL MDL 001-001096	AGEL MDL 001-001097	9/26/2003	Email re Updated Marketing Forecasts for T-Gel	Williams - 1
PTX0993	WTN0329682	WTN0329682	11/5/2004	Email Chain re T-gel 1%	Williams - 3
PTX0994	WTN0324587	WTN0324588	1/27/2006	Email Chain Fw T-Gel Approval Letter	Williams - 11
PTX0995	WTN0324614	WTN0324621	2/9/2006	R&D Monthly Update Meeting - Salt Lake City	Williams - 12
PTX0996	WTN0169865	WTN0169866	4/25/2002	Testosterone Team Meeting Minutes	Choy - 1
PTX0997	WTN0186559	WTN0186562	11/7/2002	Testosterone Team Meeting Minutes	Choy - 2
PTX0998	WTN0196873	WTN0196875	2/14/2003	Testosterone Team Meeting Minutes	Choy - 4
PTX0999	WTN0199885	WTN0199890	3/7/2003	Testosterone Gel ANDA Assembly Plan	Choy - 5
PTX1000	WTN0200830	WTN0200832	3/17/2003	Testosterone Gel Team Meeting Minutes	Choy - 6
PTX1001	WTN0208139	WTN0208140	5/12/2003	Testosterone Gel Team Meeting Minutes	Choy - 7
PTX1002	WTN0208276	WTN0208277	5/14/2003	Email Re Testosterone Gel ANDA Filed 5/14/03	Choy - 8
PTX1003	WTN0250723	WTN0250772	5/13/2003	Watson Laboratories Corona ANDA-76-737 Original Submission	Choy - 9
PTX1004	AGEL MDL 002-000689; WTN0004286	AGEL MDL 002-000690; WTN0004314	7/7/2003	Letter with attached Detailed Statement of Factual and Legal Bases for Watson's Opinion that the Orange Book Patent is Invalid, Unenforceable and/or Will not be Infringed by Watson's Product	Choy - 10
PTX1005	WTN0258597	WTN0258616	9/2/2003	Patent Amendment Letter with attached ANDA Application	Choy - 12
PTX1006	WTN0237363	WTN0237364	8/19/2003	Testosterone Gel Team Meeting Minutes	Choy - 13
PTX1007	WTN0038992	WTN0038992	9/28/2005	Email re FDA Inspection - Salt Lake City	Choy - 14

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1008	WTN0323149	WTN0323150	1/10/2006	Email Chain Fw T-Gel FDA Telephone Contact & Response 09JAN2006 (generic AndroGel)	Choy - 15
PTX1009	N/A	N/A	3/25/2011	30(b)(6) Notice of Deposition to Defendants Unimed Pharmaceuticals, LLC and Abbott Products, Inc., f/k/a Solvay Pharmaceuticals, Inc.	Hynd - 1
PTX1010	SLV133949	SLV133967	7/19/2001	Email from Jim Hynd to Murray Kay re Specialized Markets Franchise Intro - 19Jul01.ppt	Hynd - 8
PTX1011	SLV134661	SLV134661	4/30/2002	Email from Richard Stemthal to Jim Hynd re 5 year plan assumptions	Hynd - 9 (2011)
PTX1012	SLV134662	SLV134662	5/6/2002	Email from Richard Stemthal to Jim Hynd re 5 Year Plan - Revenues	Hynd - 10 (2011)
PTX1013	AGEL-MDL-016-004215	AGEL-MDL-016-004239	10/12/2004	Inter-Office Memorandum from Elaine Yang to Jim Hynd re Generic Strategy	Hynd - 14
PTX1014	SLV162278	SLV162286	N/A	Solvay Pharmaceuticals, Inc. Product Strategy 2005-2009 Plan	Hynd - 15
PTX1015	SLV455625	SLV455636	1/10/2006	Email from Murray Kay to Jim Hynd re Contingency Plan 2006.ppt CONFIDENTIAL	Hynd - 16
PTX1016	SLV510883	SLV510883	3/23/2006	Email from Elaine Yang to Jay Janco, Brian Mitchell, Jim Hynd, Peter Edwards, Murray Kay	Hynd - 17
PTX1017	SLV506469	SLV506469	5/8/2006	Email from Murray Kay to Laurie Downey, Jim Hynd, Peter Edwards re FW: NPV Valuation	Hynd - 20
PTX1018	SLV456744	SLV456744	5/12/2006	Email from Murray Kay to pcampanelli@parpharm.com, Jim Hynd re FW: Par Agreement	Hynd - 21

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1019	SLV510737	SLV510737	5/15/2006	Email from Jim Hynd to Murray Kay re RE: Besins	Hynd - 22
PTX1020	AGEL-MDL-008-006270	AGEL-MDL-008-006292	9/21/2006	Email from Jim Hynd to Rich Post, Melissa Barlow, Charles Christophel, Jeff Westfall, Debbie Griggs-Smith, Jim Grayson, Christa Townsend, Ron Piela, Pete Wardlaw	Hynd - 24
PTX1021	SLVA000010	SLVA000012	N/A	James B. Hynd Resume	
PTX1022	SLV162260	SLV162286	October 2004	Solvay Pharmaceuticals, Inc. Board of Directors Meeting & Business Review October 2004	
PTX1023	PAR045040	PAR045894	N/A	File History for US Patent No. 6,503,894	Mahoney - 11
PTX1024	AGEL_MDL_001-006113	AGEL_MDL_001-006190	N/A	US Patent No. 6,503,894	
PTX1025	WTN0225681	WTN0225721	7/7/2003	Watson's Notice of Paragraph IV Certification	
PTX1026	PADD000556	PADD000568	7/7/2003	Paddock's Notice of Paragraph IV Certification	
PTX1027	AGEL_MDL_006-0008450	AGEL_MDL_006-0008457	9/13/2006	Settlement between Unimed, Besins, and Watson	Downey 18/Buchen 25
PTX1028	AGEL_MDL_006-0008336	AGEL_MDL_006-0008339	9/13/2006	Settlement and Release between Unimed, Besins, Par, and Paddock	Downey 20
PTX1029	SOLVAY 068820	SOLVAY 068841	8/11/1995	1995 Supply Agreement	Bua 5
PTX1030	AGEL_MDL_001-010859	AGEL_MDL_001-010870	4/12/1999	Excerpt of Androgel NDA 21-015	
PTX1031	AGEL_MDL_001-015775	AGEL_MDL_001-015776	3/3/1999	Internal Solvay email string re Androgel Placebos packets	Kottayil 7
PTX1032	UPI 058389	UPI 058446	3/26/1999	Unimed's 1998 Annual Report	
PTX1033	UPI056413	UPI056413	3/31/1997	Press Release by Unimed	Dudley 21
PTX1034	D&P02938	D&P02938	8/19/1998	Press Release by Unimed	Dudley 22
PTX1035	UPIED0106672	UPIED0106673	4/21/1999	Press Release by Unimed	Dudley 23

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1036	UPIED0072534	UPIED0072535	4/29/1999	Press Release by Unimed	Swerdloff 11
PTX1037	UCLA013419	UCLA013419	00/00/1998	1998 Abstract of article "Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men	
PTX1038	AGEL-MDL-006—0000518	AGEL-MDL-006—0000574	10/23/2008	Solvay's FTC White Paper	
PTX1039	N/A	N/A	07/00/2002	Generic Drug Entry Prior to Patent Expiration: an FTC Study (July 2002)	
PTX1040	N/A	N/A	00/00/2013	PricewaterhouseCoopers' 2013 Patent Litigation Study: "Big cases make headlines, while patent cases proliferate."	
PTX1041	N/A	N/A	00/00/2015	PriceWaterhouseCoopers's 2015 Patent Litigation Study (May 2015)	
PTX1042	PAR034121	PAR034128	00/00/2000	Remington's The Science and Practice of Pharmacy, Meade Publishing Co.	
PTX1043	N/A	N/A	00/00/2014	Frakes, Michael D. and Melissa F. Wasserman, "The Failed Promise of User Fees: Empirical Evidence from the United States Patent and Trademark Office," Journal of Empirical Legal Studies, 11(4): 602-36, at 609-10 (2014)	
PTX1044	N/A	N/A	00/00/2014	Frakes, Michael D. and Melissa F. Wasserman, "Is the Time Allocated to Review Patent Applications Inducing Examiners to Grant Invalid Patents?: Evidence from Micro-Level Application Data," National Bureau of Economic Research, Working Paper No. 20337, at 8 (2014)	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1045	N/A	N/A	00/00/1998	Allison, John R. and Lemley, "Empirical Evidence on the Validity of Litigated Patents", 26 AIPLA QJ 185, 205 (1998)	
PTX1046	N/A	N/A	00/00/1995	Dunner, Donald, et al, "A Statistical Look at the Federal Circuit's Patent Decisions: 1982-1994", 5 Fed. Cir. B.J. 151, 153-55 (1995)	
PTX1047	N/A	N/A	00/00/2010	Greene, Adam; Staedman, Dewey, RBC Capital Markets, "Pharmaceuticals: Analyzing Litigation Success Rates" (2010)	
PTX1048	N/A	N/A	00/00/2011	Hemphill, Scott and Mark Lemley, Earning Exclusivity: Generic Drug Incentives and the Hatch-Waxman Act 41 (2011)	
PTX1049	N/A	N/A	7/00/2005	Islam et al., Rheological Characterization of Topical Carbomer Gels Neutralized to Different pH," Pharm. Res. Vol. 21(July 2004) at 1192	
PTX1050	N/A	N/A	00/00/2006	Janicke, Who Wins Patent Infringement Cases?, published in the AIPLA Quarterly Journal Vol. 34, No. 1	
PTX1051	N/A	N/A	02/00/2001	Lemley, Mark A., "Rational Ignorance at the Patent Office," 95 Northwestern Univ. L. Rev., Working Paper No. 46, at 2 n.3 (2001)	
PTX1052	WTN0287072	WTN0287087	N/A	Civil Docket of GA case: Unimed Pharms., Inc. v. Watson Pharms., Inc., No. 1:03-cv-2501 (N.D. Ga.)	
PTX1053	N/A	N/A	N/A	Civil Docket of GA case: Unimed Pharms., Inc. v. Watson Pharms., Inc., No. 1:03-cv-2503 (N.D. Ga.)	
PTX1054	AGEL_MDL_001-006105	AGEL_MDL_001-006112	8/22/2003	PACER 4 Plaintiff's First Amended Complaint	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1055	WTN0001734	WTN0001756	10/27/2003	PACER 8 Watson's Answer to First Amended Complaint and Counterclaims	
PTX1056	N/A	N/A	10/22/2003	PACER 14 Paddock's Answer and Counterclaim	
PTX1057	AGEL-MDL-005-0001680	AGEL-MDL-005-0001709	12/12/2003	Watson's Initial Disclosures	
PTX1058	N/A	N/A	12/1/2004	PACER 43 Modified Scheduling ORDER 1 03-2503	
PTX1059	N/A	N/A	2/7/2005	PACER 50 Modified Scheduling ORDER 1 03-2503	
PTX1060	N/A	N/A	4/8/2005	PACER 54 Modified Scheduling ORDER 1 03-2503	
PTX1061	N/A	N/A	5/25/2005	PACER 57 Modified Scheduling ORDER 1 03-2503	
PTX1062	N/A	N/A	4/14/2005	PACER 84 Consent Extension to Scheduling Order 1 03-2501	
PTX1063	N/A	N/A	5/25/2005	PACER 85 Modification to Scheduling Order 1 03-2501	
PTX1064				Withdrawn	
PTX1065	BNS0002808	BNS0002864	7/25/2005	PACER 89 Watson's Principal Claim Construction Brief -2501	
PTX1066	BNS0002422	BNS0002496	7/25/2005	PACER 59 Paddock's Opening Claim Construction Brief	
PTX1067	N/A	N/A	7/25/2005	PACER 60 Unimed's Plaintiff's Memorandum on Claim Construction -2503	
PTX1068	PAR029233	PAR029292	8/12/2005	PACER 106 Watson's Reply Claim Construction Brief - 2501	
PTX1069	PAR006687	PAR006743	8/12/2005	PACER 70 Paddock Opposition Claim Construction Brief -2503	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1070	BNS0003294	BNS0003337	8/15/2005	PACER 71 Plaintiff's Opposition Brief on Claim Construction -2503	
PTX1071				Withdrawn	
PTX1072	PAR 024468	PAR 024477	9/9/2005	Watson's Reply in Support of Its Motion to Strike Section VI of Plaintiff's Claim-Construction Memorandum	
PTX1073	PAR012574	PAR012583	8/26/2005	PACER 115 Solvay's Response to Watson's Motion to Strike Section VI of Plaintiffs' Claim Construction Memorandum	
PTX1074	N/A	N/A	9/27/2005	PACER 80-1 Paddock's Memorandum of Law in Support of Its Motions For Partial Summary Judgment - Certificate of Correction	
PTX1075	PAR012086	PAR012132	10/17/2005	PACER 81 Plaintiffs' Consolidated Memorandum of Law in Opposition To Defendants' Motions For Partial Summary Judgment - Certificate of Correction	
PTX1076	PAR012158	PAR012168	10/17/2005	PACER 82 Unimed's Statement of Additional Facts	
PTX1077	PADD037635	PADD037665	10/18/2005	PACER 90 Paddocks Memorandum ISO Motion for Partial Summary Judgment as to Written Description	
PTX1078				Withdrawn	
PTX1079				Withdrawn	
PTX1080	PAR 026476	PAR 026493	2/16/2004	Unimed's Pharms. Inc.'s Response to Watson's First Set of Interrogatories,	
PTX1081	PADD015852	PADD015873	11/11/2005	PACER 140 Watson's Reply to Plaintiffs' Consolidated Opposition to Defendants' Motions For Partial	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1082	BNS0002497	BNS0002515	11/11/2005	PACER 97 Paddock's Reply Memorandum in Further Support of its Motion for Partial Summary Judgment as to the Inapplicability and Invalidity of the Certificate of Correction	
PTX1083	N/A	N/A	10/17/2005	PACER 108 Plaintiff's Consolidated Response to Par Paddock's and Watson's Statement of Facts for Certificate of Correction	
PTX1084	PAR024573	PAR024599	11/23/2005	PACER 144 Watson's Memorandum in Support of its Motion for Partial Summary Judgment of Invalidity of Claims 1-30 for Failure to Comply with the Written Description Requirement	
PTX1085	PAR024618	PAR024657	12/19/2005	Plaintiffs' Consolidated Memorandum of Law In Opposition To Defendants' Motions For Partial Summary Judgment Of Invalidity Of Claims 1-30	
PTX1086	N/A	N/A	1/19/2006	PACER 120 Paddock's Reply Memorandum In Further Support Of Its Motion For Partial Summary Judgment As To The Invalidity Of Claims 1-30 Under 35 U.S.C. § 112	
PTX1087	PAR005487	PAR005516	1/19/2006	PACER 121 Paddock's Response to Unimed's Statement of Additional Facts Which Are Material and Present a Genuine Issue for Trial With Respect to Paddock's Motion for Summary Judgment that Claims 1-30 of the '894 Patent Are Invalid Under 35 U.S.C. § 112	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1088	PAR025508	PAR025909	3/2/2005	Solvay's Responses to Requests for Admission	
PTX1089	N/A	N/A	3/14/2011	Watson's Responses to DPP's First Set of Requests for Admission	
PTX1090	N/A	N/A	3/14/2011	Par/Paddock's Responses to DPP's First Set of Requests for Admission	
PTX1091	N/A	N/A	1/28/2016	First Supplemental Response to Direct Purchaser Plaintiffs' Interrogatories to Abbvie Products LLC	
PTX1092	N/A	N/A	N/A	Docket Sheet for 1:09-md-2084-TWT	
PTX1093	N/A	N/A	00/00/2018	Federal Circuit Statistics, "Median Time to Disposition in Cases on the merits from Docketing Date to Disposition Date"	
PTX1094	N/A	N/A	08/00/2012	37 C.F.R. § 1.56(a)	
PTX1095	N/A	N/A	08/00/2012	37 C.F.R. §§ 1.97-1.98	
PTX1096	N/A	N/A	09/00/2005	AIPLA Report of the Economic Survey 2005	
PTX1097	N/A	N/A	08/00/2012	MPEP § 609	
PTX1098	N/A	N/A	08/00/2012	MPEP § 710.02(b) (8th ed. Aug. 2001, rev. 9 Aug. 2012)	
PTX1099	N/A	N/A	08/00/2012	MPEP § 724.05-06	
PTX1100	N/A	N/A	8/00/2006	MPEP § 1481 (8th ed. August 2001, rev. 5 Aug. 2006)	
PTX1101	N/A	N/A	02/00/2003	MPEP § 1481 (8th ed. August 2001, rev. 1 Feb. 2003)	
PTX1102				Withdrawn	
PTX1103				Withdrawn	
PTX1104				Withdrawn	
PTX1105				Withdrawn	
PTX1106				Withdrawn	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1107	AGEL_MDL_002-000001	AGEL_MDL_002-000035	4/22/2005	Expert Report of Loyd V. Allen, Jr.	
PTX1108	AGEL_MDL_002-003578	AGEL_MDL_002-003623	4/25/2005	Expert Report of Joel L. Zatz Report (Watson)	
PTX1109	AGEL_MDL_002-005322	AGEL_MDL_002-005340	5/13/2005	Expert Rebuttal Report of Loyd V. Allen, Jr.	
PTX1110	AGEL_MDL_002-008218	AGEL_MDL_002-008260	5/13/2005	Expert Rebuttal Report Joel L. Zatz dated (Watson)	
PTX1111	AGEL_MDL_002-010865	AGEL_MDL_002-010886	6/6/2005	Expert Reply Report Stephen G. Kunin dated (Paddock)	
PTX1112	AGEL_MDL_002-008830	AGEL_MDL_002-008846	6/7/2005	Expert Reply Report Loyd V. Allen	
PTX1113	AGEL_MDL_002-011623	AGEL_MDL_002-011668	6/7/2005	Expert Reply Report Zatz dated (Watson)	
PTX1114				Withdrawn	
PTX1115				Withdrawn	
PTX1116				Withdrawn	
PTX1117				Withdrawn	
PTX1118				Withdrawn	
PTX1119	AGEL-MDL-016-003053	AGEL-MDL-016-003053	06/00/2005	Solvay Pharm Summary of Outside Legal Services	
PTX1120	AGEL-MDL-012-004927	AGEL-MDL-012-004971	10/00/2006	Solvay Board of Directors Meeting and Business Review October 2006	
PTX1121	WTN00291394	WTN00291454	10/1/2008	Skadden Presentation	
PTX1122	WTN00289531	WTN00289625	10/31/2008	Watsons FTC White Paper	
PTX1123	AGEL-MDL-003-001416	AGEL-MDL-003-001420	7/5/2006	Transcript of at Teleconference with Judge Thrash	
PTX1124	AGEL-MDL-003-001421	AGEL-MDL-003-001424	7/31/2006	Transcript of at Teleconference with Judge Thrash	
PTX1125	UPIED0150516	UPIED0150518	4/28/1999	Letter re Priority review	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1126	N/A	N/A	1/14/2011	Letter re Defense Election	
PTX1127	AGEL-MDL-008-018460	AGEL-MDL-008-018484	11/00/2005	Solvay Presentation from Jean-Louis Anspach, November 2005	
PTX1128	AGEL-MDL-014-037037	AGEL-MDL-014-037086	08/00/2005	Financial Highlights August 2005	
PTX1129	WTN0594294	WTN0594294	N/A	Costs and Fees Associated with Androgel Patent Litigation Aug 2003-Oct 2006	
PTX1130				Withdrawn	
PTX1131				Withdrawn	
PTX1132	AGEL_MDL_002-002320	AGEL_MDL_002-002328	N/A	Weiner Deposition Exhibit 21, Formulation Data	
PTX1133	AGEL_MDL_002-008767	AGEL_MDL_002-008769	N/A	Weiner Deposition Exhibit 22, Watson excerpt of ANDA	
PTX1134	N/A	N/A	N/A	Weiner Deposition Exhibit 24, Formulation	
PTX1135				Withdrawn	
PTX1136				Withdrawn	
PTX1137	AGEL MDL 002-011552	AGEL MDL 002-011558	00/00/2000	The Handbook of Pharmaceutical Excipients, Monograph on Carbomer	
PTX1138	N/A	N/A	8/10/2011	CBT Flint Partners, LLC v. Return Path, Inc., et. al., Case no. 1-07-cv-01822	
PTX1139	N/A	N/A	4/8/2013	Selex Communications, Inc. v. Google, Inc., Case No. 1-09-cv-02927	
PTX1140	N/A	N/A	6/14/2017	Unimed 10-k 04-01-1996 Certified	
PTX1141	N/A	N/A	6/14/2017	Unimed 10-k 03-31-1997 Certified	
PTX1142	N/A	N/A	6/14/2017	Unimed 10-k 03-30-1998 Certified	
PTX1143	N/A	N/A	6/14/2017	Unimed 10-k 03-30-1999 Certified	
PTX1144	N/A	N/A	6/14/2017	Unimed 10-ka 04-17-1998 Certified	
PTX1145	N/A	N/A	9/27/2019	Rule 1006 Summary of Solvay's Litigation Fees and Costs Charged by Patent Litigation Attorneys Mayer Brown	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1146	ABBVIE- AGEL00981558	ABBVIE- AGEL00981562	11/30/2003	Invoice	
PTX1147	ABBVIE- AGEL00981563	ABBVIE- AGEL00981571	11/30/2003	Invoice	
PTX1148	ABBVIE- AGEL00981118	ABBVIE- AGEL00981123	12/31/2003	Invoice	
PTX1149	ABBVIE- AGEL00981124	ABBVIE- AGEL00981137	12/31/2003	Invoice	
PTX1150	ABBVIE- AGEL03267075	ABBVIE- AGEL03267081	9/30/2005	Invoice	
PTX1151	ABBVIE- AGEL03267082	ABBVIE- AGEL03267095	9/30/2005	Invoice	
PTX1152	ABBVIE- AGEL00981969	ABBVIE- AGEL00981978	10/31/2005	Invoice	
PTX1153	ABBVIE- AGEL00981949	ABBVIE- AGEL00981968	10/31/2005	Invoice	
PTX1154	ABBVIE- AGEL00981979	ABBVIE- AGEL00981983	11/30/2005	Invoice	
PTX1155	ABBVIE- AGEL00981984	ABBVIE- AGEL00982000	11/30/2005	Invoice	
PTX1156	ABBVIE- AGEL00982060	ABBVIE- AGEL00982069	12/31/2005	Invoice	
PTX1157	ABBVIE- AGEL00982041	ABBVIE- AGEL00982059	12/31/2005	Invoice	
PTX1158	ABBVIE- AGEL00982070	ABBVIE- AGEL00982076	1/31/2006	Invoice	
PTX1159	ABBVIE- AGEL00982077	ABBVIE- AGEL00982096	1/31/2006	Invoice	
PTX1160	ABBVIE- AGEL00982116	ABBVIE- AGEL00982127	2/28/2006	Invoice	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1161	ABBVIE- AGEL00982097	ABBVIE- AGEL00982115	2/28/2006	Invoice	
PTX1162	ABBVIE- AGEL00982013	ABBVIE- AGEL00982018	3/31/2006 & 4/30/2006	Invoices	
PTX1163	ABBVIE- AGEL00982001	ABBVIE- AGEL00982012	3/31/2006 & 4/30/2006	Invoices	
PTX1164	ABBVIE- AGEL00982152	ABBVIE- AGEL00982157	5/31/2006	Invoice	
PTX1165	ABBVIE- AGEL00982158	ABBVIE- AGEL00982167	5/31/2006	Invoice	
PTX1166	ABBVIE- AGEL00982174	ABBVIE- AGEL00982179	6/30/2006	Invoice	
PTX1167	ABBVIE- AGEL00982168	ABBVIE- AGEL00982173	6/30/2006	Invoice	
PTX1168	ABBVIE- AGEL00982180	ABBVIE- AGEL00982186	7/31/2006	Invoice	
PTX1169	ABBVIE- AGEL00982187	ABBVIE- AGEL00982195	7/31/2006	Invoice	
PTX1170	ABBVIE- AGEL00982019	ABBVIE- AGEL00982025	8/31/2006	Invoice	
PTX1171	ABBVIE- AGEL00982026	ABBVIE- AGEL00982040	8/31/2006	Invoice	
PTX1172	ABBVIE- AGEL00982196	ABBVIE- AGEL00982203	9/30/2006	Invoice	
PTX1173	ABBVIE- AGEL00982204	ABBVIE- AGEL00982215	9/30/2006	Invoice	
PTX1174	ABBVIE-AGEL0098213	ABBVIE-AGEL0098215	3/31/2006	Invoice	
PTX1175	PAR343633	PAR343635	4/17/2006	Email from Ed Maloney to pcampanelli@parpharm.com Re: Georgia	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1176	PAR344067	PAR344067	8/10/2006	Email from Paul Campanelli/PAR to Kay Murray Re: Meeting for Monday	
PTX1177	PAR459186	PAR459187	5/10/2006	Email from Robert Campanelli to Paul Campanelli/PAR@PAR Re: New product launch long term forecast	
PTX1178	PAR463298	PAR463300	9/7/2006	Meeting Summary Report containing issues and status of products	Campanelli - 12
PTX1179	PAR344805	PAR344805	9/8/2006	Email from Joseph Todisco/Par to Paul Campanelli/PAR@PAR Re: BDL&L Presentation - First Draft	
PTX1180	AGEL-MDL-006- 0008127	AGEL-MDL-006- 0008143	4/2/2008	Solvay Pharmaceuticals, Inc. Responses to Civil Investigative Demand No. 0710060 Responses to Specifications 36, 38, 40, 43, 45, 46 and 51	
PTX1181	FTC-955-00013219	FTC-955-00013225	6/22/2007	Solvay Pharmaceuticals, Inc. Responses to Civil Investigative Demand No. 0710060 Responses to Interrogatories 20 and 22	
PTX1182	FTC-955-00006476	FTC-955-00006479	10/5/2007	Watson Pharmaceuticals, Inc. Responses to Civil Investigative Demand, File No. 071-0060 Responses to Specifications 8, 16 and 17	
PTX1183	MEI_ANDRO 00000003	MEI_ANDRO 00000004	10/4/2002	Agreement for Assignment of Claims between Meijer Inc., and Frank Kerr Company, dated October 4, 2002	Romano - 7
PTX1184	ABBVIE- AGEL00003044	ABBVIE- AGEL00003044	1/11/2009	Email Re 1.62% eCTD-NDA	
PTX1185	ABBVIE- AGEL02224100	ABBVIE- AGEL02224150	10/1/2014	Email Re and Encl AndroGel 2015 Plan Deck for Chase Review	
PTX1186	ABBVIE- AGEL02228568	ABBVIE- AGEL02228591	Oct 2014	AbbVie 2015 Plan WJC Review Pricing October 2014	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1187	ABBVIE- AGEL03113714	ABBVIE- AGEL03113727	7/20/2015	Presentation: AndroGel 1.62% Update 2015 Q3 JCC July 20th, 2015	
PTX1188	AGEL MDL 003- 001425	AGEL MDL 003- 001429	9/6/2006	Transcript of Telephone Conference before The Honorable Thomas W. Thrash (Status Conference)	
PTX1189	AGEL-MDL-006- 0003533	AGEL-MDL-006- 0003535	4/28/2008	Email RE and Encl Documents for Laurie Downey's files	
PTX1190	AGEL-MDL-013- 034411	AGEL-MDL-013- 034412	2/6/2008	Email Re Five-Year Plan and Encl Copy of Financial Package 2008-2012 - 2007 Actuals	
PTX1191	CVS-ANDRO-0076042	CVS-ANDRO-0076042	12/31/2014	Email re Generic Contract in works for Testosterone Gel 1% (Brand Androgel 1% 25mg)	
PTX1192	PADD002085	PADD002086	1/17/2006	Email re Agenda for T-Gel Meeting and Encl Team Meeting Minutes and Agenda Topics	
PTX1193	PADD-MDL-00018811	PADD-MDL-00018920	6/28/2011	Email re TESTOSTERONE GEL 1% and Encl Various Agreements re Same	
PTX1194	PAR012133	PAR012157	10/17/2005	Plaintiffs' Consolidated Response to Defendants Watson and Paddock's Statements of Material Facts as to Which There are No Genuine Issues to be Tried (Unimed v. Watson and Paddock, 1:03- cv-2501 and 1:03-cv-2503)	
PTX1195	PAR344604	PAR344604	5/9/2006	Email Re deal with Paddock	
PTX1196	PAR458610	PAR458613	9/13/2006	Letter Agreement from Par Pharmaceutical to Paddock Laboratories, Inc. re Backup Manufacturing and Supply Agreement	
PTX1197	SLV165599	SLV165600	2/2/2006	Email re AndroGel Patent Litigation Proceedings	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1198	SLV417625	SLV417627	2/24/2006	Email re FW: GENERIC ANDROGEL APPROVAL and Encl Watson National Accounts Letter	
PTX1199	SLV448304	SLV448306	8/28/2006	Draft Press Release: "Solvay Pharmaceuticals, Inc. Reaches Settlements of AndroGel Patent Litigation With Watson Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. ...[what about Paddock]?"	
PTX1200	SLV456271	SLV456272_A	4/14/2006	Email Solvay generic transition plan and Encl Presentation: "Solvay Pharmaceuticals Strategic Response to Generic Competition Transition Planning March 24, 2006"	
PTX1201	SLV475149	SLV475152	4/27/2009	Presentation: "Watson Partnership Proposal"	
PTX1202	SLV475153	SLV475160	4/28/2006	Email re and Encl Presentation: "Solvay/Watson Co-Promotion of AndroGel to Urologists: Proposed Preliminary Terms"	
PTX1203	SLV475161	SLV475184	6/28/2006	Email re and Encl Co-Promotion Agreement between Solvay and Watson	
PTX1204	SLV475210	SLV475229	9/13/2006	Email re and Encl Presentation: "September 13 Director's Update" by Jim Hynd	
PTX1205	SLV475230	SLV475252	9/15/2006	Email re and encl Presentation: "September 13 Director's Update" by Jim Hynd	
PTX1206	SLV477326	SLV477377	9/1/2006	Email RE and Encl Redlines of Par / Unimed Settlement Agreement and PLA as of 8/31/06	
PTX1207	SLV503328	SLV503330	6/14/2006	Email Re and Encl Par Forecast 06-14-06	
PTX1208	SLV506141	SLV506141	9/1/2006	Email Re: Settlement Agreement	
PTX1209	SLV510566	SLV510566	4/10/2006	Email RE: Watson meeting	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1210	SLV582889	SLV582923	8/23/2006	Draft Backup Manufacturing and Supply Agreement Between Unimed, Basins and Par	
PTX1211	SLV585099	SLV585101	5/24/2006	Email Re and Encl Presentation: Tulip May-24 2006	
PTX1212	SOLVAY048243	SOLVAY048243	4/12/1999	Androgel Manufacturing Specification	
PTX1213	WPI-E-0900420	WPI-E-0900443	8/1/2006	Email Re Co-Promotion Agreement and Encl Solvay co-promote 7-31-06 (Watson redline).DOC	
PTX1214	N/A	N/A	3/14/2011	Defendant Watson Pharmaceuticals, Inc.'s Responses to Direct Purchaser Plaintiffs' First Set of Requests for Admissions dated March 14, 2011	
PTX1215	N/A	N/A	3/14/2011	Par/Paddock's Response to Direct Purchaser Plaintiffs' First Set of Requests for Admission dated March 14, 2011	
PTX1216	N/A	N/A	7/15/2011	Direct Purchaser Class Plaintiffs' Supplemental Responses to Defendants' First Set of Interrogatories, dated July 15, 2011	
PTX1217	N/A	N/A	4/29/2015	Par Pharmaceutical Companies, Inc. and Paddock Holdings, LLC's Responses to Direct Purchaser Plaintiffs' First Set of Interrogatories dated April 29, 2015	
PTX1218	N/A	N/A	2/12/2016	Par Pharmaceutical Companies, Inc. and Paddock Holdings, LLC's Supplemental and Amended Responses to Direct Purchaser Plaintiffs' First Set of Interrogatories dated February 12, 2016	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1219	N/A	N/A	9/2/2016	Retailer Plaintiffs' Supplemental Responses to Defendant AbbVie Products LLC's Interrogatories dated September 2, 2016	
PTX1220	N/A	N/A	N/A	Proposed 1006 - Plaintiffs' Purchases May 22, 2009 - December 31, 2015	
PTX1221	SLV471032	SLV471052	7/17/2007	Email from Mike Dornhecker to Laurence Downey, James Hynd, Murray Kay, et al. re: FW: AndroGel Transfer - July 12, 2007 w/ Attach: Androgelmakelbuy.ppt; AndroGel Transfer Task Force 12-July-2007.ppt	
PTX1222	AGEL-MDL-009-00696	AGEL-MDL-009-00696	9/28/2006	Email chain from L. Dale to R. Malladi, "re: AndroGel LV additional stability lots"	
PTX1223	SLV532591	SLV532607	8/14/2007	Watson JCC 8-22-07.ppt	
PTX1224	SLV584888	SLV584903	8/15/2007	Watson JCC8-22-7.ppt	
PTX1225	WTN0295569	WTN0295646	1/20/2009	Re: Updated Financial Reporting Package and Q4 Financial Reporting Package - 1-16-09.pdf	
PTX1226	WTN0583008	WTN0583008	12/31/2007	Product Line Financial Statements YTD as of December 31, 2007	
PTX1227	WTN0583105	WTN0583105	12/31/2009	Brand Product Line Financial Statements YTD as of December 31, 2009	
PTX1228	WTN0583138	WTN0583138	12/31/2010	Global Brand Product Line Financial Statement YTD as of December 31, 2010	
PTX1229	PAR328228	PAR328234	3/20/2006	Re and Encl Draft of Par 2005 Annual Report	
PTX1230	PAR328247	PAR328247	8/31/2006	Email re Solvay - Correction to Previous Letter	
PTX1231	PAR459176	PAR459177	5/10/2006	Email re Deal (Par/Paddock)	
PTX1232	PAR259057	PAR259068	6/28/2004	Email Re and Encl Par Presentation at the CIBC World Markets Meeting in NYC	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1233	AGEL-MDL-015-01210	AGEL-MDL-015-01210	5/12/2008	Solvay/Watson JCC Minutes 4.16.08	
PTX1234	AGEL-MDL-008-02096	AGEL-MDL-008-02099	10/1/2008	2008 10 01 Strativa AndroGel JCC Meeting.ppt	
PTX1235	AGELMDL012001851	AGELMDL012001894	7/20/2005	Email re McKinsey Slides (Latest Version) with attached presentation	
PTX1236	PAR-MDL-00180092	PAR-MDL-00180094-18	6/13/2007	Email from John MacPhee to Nefertiti Greene with attachment	
PTX1237	ABBVIE-AGEL0028381	ABBVIE-AGEL0028382	N/A	Presentation entitled Testim Authorized Generic Writers First Look	
PTX1238	ABBVIE-AGEL0001042	ABBVIE-AGEL0001053	N/A	Presentation entitled Androgel 1.62% Go-To-Market Overview	
PTX1239	ABBVIE-AGEL0321021	ABBVIE-AGEL0321021	3/16/2015	Email from Michael Kuderka to Michael Gautsch and Steven Closter with attachment	
PTX1240	ABBVIE-AGEL0313868	ABBVIE-AGEL0313868	9/8/2011	Email chain from B. Bautista to F. Jaeger, "BCBS of LA"	
PTX1241	ABBVIE_AGEL003421	ABBVIE-AGEL0034216	4/18/2011	SMART Panel Findings for AndroGel	
PTX1242	ABBVIE-AGEL0276171	ABBVIE-AGEL0276175	8/8/2013	Email chain from F. Jaeger to M. Gautsch, "FW: PriceSpective - AndroGel Workshop Deck Draft" with attached AndroGel LOE Scenario Planning_v3.pptx	
PTX1243	ABBVIE-AGEL0080312	ABBVIE-AGEL0080312	1/10/2012	Email chain from M. Gautsch to P. Wardlaw and F. Jaeger, "re: FW: AndroGel Brand Team"	
PTX1244	ABBVIE-AGEL0033761	ABBVIE-AGEL0033761	1/5/2012	Email from Metabolics and GI Care to Metabolics and GI Care, et al., "Send on Behalf of Marty Trent Comer, National Sales Director"	
PTX1245	ABBVIE-AGEL0277339	ABBVIE-AGEL0277344	7/29/2010	Abbott Products, Inc. Review Jim Hynd	
PTX1246	PAR267702	PAR267711	9/14/2006		
PTX1247	PAR327785	PAR327859	1/3/2006	2006 Strategic Plan Planning Meeting	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1248	SLV453540	SLV453543	10/16/2007	Par Call Performance Sales Strategy Feb. Monthly Report	
PTX1249	WTN0004618	WTN0004624	9/14/2006	Re Androgel Settlement - External Communications Follow-Up	Amato - 11
PTX1250	ASCARXED00001256	ASCARXED00001256	7/15/2014	Re Important Information Concerning Therapeutically Equivalent Product Substitution	James - 20
PTX1251	SLV446960	SLV446961	N/A	2007-2011 Plan - Current Developments	
PTX1252	PADD-MDL-00006362	PADD-MDL-00006362	6/13/2008	Email from E. Maloney to B. Mink, "re: Solvay equipment"	
PTX1253	PAR463303	PAR463305	6/12/2006	Paddock/Par BiWeekly Meeting summary Report	
PTX1254	PAR-MDL-00189778	PAR-MDL-00189781	11/10/2010	First Amendment to Co-Promotion Agreement between Abbott Laboratories and Par Pharmaceutical, Inc.	
PTX1255	PAD 0003538	PAD 0003999		Par ANDA No. 76-744	
PTX1256	AGEL MDL 002-003556	AGEL MDL 002-003577		Spec for Watson's product	
PTX1257	PAD0004000	PAD0004603		Spec for Par's product	
PTX1258	AGEL MDL 002-008767	AGEL MDL 002-008769		WATSON ANDA Excerpts	
PTX1259	WTN0251046	WTN0251098		Watson ANDA Mfg Process	
PTX1260				Intentionally Omitted	
PTX1261	UPI 060437 B	UPI 060437 B	5/11/1999	CBS newscast recording	
PTX1262			00/00/2007	Chemical Principles by Steven Zumdahl	
PTX1263	AGEL_MDL_001-025261	AGEL_MDL_001-025273	01/00/2000	United States Pharmacopeia National Formulary (2000)	
PTX1264	AGEL MDL 001-021554	AGEL MDL 001-021689		Unimed's Study regarding testosterone absorption	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1265	AGEL MDL 001-022439	AGEL MDL 001-022678	4/6/1999	Unimed's UMD 96-017	
PTX1266	UPI051940	UPI051952	10/24/1997	UMD-97-023 study	
PTX1267	AGEL_MDL_001-008221	AGEL_MDL_001-008328	11/2/1998	UMD 98-012 Report Nov. 2, 1998	
PTX1268	AGEL MDL 001-025756	AGEL MDL 001-025893	1/22/1999	UMD 98-012 Report Jan. 22, 1999	
PTX1269	UPIED0186109	UPIED0186181	4/12/1999	UMD-98-037 study	
PTX1270	AGEL MDL 001-008357	AGEL MDL 001-008910	4/6/1999	UMD-99-017-IR Report Apr. 6, 1999	
PTX1271	AGEL MDL 001-012918	AGEL MDL 001-013216	8/27/1999	UMD-99-017-FR Aug. 27, 1999	
PTX1272	SOLVAY ED 0039306	SOLVAY ED 0039338	4/1/1999	UMD 99-948, "In Vitro Percutaneous Absorption and Distribution Studies of 1% Testosterone Gel (T-Gel) Test Formulations in Human Skin"	
PTX1273				Intentionally Omitted	
PTX1274			00/00/1998	Hernandez, M.J., Pellicer, J., Delegido, J., Dolz, M. Rheological characterization of easy to disperse (ETD) Carbopol hydrogels, J. Disper. Sci. Technol., 1998, 19, 31-42	
PTX1275			00/00/2008	Kaushik, D., Batheja, P., Kilfoyle, B., Rai, V., Michniak-Kohn, B. Percutaneous Penetration modifiers: enhancement vs. retardation. Expert Opinion on Drug Delivery, (2008), May 5 (5), 517-529	
PTX1276			00/00/2010	Kaushik, D., Costache, A., Michniak-Kohn, B. Percutaneous penetration modifiers and formulation effects: Part I. International J. of Pharmaceutics (2010), 386, 42-51	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1277			00/00/2010	Kaushik, D., Costache, A., Michniak-Kohn, B. Percutaneous penetration modifiers and formulation effects: Thermal and Spectral Analyses. AAPS Pharm Sci. Tech. (2010) Sept. 11 (3) 1068-8	
PTX1278				Withdrawn	
PTX1279			00/00/1993	Roberts and Walker, "Water: The Most Natural Penetration Enhancer," Pharmaceutical Skin Penetration Enhancement (Ed. Walters and Hadgraft, 1993)	
PTX1280			02/00/2010	Relative Uptake of Minoxidil into Appendages and Stratum Corneum and Permeation through Human Skin <i>In Vitro</i> ", Journal of Pharmaceutical Sciences, Vol. 99, No. 2, February 2010	
PTX1281			00/00/2002	Sanz Taberner, T., Martin-Villodre, A., Pla-Delfina, J.M., Herraiez, J.V. Consistency of Carbopol 971-P NF gels and influence of soluble and cross-linked PVP, International J. Pharmaceutics, 2002, 233, 43-50	
PTX1282	AGEL_MDL_001-003081	AGEL_MDL_001-003082	01/00/2002	Noveon TDS-64 (2002)	
PTX1283	AGEL_MDL_002-005472	AGEL_MDL_002-005476	07/00/1997	Noveon TDS-60 (1997)	
PTX1284	AGEL_MDL_001-002882	AGEL_MDL_001-002884	10/00/1998	Noveon TDS-237 (1998)	
PTX1285				Intentionally Omitted	
PTX1286				Intentionally Omitted	
PTX1287	PADD022767	PADD022767		Noveon Bulletin	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1288	AGEL_MDL_002-005946	AGEL_MDL_002-005956		Bulletin 11 – Thickening Properties	
PTX1289			00/00/1997	HAWLEY'S CONDENSED CHEMICAL DICTIONARY 784 (13th ed. 1997)	
PTX1290				Intentionally Omitted	
PTX1291				Intentionally Omitted	
PTX1292			1/9/2017	Weiner Exhibit 41	
PTX1293			1/9/2017	Weiner Exhibit 42	
PTX1294			1/9/2017	Weiner Exhibit 43	
PTX1295			1/9/2017	Weiner Exhibit 44	
PTX1296	SOLVAY 108136	SOLVAY 108137	8/16/1999	Email from Kate Robertson to Dave Knocke re HIV Roundtable	
PTX1297				Intentionally Omitted	
PTX1298				Intentionally Omitted	
PTX1299				Intentionally Omitted	
PTX1300				Intentionally Omitted	
PTX1301				Intentionally Omitted	
PTX1302	UPIED0038278	UPIED0038279	2/16/1999	Internal Solvay email string	
PTX1303	UPIED0070553	UPIED0070554	05-3-10-99	Solvay e-mail string	
PTX1304	UPIED 0023864	UPIED 0023865	3/3/1999	Email from Marcy Vella to Michelle Alm re Androgel Placebo packets	
PTX1305	UPIED 0023844	UPIED 0023844	2/17/1999	Email from David Knocke re T-Gel Placebos	
PTX1306	SOLVAY ED 0058350	SOLVAY ED 0058351	4/22/1998	Fax from Solvay	
PTX1307	BESFR 003084	BESFR 003085	2/24/1999	Fax from Unimed to Besins re Tgel Sachets	
PTX1308	BESFR 004461	BESFR 004462	5/7/1999	Letter from Sandrine Hoesch to Michelle Alm	
PTX1309	AGEL MDL 001-012887	AGEL MDL 001-012888		Program & Abstracts	Faulkner -12

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1310	AGEL MDL 002-003939	AGEL MDL 002-003949	9/26/1995	Besins Lab Notebook	
PTX1311	WPI-FLH-000986	WPI-FLH-000996		Besins Lab Notebook	
PTX1312	AGEL MDL 002-004093	AGEL MDL 002-004123	4/3/1998	Letter to Unimed from Besins	
PTX1313			10/11/2007	Malladi Application	Weiner - 46
PTX1314	WTN0216591	WTN0216608	00/00/1991	Ranade, et al., Drug Delivery Systems: Transdermal Drug Delivery J Clin Pharmacol 1991; 31:401-418.	
PTX1315				Withdrawn	
PTX1316			00/00/1983	Wester, et al., Cutaneous Pharmacokinetics: 10 Steps to Percutaneous Absorption, Drug Metabolism Reviews, 14(2), 169-205 (1983)	
PTX1317			1/16/1997	Application of in vitro human skin models to dermal irritancy: a brief overview and future prospects, Toxicology in vitro, (11)(3): 305-312	
PTX1318	AGEL_MDL_002-008659	AGEL_MDL_002-008664	00/00/1988	Buck et al., Bioavailability of Topically Administered Steroids (1988)	
PTX1319			00/00/1971	Scheuplein et al., Permeability of the skin, Physiol. Rev. 51 (1971) 702-747	
PTX1320			00/00/1989	Lochhead RY, Davidson JA and Thomas GM, Polymers in aqueous media, American Chemical Society, pp.113-147 (1989)	
PTX1321	AGEL MDL 002-005270	AGEL MDL 002-005309	10/3/1992	Letter from Guy Courraze to Mrs. Salin-Drouin re Study	
PTX1322	AGEL MDL 002-003950	AGEL MDL 002-003981	5/23/1995	In Vitro Percutaneous Absorption in Man of Testosterone Formulated in Different Water Alcohols-Gels	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1323			00/00/1988	Weidmann, T.S., Influence of Hydration on epidermal tissue, J. Pharm. Sci 77:1037-1041,1988	
PTX1324				Withdrawn	
PTX1325			1/8/2003	Office Action (application no. 10/033101)	
PTX1326			1983	Barry, B.W. Chapter 6 in Dermatological Formulations: Percutaneous Absorption, Marcel Dekker, Inc. (1983)	
PTX1327				Brown, U.S. Patent No. 2,798,053	
PTX1328	PAR 037729	PAR 037731	5/1/1998	Noveon Bulletin (May 1998)	
PTX1329	AGEL MDL 002-008767	AGEL MDL 002-008769		List of Ingredients of Watson's Product - Formulation Data	Weiner - 22
PTX1330	MPI 010147	MPI 010147	3/12/1998	Contents of AndroGel Placebo	
PTX1331			4/12/1999	Chemistry, Manufacturing and Controls section of Unimed's New Drug Application (filed with FDA)	
PTX1332				Intentionally Omitted	
PTX1333				Intentionally Omitted	
PTX1334				Intentionally Omitted	
PTX1335				Intentionally Omitted	
PTX1336				Intentionally Omitted	
PTX1337				Intentionally Omitted	
PTX1338				Intentionally Omitted	
PTX1339				Intentionally Omitted	
PTX1340				Intentionally Omitted	
PTX1341				Withdrawn	
PTX1342				Intentionally Omitted	
PTX1343				Intentionally Omitted	
PTX1344	BESFR015641	BESFR015642		Solubility Figures	
PTX1345				Intentionally Omitted	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1346				Noveon Bulletin 14	
PTX1347	UPIED 0186224	UPIED 0186271		UNIMED NDA Pharmacokinetics Partial	
PTX1348			6/29/2015	816 Notice of Allowance	
PTX1349			12/26/2014	816 Office Action	
PTX1350	WTN0250862	WTN0250862		Watson ANDA No. 76-737	
PTX1351			01/00/2010	Pay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions, An FTC Staff Study	
PTX1352			7/8/2010	Basaria, S., et al. Adverse Events Associated with Testosterone Administration, The New England Journal of Medicine, Vol. 363, No. 2	
PTX1353			2/27/2019	10-K AbbVie Inc. for fiscal year ended December 31, 2018	
PTX1354			11/6/2019	10-Q AbbVie Inc. for quarterly period ended September 30, 2019	
PTX1355			01/00/2014	Finkle, et al., Increased Risk of Non-Fatal Myocardial Infaction Following Testosterone Therapy Prescription in Men, PLOS One, Vol. 9, Issue 1 (January 2014)	
PTX1356			8/12/2013	Braun, Promotiong "Low T" A Medical Writer's Perspective, JAMA Intern Med. 2013, Vol. 173 No. 15	
PTX1357			8/12/2013	Swartz and Woloshin, Low "T" as in "Template" How to Sell Disease MAMA Intern Med., Vol. 173 No. 15	
PTX1358			8/20/2012	Dubowitz, et al., Low-T, High Profit?	
PTX1359				Rule 1006 Summary - Annual AndroGel Sales Volumes and Prices 2004 - 2010	
PTX1360				Rule 1006 Summary - Annual AndroGel Sales Volumes and Prices 2004 - 2010	

PLAINTIFFS' TRIAL EXHIBIT LISTNovember 15, 2019

PTX #	BegBates	EndBates	Date	Description	Also Referenced As
PTX1361				Rule 1006 Summary - DPP Purchase Volume	
PTX1362				Rule 1006 Summary - Generic Penetration Rates Used in Overcharge Calculations	
PTX1363				Rule 1006 Summary - Monthly Prices of AndroGel and Injectables from Cremieux's Work Papers January 2006 - January 2014	
PTX1364				Rule 1006 Summary - Prices Relative to Brand WAC	
PTX1365				Lichtenberg, The Impact of New Drug Launches on Longevity: Evidence from longitudinal, Disease-Level Data from 52 Countries, 1982- 2001, Intern J. of Health Care Finance and Economics, 5, 47-73, 2005	